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V 
Summary 
Neurodegenerative disorders such as Alzheimer’s disease, Huntington’s disease, Parkinson’s 
disease, Amyotrophic Lateral Sclerosis or Prion diseases are chronic, incurable and often fatal. The 
risk to develop neurodegeneration increases with age, making these pathologies especially 
devastating in aging industrialized societies. Neuronal death leads to functional impairment of the 
affected region. A cardinal feature of all neurodegenerative disorders is the accumulation of 
misfolded and aggregated proteins. Depending on the disease, these aggregated proteins are cell type 
specific and have distinct cellular localizations, compositions and structures. Despite intensive 
research, the contribution of protein misfolding and aggregation to the cell type specific toxicity is 
not completely understood. The increasing availability of “omics” approaches opens up novel 
strategies to characterize the physiological properties of neurons and to investigate pathological 
changes in the context of neurodegeneration. In recent years, quantitative proteomics has matured 
into an exceptionally powerful technology providing accurate quantitative information on almost all 
cellular proteins as well as protein interactions, modifications, and subcellular localizations, which 
cannot be addressed by other omics technologies.  
The aim of this thesis is to investigate key features of neurodegeneration such as misfolded 
proteins and toxic protein aggregates with cutting edge proteomics, presenting a technological “proof 
of concept” and novel insights into the (patho)physiology of neurodegeneration. In article 1, we 
analyzed the complete proteome of primary motoneurons, providing a reference protein inventory 
for these specialized cells. Such data can help to understand the physiological properties of these 
cells and their vulnerabilities causing specific pathologies. Furthermore, we compared primary 
neurons to neuronal model cell lines commonly used in research. We provided quantitative measures 
on proteomic differences, but also demonstrated that some disease relevant proteins and pathways 
are unchanged. Based on these data, the suitability of cellular model system for motoneuron studies 
can be evaluated. 
Cells have evolved sophisticated mechanisms to maintain homeostasis of the proteome 
(proteostasis). Chaperones facilitate folding and can rescue partially unfolded proteins. Misfolded 
proteins and aggregates are usually degraded by the ubiquitin proteasome pathway and autophagy. 
Failure of proteostasis causes accumulation of protein aggregates and is a feature of almost all 
neurodegenerative disorders. However, a comprehensive understanding of how aggregates can exert 
toxicity is still missing. In article 2, we designed a proteomics approach to investigate the quantitative 
composition of Amyotrophic Lateral Sclerosis associated aggregates composed of poly-dipeptide 
VI 
repeats. These aggregates displayed strong association with many different proteins including a 
significant part of the ubiquitin / proteasome system. Moreover, we identified new disease relevant 
proteins such as the cargo adapter protein Unc119. Characterization of Unc119 function revealed 
that its sequestration causes neuron specific toxicity. 
In order to gain new insights into the cellular responses to toxic protein aggregates, we 
investigated huntingtin aggregates in yeast. In article 3, Hartl and coworkers first identified proteins 
in yeast that modulate huntingtin toxicity. We set out to quantify changes in the aggregate 
composition by proteomics and correlated these changes with the toxicity. We showed that a 
prion-like domain of the endogenous protein GTS1p reduces huntingtin aggregate toxicity by altering 
the aggregate structure and composition. It also increases accessibility for chaperones while 
preventing the aggregate from sequestering other cellular factors. These findings suggest novel 
cellular strategies to cope with proteostasis stress. 
Alzheimer’s disease is the most prominent neurodegenerative disorder. The accumulation of 
extracellular protein aggregates, amyloid Aβ plaques, and intercellular amyloid tangles are cardinal 
features of Alzheimer’s disease. The proteolytic pathway in which Aβ is generated from the amyloid 
precursor protein by the γ- and β-secretase has been extensively studied. In theory, the inhibition of 
β-secretase should prevent production of neurotoxic peptides, however, studies on β-secretase 
knockout mice revealed the development of neurological defects 23. In a collaborative effort with the 
group of Christian Haass we identified a novel proteolytic pathway of the amyloid precursor protein. 
Employing high performance mass spectrometry instrumentation and an optimized proteomic 
workflow, we identified and characterized a so far unknown neurotoxic peptide, termed Aη-α 
(article 4 in press). This finding provides a new perspective on Alzheimer’s disease pathology. 
Intriguingly, the production of neurotoxic Aη-α competes with β-secretase activity, which at least 
partially explains the neurological defects in β-secretase knockout mice and is highly relevant for drug 
development. 
Cutting edge proteomics technology today allows the identification of more than 10,000 
proteins in individual cell types (article 1). However, proteomics still greatly benefits from increased 
mass spectrometer performance in terms of number of identified peptides and quantification 
accuracy. We evaluated the performance of the latest generation of hybrid quadrupole Time-of-Flight 
and quadrupole Orbitrap mass spectrometers in article 5 and article 6. For the Orbitrap we assessed 
the complexity of the parameter space that affects machine performance by applying mathematical 
models. These data allowed us to determine the optimal settings and to maximize mass spectrometer 
performance.
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“Any time scientists disagree, it's because we have insufficient data. Then we can agree on what 
kind of data to get; we get the data; and the data solves the problem. Either I'm right, or you're 
right, or we're both wrong. And we move on. That kind of conflict resolution does not exist in 
politics or religion.” 
Neil deGrasse Tyson 24 
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1. Neurodegeneration
“The human brain has 100 billion neurons, each neuron connected to ten thousand other neurons. 
Sitting on your shoulders is the most complicated object in the known universe.” 
Michio Kaku 25 
1.1. The Neuronal Network 
The human brain is one of the most complex systems known. More than 86 billion neurons are 
estimated to structure a network controlling most body functions and reflecting our consciousness 26. 
The connectivity of neuronal circuits exhibits enormous plasticity during development and to a lower 
extent also in adults. Neurons themselves are very specialized and morphologically distinct cells. 
Motoneurons, for instance, are extremely elongated cells that connect the brain with muscles of the 
body. Neurons are highly connected to each other via cellular extensions called dendrites, which 
receive stimuli from synapses of other neurons. Starting with only a few at birth, some neurons 
eventually develop up to 100,000 dendrites, providing thousands of dynamic synaptic connections to 
other neurons, eventually reaching a network complexity of 100 trillion connections 27-29. Within this 
neuronal network, information is electrically and chemically coded and transmitted. This dynamic 
connectivity in the brain is one of the key elements in cognitive processes such as learning and 
memory formation. 
A 90 years old person will not outrun a 20 years old person but might well beat her in chess. 
Rodriguez and coworkers pointed out that the brain is one of the few organs that can remain 
functional even in old age 30. Specialized non-neuronal cells, termed glial cells, maintain the 
homeostasis of the neuronal network over decades. Interestingly, glial cells have at least similar 
abundance as neurons 26. Some glial cells such as the oligodendrocytes (or Schwann cells in the 
peripheral nervous system) insulate neurons with myelin sheaths, providing metabolic and structural 
support while increasing efficiency of neuronal signaling along axons 30. Astroglia play a central role 
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in modulating the synaptic activity as well as neuronal 
crosstalk 11. Glial cells also protect against infection and 
tissue malfunction. In particular microglia, which 
essentially are brain-resident macrophages, provide a 
pro- or anti-inflammatory environment 18. Their limited 
capacity for regeneration and their unique metabolic, 
functional and morphological features render neurons 
particular vulnerable. Deterioration of homeostasis in the 
nervous system is associated with a spectrum of 
neurodegenerative disorders. 
Glia Cells and Neuronal Signaling 
The initial assumption that glia cells 
do not directly participate in 
neuronal signaling was challenged in 
studies performed on astrocytes, the 
most common type of glia cells in the 
brain. These demonstrated the 
capacity of astroglia to release 
gliotransmitters (ATP or glutamate), 
which modulate synaptic activity and 
trigger excitatory or inhibitory 
responses in the neurons 11. 
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1.2. Pathological Events in Neurodegeneration 
Local and global neuron death leads to functional impairment of the affected region and causes 
incurable and often fatal disorders such as Alzheimer’s disease (AD), Huntington’s disease (HD), 
Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS) or Prion diseases. These diseases 
are associated with a spectrum of pathological changes on the cellular level, for many of which the 
question of cause or consequence is not yet solved. 
The hallmark of all neurodegenerative disorders (ND) 
is accumulation of misfolded and aggregated proteins 
(Table 1). This accumulation and the risk of developing a 
ND both increase with age, rendering it an increasing burden 
for industrialized societies 31-33. The protein aggregates often 
have disease specific properties such as composition, 
localization and structure. Some of these aggregates, 
however, occur in multiple pathologies. For instance, alpha 
synuclein inclusion are characteristic for PD, but can also be 
detected in 50 % of all AD cases 34. It is well established that 
aggregates and misfolded oligomers can exert toxicity in 
cells 35,36. Apart from this direct toxicity, consequent decline 
of proteostasis can further promote accumulation of 
misfolded proteins. Being both cause and consequence 
renders protein misfolding a catastrophic self-promoting 
cascade 37.  
The risk of developing ND is associated with a variety of genetic mutations. In the case of HD, 
mutations in a single gene resulting in an elongated polyQ stretch of the huntingtin protein (HTT) 
are causing the pathology. For other NDs, alterations in more than one risk allele have been reported. 
Mutations in the amyloid precursor protein APP or its processing enzyme PSEN1 can lead to an early 
onset AD and dozens of mutations are associated with ALS and FTD 38,39. Neurodegeneration is 
accompanied by a deterioration of several cellular processes, including the proteasome / ubiquitin 
system (UPS), oxidative stress response, neurotransmission (excitotoxicity), mitochondrial function, 
and RNA metabolism and axonal or dendritic transport (Figure 1) 40. In addition, a growing body of 
evidence points towards a disturbed cellular communication in neurodegeneration. Astroglia 
degeneration and altered neuronal crosstalk, as well as inflammatory processes can weaken neuronal 
homeostasis 30,41. Microglia can be activated by protein aggregates and an impairment of the blood 
Major Causes of Death 
The life expectancy in developed 
countries has doubled in the last 
two centuries, which renders age 
related pathologies a growing 
problem 1,2. NDs are now among 
the major age related causes of 
death. In contrast to many other 
diseases, neurodegeneration asso-
ciated fatalities are still rising and 
the WHO projects that in 2050, 106 
million people will suffer from 
NDs 6,7. 
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brain barrier can amplify the neuronal decay by promoting neuroinflammation 42,43. Especially these 
inflammatory processes are considered a major driver of widespread neuronal death. 
Taken together, multiple factors contribute to the development and progression of 
neurodegenerative disorders. In 2007 Sulzer suggested a “Multiple hit hypotheses” for PD in analogy 
to cancer 44. This assumption probably also holds true for other NDs where genetic and environmental 
factors modulate disease onset and progression. 
Figure 1 Pathological alterations in neurodegeneration: Apart from the accumulation of protein aggregates, 
neurodegenerative disorders involve a variety of intra- and intercellular processes (depicted in red). The 
discrimination of primary and secondary effects is usually difficult due to slow disease progression before 
manifestation of symptoms 18,30,34,40,41,45. 
Inflammation in Neurodegeneration 
Inflammation is essential to maintain homeostasis by removing pathological stimuli and by promoting the 
healing process. If dysregulated, inflammation is deleterious especially for tissues with limited 
regenerative capacity such as the central nervous system (CNS). Under physiological conditions, the CNS 
is an immune privileged organ and therefore insulated from many activities of the immune system. It 
lacks connection to the lymphatic system and the blood-brain barrier shields the CNS from 
immunoglobulin and immune cell infiltration. Resident microglia remove cell debris, clear off neurotropic 
pathogens and tumors but in contrast to their blood-circulating counterparts provide a rather anti-
inflammatory environment 18. 
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Table 1 Major NDs with characteristic protein aggregates 46,47 
Diseases Pathology Aggregates Location 
Alzheimer's disease46 
whole brain, mental 
impairment 
TAU Cytoplasm 
Amyloid Beta 
(Aβ) 
Extracellular 
Creutzfeldt–Jakob disease46 
whole brain, mental 
impairment 
Prion protein 
(PrPsc) 
Cytoplasm 
Extracellular 
Polyglutamine expansions 
(including Huntington’s 
disease or spinocerebellar 
ataxia)46 
whole brain, mental 
impairment, behavioral 
changes 
PolyQ proteins 
nuclei and 
cytoplasm 
ALS and Frototemporal 
dementia 47,48  
motoneurons and 
temporal and prefrontal 
cortex, paralysis and 
mental impairment 
SOD1, TDP43, 
poly dipeptide 
repeat 
nuclei and 
cytoplasm 
Parkinson's disease 34 
substantia nigra, 
motorsymptoms 
Lewis bodies 
(α-synuclein) 
cytoplasm 
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1.3. Amyotrophic Lateral Sclerosis 
ALS is a rare and fatal ND of the motorsystem, affecting 1 in 50,000 people. Degeneration of upper 
and lower motoneurons in the brain stem and spinal cord as well as in the motor cortex lead to 
progressive and ultimately complete paralysis. Most patients die within three to five years, although 
in rare cases can survive much longer 47. Death is usually caused by loss of neurons that innervate 
breathing. Recent evidence suggests that ALS is at one extreme in a disease continuum whose other 
extreme is frontotemporal dementia (FTD), a pathology characterized by the progressive loss of 
neurons in the temporal and prefrontal cortex causing mental retardation and behavioral changes 49. 
As with most NDs, one hallmark of ALS is the accumulation of misfolded proteins in the 
cytosol and nucleus. These aggregates have different properties depending on the genetics of the 
pathology. The number of genes that contribute to ALS pathology is very large compared to other 
NDs and currently the ALSOD database lists 126 ALS-related genes (2015/21) 38. Strikingly, genetic 
causes are only identified for 10 % of all ALS cases. This could be an underestimation due to 
incomplete knowledge of the disease genetics 50. The corresponding proteins are involved in diverse 
cellular processes such as reactive oxygen species detoxification (SOD1), RNA metabolism 
(TDP-43, FUS), the cytoskeleton (DCTN1, MAPT) or proteostasis (UBQLN2). Some of the ALS 
cases are associated with loss of function mutations, but most are linked to gain of function 
mutation 47. Although the specific pathological manifestations of ALS suggest a common link 
between the associated genes, a common ALS disease mechanism remains elusive. Progression of 
ALS is promoted by neuroinflammation, which is mediated by microglia switching from immune 
suppressive to pro-inflammatory phenotype and T-cell invasion 18.  
In 2011 two groups independently reported the most common genetic cause for ALS and 
FTD 51,52. The associated hexanucleotide expansion in an intronic sequence accounts for 40 % of the 
inherited instances of ALS and was also found in 7 % of all sporadic (no family history) ALS cases 53. 
The physiological function of the c9orf72 protein is unknown and three different pathological 
mechanisms have been proposed. First, the repeat expansion alters the splicing of the c9orf72 protein, 
which might lead to a haploinsufficiency 54. A similar mode of action has been described for 
mutations in progranulin (PGNR), which are causing FTD 55,56. Second, the hexanucleotide repeat 
expansion is transcribed, leading to high amounts of mRNA that accumulate in RNA foci. These 
RNA foci have been suggested to be toxic by sequestering RNA binding proteins, similarly as 
described for myotonic distrophy type 2, where the pathology is linked to RNA repeats that act as a 
sink for splicing factors 54,57. Third, hexanucleotide repeat associated peptide aggregates might 
themselves cause toxicity. In support of this possibility, two groups reported a start-codon 
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independent translation, termed ‘RAN’ translation 58, of the hexanucleotide repeat resulting in 
different species of aggregation prone dipeptide repeats 48,59.  
Figure 2 ALS and FTD pathology: A) FTD and ALS comprise the extremes of a common disease spectrum. ALS 
primarily affects the motorcortex, motoneurons in the brain stem as well as lower motoneurons in the spinal 
cord. In contrast, FTD is characterized by increasing degeneration in the frontal and temporal lobe 47 
(adapted 60). B) Various genes cause ALS and FTD pathology. While mutations in some genes specifically lead 
to either ALS or FTD pathology, the most common genetic cause c9orf72 is shared by both (adapted 61). C) For 
ALS, neurological pathology depends on the genetics. Mutation in some genes tend to cause motor phenotype 
while some are also associated with other symptoms (adapted 61) (CMT: charcot-marie-tooth disease; POA: 
primary open-angle glaucoma; SMA / PMA: spinal muscular atrophy / progressive muscular atrophy; 
AOA2:ataxia with oculomotor apraxia type 2)  
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1.4. Expansions of Repetitive Genetic Elements in 
Neurodegeneration 
Expansions of repetitive genetic elements, termed microsatellite expansions, are associated with 
various NDs such as above described c9orf72 associated ALS and FTD 62, HD, spinal bulbar 
muscular atrophy, and spinocerebellar ataxia types 1, 2, 3, 6, 7, and 17 or fragile X-associated tremor 
ataxia syndrome. These repeats were traditionally termed either coding or noncoding repeats, 
depending whether or not they are located within an ATG-initiated open reading frame. Among 
those, poly glutamine (polyQ) associated pathologies comprise a prominent group of repeat 
associated neurological disorders with toxic gain-of-function on the protein level (see chapter 1.6.2). 
Noncoding repeats can also mediate toxicity on the transcriptional level where the RNA acts as a 
sink for RNA binding proteins. Beside these two mechanisms, repetitive genetic elements can prime 
toxicity via repeat associated non-ATG translation (‘RAN’ translation 62). 
In most cases, mRNA translation in eukaryotes is initiated by the AUG start codon. However, 
this canonical translation does not cover the whole spectrum of proteins and many instances of 
alternative translation initiations have been reported 63. In 2011 a novel mode for AUG independent 
translation of microsatellite repeat expansions was reported, which does not initiate via Met-tRNA 64. 
A RAN translation to polyQ for repetitive CAG but not CAA sequences was observed, which 
indicates that initiation depends on the capacity to form RNA hairpins 64. This hairpin mediated 
translation mimics the initiation tRNA with a RNA stem loop structure and is mechanistically similar 
to that at internal ribosome entry sites used by certain viruses 58. RAN translation occurs in several 
microsatellite disorders such as spinocerebellar ataxia type 8 or FTD and c9of72 pathology of 
ALS 48,59,64. In RAN translation, all three reading frames are translated. The resulting proteins can 
vary in abundance, which might be due to different translation efficiency or protein stability. The 
efficiency of RAN also depends on the repeat length. A minimum length can be required and 
simultaneous translation on very long repeats can increase the amount of the corresponding protein 64. 
Introduction – Neurodegeneration 
21 
1.5. Protein Folding 
1.5.1. Protein Structure and Function 
Despite the diversity of NDs, protein misfolding and aggregation are cardinal features. The 
functionality of proteins depends on the three-dimensional shape that emerges from the folding of 
the poly-amino acid sequence. The folding of proteins is a complex and yet not fully understood 
process. In the 1960s Anfinsen and co-workers performed refolding experiments and hypothesized 
that all the information for the correct tertiary structure 
is encoded in the primary structure of the polypeptide 
allowing it to de novo fold into the native 
conformation 65. Even for small polypeptides its degrees 
of freedom result in a combinatorial explosion that 
would make a stochastic folding process impossible. 
Instead of pure stochastic path, the folding therefore has 
to happen in a more guided manner. Several groups 
suggested a funnel-like energy landscape shaped by the 
thermodynamic properties of all possible 
conformations 66. This energy landscape would facilitate 
a guided folding process within the Anfinsen 
assumption. In addition, the environment of the protein 
affects the thermodynamics and kinetics and the stable 
conformations and folding pathways can be remodeled 
and controlled. Enzymes facilitating cis-trans 
isomerization of proline (peptidyl-prolyl isomerases) 
and disulfide isomerases can effectively reduce kinetic 
barriers in the folding process 67,68. For small proteins 
(100 amino acids), folding usually happens on a sub-
second time scale and involves interaction of key 
residues and reduction of hydrophobic surfaces 69. In 
contrast, for larger proteins this process is more 
complicated with folding taking place simultaneously at 
different parts of the protein and involving multiple 
folding intermediates 70,71. Those intermediates can 
promote further folding but can also act as a trap for 
incorrect conformations 72,73. 
Figure 3 Protein conformation energy 
landscape: A simplified energy funnel that 
depicts the thermodynamic stability of 
protein conformations and kinetic barriers. 
Folding intermediated can either fold 
spontaneously or are assisted by chaperones. 
Protein misfolding or partial folding can 
promote potentially harmful amorphous or 
amyloid aggregates or oligomers 
(adapted  17). 
The Levinthal Paradox 
The Levinthal paradox is a thought 
experiment that shows that protein 
folding cannot be a random process 14. 
The combinatorial explosion would not 
allow folding of even small proteins 
within observed time scales of seconds 
to minutes. Assuming three degrees of 
freedom per amino acid and a sampling 
rate of 1013 conformations per second, 
a 16mer samples all conformations in 
less than 2 µs, a 38mer takes one day, a 
45mer a whole PhD period (three 
years) whereas a 66mer might not have 
been folded since the ‘big bang’.
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1.5.2. Protein Quality Control 
The assumption that all polypeptides directly fold into their native conformation only holds true for 
some small proteins or in vitro systems. A tendency to aggregate under certain conditions can be 
observed for a wide spectrum of sequences and it has been suggested to be an inherent property of 
polypeptide chains 74. In order to function properly, proteins retain conformational flexibility after 
folding, rendering the native structure only marginally thermodynamically stable 17. To facilitate and 
maintain correct conformation and prevent trapping of 
folding intermediates, cells have evolved a sophisticated 
set of quality control mechanisms. This proteostasis 
network consists of hundreds of proteins. De novo folding, 
refolding, oligomeric assembly, protein trafficking, 
disaggregation and proteolytic digestion is assisted by 
over 200 chaperones and cochaperones. In addition, 
roughly 600 proteins of ubiquitin / proteasome and 
autophagy system are responsible for removing 
misfolded, aggregated or obsolete proteins 17. 
Chaperones assist proteins in a concerted manner to maintain or fold into the native state 75. 
The general principle is to reshape the energy funnel transferring aggregation prone intermediates to 
the native state and to shield them from deleterious interactions 76. Chaperones do not directly 
contribute conformational information and usually do not accelerate folding directly but instead 
promote correct protein folding indirectly by inhibiting competing processes. Chaperone families 
like HSP70 and the chaperonins HSP60 are multimeric molecular machines. They recognize 
hydrophobic sidechains and engage in co-factor and ATP dependent binding and release cycles. The 
first hurdle a polypeptide that belongs to a large domain (for instance 100 to 300 amino acids) faces, 
is that the nascent chain exiting the ribosome will not have all the native intramolecular moieties 
available for correct folding, but instead could favor non-native interactions via exposed hydrophobic 
regions. In eukaryotes, the ribosome-associated complex (RAC) and nascent polypeptide associated 
complex (NAC) are responsible for stabilizing the nascent chain. In prokaryotes, this process is 
facilitated by the trigger factor (TF). Downstream of this initial interaction the polypeptide can 
interact with HSP70s (DnaK in prokaryotes) and the co-chaperone HSP40 (DnaJ in prokaryotes), 
which inhibit premature misfolding. Some proteins require further assistance to fold correctly into 
their native state. This posttranslational process is mediated by chaperonins (HSP60 of mitochondria, 
GroEL in bacteria or TRiC in eukaryotic cytosol). Chaperonins are large double ring complexes that 
act downstream of HSP70s and can enclose translated proteins of up to 60 KDa in a cylindrical cage. 
Intrinsically Disordered Proteins 
Some proteins do not have a defined 
secondary and tertiary structure but 
contain major disordered regions. 
Those flexible interfaces are thought 
to participate in cellular signaling. 
The structural flexibility allows 
conformational adaption to different 
interaction partners but can make 
the protein specifically vulnerable to 
misfolding 16. 
Introduction – Neurodegeneration 
23 
Chaperonins remove entropic and kinetic barriers in the folding path while increasing the energetic 
penalty for misfolding. The confinement provides a defined chemical environment and concentration 
and restricts steric freedom of the unfolded conformation. Complete folding of proteins can require 
multiple cycles of confinement and release, which is triggered by ATP hydrolysis. In contrast to 
HSP60s chaperonins, the TRiC does not require HSP10 (GroES in prokaryotes) and has substantially 
longer cycle times 17. 
After successful folding, the cell has to assure surveillance of proteins. Random structural 
fluctuations in folded proteins or external perturbations, such as heat stress, can expose aggregation 
prone intermediates that can accumulate over time. In such cases, the chaperones shield partially 
unfolded proteins, which provides time for refolding while excluding detrimental effects on other 
proteins 77. Highly abundant chaperones of the HSP90 family act downstream of the HSP70 system 
and assist in final maturation and stabilization of proteins. Among the HSP90 clients are numerous 
proteins involved in signal transduction making HSP90 a proteostasis hub for signaling pathways 17. 
The unfoldase activity of HSP100 chaperones (bacterial ClpB, yeast Hsp104) contributes to refolding 
and degradation 78. 
If the cellular rescue system for misfolded proteins fails, cells need to eliminate these proteins 
(Figure 4). For this purpose different protein clearance pathways have evolved 45. One of these is 
autophagy, by which large aggregates are encapsulated and degraded in lysosomes. A related 
pathway, chaperone assisted autophagy, degrades individual proteins by a chaperone guided 
translocation to the lumen of lysosomes 79. Moreover, the UPS can mediate protein degradation. The 
proteasome is a barrel-shaped protein complex that requires at least a partial unfolding of substrate 
proteins for their degradation. Finally, cells dilute aggregates via cell division 80. 
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1.6. Deterioration of Proteostasis 
When the cellular folding and degradation machinery fails to maintain proteostasis, misfolded 
proteins and protein aggregates accumulate. Many factors promote the decline of the proteostasis 
network. Age decreases the capacity of proteasomal degradation pathways and of autophagy 81,82. 
This inevitably increases the burden of aggregated proteins as shown in the C.elegans and 
D.melanogaster model systems 83-85. A study performed in 2012 further underlined the detrimental 
effects of age related accumulation of misfolded proteins, by showing that knockdowns of 
aggregation prone proteins in C.elegans can result in increased lifespan 86. Several studies link 
impaired autophagy to the reduced capacity to clear aggregates, eventually leading to 
neurodegeneration 87-90. Moreover, aggregates themselves have been suggested to compromise 
proteostasis resulting in a “viscous circle” of aggregates and impaired protein folding 37. 
Besides impaired cellular capacity to degrade and clear misfolded proteins, other factors 
contribute to accumulation of aggregated proteins. Remarkably, in some instances point mutations 
are sufficient to induce protein aggregation. This was demonstrated, for instance, for systemic 
amyloidosis, transthyretin amyloid pathologies and a luciferase aggregation sensor 91-93. Moreover, 
the local environment affects protein conformation. Dialysis associated amyloidosis is a pathology 
in which very high protein concentrations and an altered environment by themselves change the 
aggregation propensity of the plasma protein beta-2-microglobulin (B2m) 94. This is not surprising 
considering that the aggregation process is a higher order reaction and therefore concentration 
dependent, as the initial crystallization enthalpy needs to outweigh the entropic penalty 95. Finally, 
chemical modifications, heat and cold stress can induce protein misfolding 96,97.  
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Figure 3 Protein life-cycle: Proteostasis is maintained by various cellular machineries. Misfolded proteins are 
rescued by chaperones or degraded via the ubiquitin proteasome system. Very large aggregates cannot be 
degraded in the proteasome and are decomposed by autophagy instead. Failure of the proteostasis system 
can lead to the accumulation of harmful misfolded proteins and is a general feature of neurodegeneration 
(adapted 37). 
1.6.1. Misfolded Proteins 
Proteostasis deficiency and formation of protein aggregates are associated with many diseases like 
type 2 diabetes, peripheral amyloidosis, lysosomal storage disease, cancer, cystic fibrosis and 
cardiovascular disease. However their most prominent role is in neurodegeneration 17. Aggregates 
differ with regard to their localization within or outside the cell and their structural properties. Many 
aggregates form ordered amyloid fibrils of 6 to 10 nm with cross-β structure, in nucleation dependent 
polymerization 98-101. In addition to highly ordered amyloid-sheets, amorphous aggregates can be 
observed. Beside these insoluble inclusion, misfolded proteins can also form soluble oligomers. 
Whether proteins adapt amyloid, amorphous or oligomeric structures depends on the amino acid 
sequence and the chemical and physical context 96. 
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Protein misfolding has a negative effect on cell viability 37. Whether this is caused by toxicity of large 
aggregates or oligomeric intermediates is controversial and may depend on the circumstances 101,102. 
Compared to oligomers large aggregates have a relative small surface to mass ratio and thereby a 
small interface to the cell. Therefore, creating very large aggregates can be an effective way to reduce 
the exposure of misfolded proteins. However, the reduced interface also compromises accessibility 
for the cellular clearance machinery. In sum, the toxicity of soluble oligomers seems to be higher 
than that of large aggregates 37,103. Many mechanisms have been proposed by which protein 
aggregates and oligomers mediate toxicity. In contrast to ‘loss of function’ by removal of the 
aggregating protein itself, ‘gain of function toxicity’ can induce toxicity via multiple routes. For 
instance, aggregated proteins might cause inflammation, deteriorate membrane integrity and 
compartmentalization, gradually compromise the proteostasis machinery or sequester essential 
cellular factors into the aggregate 35,104,105. 
1.6.2. Poly Glutamine Toxicity 
Despite the general capacity to misfold, some sequence features such as polyQ stretches render 
proteins specifically aggregation prone. Several inherited polyQ associated pathologies are known: 
SCA type 1, 2, 3, 6, 7 and 17, dentatorubal-dallidoluysian, spinobulbar muscle atrophy and HD 106. 
Among these nine, HD is the most prominent one. HD is a neurodegenerative disorder that impairs 
motorcontrol, causes behavioral changes and mental decline. In HD patients, the expansion of a CAG 
repeat in exon 1 of the huntingtin gene translates to an aggregation prone and toxic protein containing 
an elongated polyQ stretch 107. Normal alleles of HTT usually contain 16 to 20 repeats, while more 
than 35 repeats are associated with high penetrance of HD 106. The elongated polyQ stretch in HD 
leads to the deposition of aggregated htt in the cytosol and nucleus. These aggregates are β-sheet 
rich, highly ordered amyloid fibers that interact with hundreds of proteins 108,109. The sequestration 
of many different proteins could explain why HD, despite being a monogenetic disease, causes a 
wide set of cellular dysfunctions, like transcriptional dysregulation, impaired protein degradation, 
mitochondrial dysfunction, disrupted neuronal signaling and impaired protein folding 106. HTT is not 
only relevant from a pathological point of view but offers a good model to study the effects of toxic 
protein aggregates. Chaperones such as HSP70 and TRiC can specifically block formation of 
fibrillary amyloid HTT aggregates in yeast. HSP70 seems to interfere with initial nucleation, 
allowing TRiC binding formation of less toxic amorphous HTT aggregates 110,111.  
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1.6.3. ‘Contagious’ Protein Misfolding in Prion Diseases 
The central role of protein misfolding in neurodegeneration is underlined by transmissible prion 
disorders. Prion-disorders share many characteristics with other NDs including brain vacuolation, 
astrogliosis, spreading neuronal death and protein aggregation 112. However, they differ by being 
transmissible and are referred to as transmissible spongiform encephalopathies (TSEs). This 
transmission was observed in nature and can be performed in vitro across some species. Vectors for 
the misfolding information is the prion protein PrPSC that amplify this information in an autocatalytic 
fashion (Figure 5). The paradigm example of a TSE is bovine spongiform encephalopathy (BSE) and 
its associated human pathology, the variant Creutzfeldt-Jakob disease (vCJD) 113,114. Other prominent 
prion diseases are Scrapie in sheeps and Kuru in humans. Kuru was mainly transmitted via 
cannibalism in the highlands of Papua New Guinea 115.  
Prions are epigenetic elements in that they can carry and store information without directly 
using nucleic acids. Prions can exist in different strains, outcompete each other during propagation 
and thereby undergo natural selection 116-118. Instead of always being toxic, such a system of 
replicating information could potentially be employed functionally by the cell. In yeast, many 
proteins have been annotated as potential prions 119, 
for instance, the [PSI+], which is a prion form of the 
translational release factor SUP35. Although [PSI+] 
is almost exclusive to yeast lab strains, positive 
effects mediated by this prion have been suggested. 
The prion conversion to [PSI+] causes a certain 
degree of read-through capacity during translation 
that compensates nonsense codon mutations and can 
result in C-terminal elongated proteins 120. Article 3 
shows a paradigm example of how prions in yeast 
help the cell to survive proteostasis stress by 
associating with otherwise toxic aggregates. 
Intriguingly, many proteins on higher organism also 
have prion like domains 121. 
Figure 4 (Auto)catalytic propagation of prions: 
Prions can propagate and amplify folding 
information. Their high physical and chemical 
resistance is probably one of the reason for the 
contagiousness of prion-associated pathologies 
like Kuru or BSE.  
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1.7. Central Role of the Proteome 
Impaired proteostasis is the cardinal feature of NDs. Knowledge about the proteome and its 
pathological disturbance before and during neurodegeneration might therefore be one of the most 
promising steps in understanding NDs and in providing a rational basis for prevention, early diagnose 
and treatment. However, analysis of the proteome is exceptionally challenging because it is made up 
of thousands of proteins with vastly different abundances and diverse chemical properties. 
Furthermore, proteins cannot be amplified like oligonucleotides. However, mass spectrometry (MS) 
is potentially a universal and extremely specific detection technology for proteins. Recent 
improvements in MS and associated proteomics technologies now provide a novel tool set for a 
comprehensive and unbiased view on diseases such as neurodegeneration as will be explained in the 
chapters below. 
Unraveling the Identity of Prions 
In the 1960s an unusual high resistance to irradiation and ionization and very small size of the pathological 
agent in Scrapie suggested a so far unknown pathological entity 3,4. In 1967, Griffith suggested an 
autocatalytic replication mechanism for a toxic protein 9. Such a protein was termed prion (proteinaceous 
infectious particle (Greek on = 'being')) by Stanley Prusiner five years later 19. This protein hypothesis was 
substantiated by showing that affinity enrichment of the prion protein (PrP) allows isolation of the 
transmissible agent 20. In 1993 Brueler et al. demonstrated that mice lacking the PrP gene are resistant to 
Scrapie infection in contrast to the wild type. However, it took another 14 years to finally prove the 
“protein only” hypothesis by de novo generation of infectious prions converting native PrPC to the toxic 
PrPSC 22. 
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2. Quantitative Mass Spectrometry
Based Proteomics 
“…the constantly evolving gravimetric balance has been a faithful servant of the laboratory 
chemist and has played a major role in developing the analytical methods that are the foundation 
of contemporary chemical science. Perhaps the ultimate stage in the evolution of that balance is 
represented by the modern mass spectrometer. It is able to determine with high precision the 
masses of individual atoms and molecules by transforming them into ions and measuring the 
response of their trajectories in vacuo to various combinations of electric and magnetic fields.” 
John B. Fenn 2002 Nobel Laureate in Chemistry 122 
The central dogma of molecular biology states that the information is passed from DNA to RNA and 
is finally translated into proteins. Although there are exceptions to this unidirectional path, in most 
cases proteins are the functional entities in cells, working as enzymes, carriers or structural elements. 
The analysis of proteins has always been challenging due to their complex chemical nature and the 
absence of amplification procedures. Determining the mass of proteins using a mass spectrometer 
(MS) is one way to characterize them. Efficient ionization is a prerequisite for MS analysis. For 
decades, the fragile nature of proteins was not compatible with existing ionization techniques. In the 
late 80s, two gentle ionization techniques, electrospray ionization (ESI) and Matrix-assisted laser 
desorption / ionization (MALDI), paved the way to finally analyze proteins 123,124. These technologies 
earned the Nobel Prize and proved to be the nuclei for the emerging field of proteomics. One of the 
advantages of ESI compared to MALDI is that proteins or peptides are ionized from the liquid phase. 
Therefore, ESI can be directly coupled to liquid chromatography and allows the analysis of complex 
protein and peptide mixture 125,126. 
By far the most common way used to analyze complex protein mixtures is the bottom up 
approach (shotgun proteomics). Shotgun proteomics uses enzymes to digest proteins into specific 
peptides, which are then individually analyzed. Subsequently, downstream bioinformatics analysis 
reassembles the proteins from these peptides. In contrast, top-down proteomics subjects complete 
proteins to MS analysis. This has the advantage in principle that the entire protein with its specific 
combination of processing and modification events is analyzed together. This can be beneficial for 
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investigating isoforms or posttranslational modifications (PTMs) but is so far mainly limited to 
purified proteins. This is because the chromatographic separation is much more challenging and high 
molecular weight and complex charge patterns of the molecules make the MS spectra more difficult 
to obtain and to interpret 127. 
 
2.1. The Proteome 
With slightly more than 20,000 genes, H. sapiens is placed half way between G.gallus (chicken) and 
V.vinifera (grape) in terms of genome size 128. It is apparent that the number of genes is not indicative 
for the “complexity” of these organisms. Moreover, each cell within an organism contains the same 
set of genes but can show a completely different functionality. Physiological differences therefore 
have to originate from regulation of these genes, their translation into proteins, modification, 
localization and complex formation of these proteins. How many proteins individual human cells 
express at any time point is cell type specific and can exceed 10,000 129. Taking into account PTMs 
and splice variants increases the complexity of the proteome dramatically 130,131. With MS based 
proteomics, different layers of proteomes can be characterized. Conceptually most straightforward is 
the investigation of complete proteomes of cells or tissues. Such studies aim for high depth (>10,000 
proteins) to characterize the complete system 132,133. Biological functions that involve protein-protein 
interactions, substoichometric protein modifications or specific cellular localizations, cannot be 
addressed with a complete proteome approach. In such cases, isolation and enrichment strategies are 
employed during sample preparation. Examples for subproteomes are protein aggregates 
characterized in article 2 and 3, the class of plasma membrane proteins such as receptors, secreted 
proteins, vesicular proteins or class of proteins bearing specific PTMs 134-137.  
 
2.2. Interaction Proteomics 
Many proteins mediate their functions by interaction with other proteins, forming stable complexes 
or engaging in transient interactions. To study these interactions, classically proteins were isolated 
via affinity purification and interacting proteins were detected using Western Blots techniques. This 
targeted approach requires prior hypotheses to test for suspected interacting proteins and is only 
semi-quantitative. Common technologies like yeast two hybrid and affinity purification coupled to 
MS (AP-MS) have paved the way to high-throughput screening 138,139. Initially, low resolution MS 
only allowed to identify but not quantify proteins. Therefore, sample preparation had to be 
sufficiently stringent to avoid background binding of proteins, which could compromise proper 
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identification of prey proteins. The increasing availability of quantitative MS facilitated a new 
strategy that reveals protein-protein interactions by quantitative enrichment 140. With a quantitative 
readout, proteins binding nonspecifically can be discriminated from preys and used as internal control 
in form of stable background. This allows affinity enrichment instead of (harsh) purification and 
offers benefits such as preservation of near physiological conditions and the detection of weak 
interactors 141. In article 2 and 3 we employed such an approach to quantify proteins interacting with 
insoluble ALS associated aggregates in primary neurons and the huntingtin interactome in yeast. 
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2.3. From Cells to Proteomes 
2.3.1. Sample Preparation 
Shotgun proteomics requires the proteolytic digestion of proteins to peptides and the removal of any 
agents that are incompatible with MS. Over the years, many different lysis, enrichment and 
fractionation protocols have been developed. Currently, there is not one approach, which fits all 
purposes and the decision which method to select depends on criteria including the amount of 
material, the source (tissue, cell culture), the biological question or the quantification method to be 
employed. In the following, the major steps in sample preparation are described. 
Figure 5 Workflow of an in solution sample preparation: Proteins are isolated or enriched from biological 
sources. In order to breakdown the cells or tissue environment and to solubilize the proteins, mechanical forces 
(for instance sonication), increased temperature and chemical agents (detergents or chaotropic agents) are 
used. Reduction and alkylation may be followed by removal of unwanted buffer components (detergents) and 
the proteins are enzymatically digested. Resulting peptides are desalted and subjected to the liquid 
chromatography coupled MS analysis. 
Lysis: The purpose of lysing the biological material is to efficiently extract proteins. Depending on 
the biological question of the study, either the native state is preserved by using physiological buffers 
with mild detergents such as 1 % NP-40 (for instance for subsequent immunoprecipitation) or all 
proteins are denatured (complete proteome analysis). The latter approach employs harsh detergence 
(e.g. 4 % SDS or triton) or chaotropic agents (high molar urea or guanidinium chloride) to denature 
all proteins and dissolve the lipids. Mechanical breakdown steps such as sonication, bead-milling, 
rotor stator, blending and heating of the sample often accompany lysis (note however that heating 
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promotes decomposition of urea and carbamidomethylation of amines). During native lysis, protease 
inhibitors are often used to avoid premature proteolysis.  
Reduction and alkylation: Disulfide bonds and oxidation of cysteins to sulfenic acid, sulfinic 
acid and cysteic acid expands the number of peptide forms to be considered during analysis. This can 
be avoided by reducing cysteins with DTT or TCEP and then alkylating them either during or after 
lysis. Commonly used alkylation agents are 2-iodoacetamide (IAA) and 2-chloroacetamide (CAA). 
While the kinetic for IAA is faster, CAA is less prone to alkylate amines at lysine and arginine 
residues. Depending on the proteases used, the alkylation agent should either be removed or 
quenched.  
Sample cleanup: Most detergents need to be removed before proteolytic digestion. In 
addition, most detergents are incompatible with MS analysis, as they coelute with peptides, ionize 
very well in electrospray and thereby obscure ionization. Acetone or ethanol precipitation of the 
proteins or membrane based cleanup (FASP) 142 can be employed if the protein amount is in the low 
microgram range or higher. For the sub-microgram scale, it is usually advisable to either use MS 
compatible detergents or chaotropic agents for lysis and to omit the sample cleanup.  
Digestion: The most characteristic step of bottom-up 
shotgun proteomics is the enzymatic digestion of the proteins to 
peptides. Trypsin is the most common protease in proteomics 
(see box) but often the lysine specific enzyme LysC is used as 
well. LysC is active at 8 M urea and has a higher efficiency than 
trypsin in cleaving C-terminal to lysine. The sequential use of 
both enzymes allows the digestion at strongly denaturing 
condition. This facilitates enzymatic breakdown of tightly 
folded proteins 143. To maximize sequence coverage (with the 
penalty of increasing complexity) a separate digest of LysC and 
trypsin can be performed and peptides can be mixed prior to 
analysis. Protease activities can be quenched by low pH. In 
addition to LysC and trypsin, other enzymes can be employed 
in shotgun proteomics such as chymotrypsin (C-terminal to 
aromatic residues) or GluC-D (C-terminal to aspartate and 
glutamate) to increase the peptide coverage of the proteins or to 
generate peptides with different properties 144. Before peptides 
are separated by liquid chromatography (LC) a salt removal and 
filtering step is performed, based on the principle of solid phase 
extraction. This also allows fractionation, if desired 145. 
The “Gold Standard” Trypsin 
Trypsin digestion offers many 
advantages in shotgun pro-
teomics. (1) It specifically 
cleaves C-terminal to arginine 
and lysine (if not followed by 
proline). Under acidic 
conditions, this leaves every 
peptide with at least two 
positive charges (at their 
N-terminus and side chain of the 
terminal residue). The additional 
charge allows peptide 
discrimination from usually 
single charged non-peptide 
contaminants such as polymers. 
(2) The stability of trypsin 
suppresses auto-digestion and 
allows the proteolysis to take 
place under mild denaturing 
condition. (3) The distribution of 
lysine and arginine in proteomes 
generates on average ten amino 
acid long peptides. Peptides 
with this length have a high 
chance of uniqueness and are 
suitable for high resolution 
analysis in commonly used mass 
analyzers 8. 
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2.3.2. Chromatography 
After digestion, complex proteome samples contain more than 100,000 unique peptides 132,146. This 
peptide complexity cannot be resolved directly in the MS but needs to be separated 
chromatograpically. This employs the affinity of the analyte (e.g. peptides) to a stationary phase and 
gradual elution by increasing solubility in a mobile phase. The affinity principle is based either on 
the coulomb interactions or hydrophobic interaction. Most MS used in shotgun proteomics work in 
the positive mode, which means that positively charged 
peptides are analyzed. At low pH peptides have a high 
affinity to C18-silica in aqueous solutions and can be 
separated over time by increasing the organic content (e.g. 
acetonitrile) of the mobile phase. 
Chromatography is a critical part of the shotgun 
proteomics workflow. Reproducible elution profiles and 
efficient peptide separation have significant impact on the 
data quality. Downstream bioinformatics analysis attempts 
to match peptides to each other by their retention times and 
therefore relies on highly reproducible chromatography 
(see chapter 2.7). Koch et al. reported an almost linear 
relation between the number of peptide identifications and 
the resolving power 147. The resolving power can be 
optimized in different ways. Column length: Longer 
columns allow for more interactions between the analytes 
and the stationary phase (more plates), which in turn 
increases the resolution 148. Column diameter: A smaller 
inner diameter increases chromatographic resolution by 
reducing the number of flow paths (eddy diffusion). 
However, a smaller inner diameter will inevitably increase 
the backpressure 148. Column filling: Smaller and more 
uniform particles as filling material reduce eddy diffusion 
and the negative effect of mass transfer. Gradient length: 
Longer gradients increase the resolution but can also cause 
peak broadening and consequently reduction of the ion 
current due to dilution. Both these negative effects can be 
compensated with higher flow rates, which however, leads 
Resolving Power 
A central parameter of chro-
matography is the resolving power 
(peak capacity) or simply the number 
of peaks that can be separated from 
each other in the gradient. The 
resolving power is determined by the 
number of theoretical plates (Nt), 
which is the number of interfaces 
between the two phases where 
exchange of the analytes takes place. 
The plate number is proportional to 
the column length (H) and inversely 
proportional to the height equivalent 
to a theoretical plate (HETP), which is 
given by the Deemeter equation 12 
𝑁𝑡 =
𝐻
𝐻𝐸𝑇𝑃
𝐻𝐸𝑇𝑃 = 𝐴 +  
𝐵
𝑢
+ 𝐶𝑢 
A is the eddy diffusion, which is the 
variation of analyte channeling speed 
in the column caused by in-
homogeneous column packing. B 
describes the dispersion by random 
diffusion of the analytes. The slower 
the flow rate u the longer this 
diffusion can take place, leading to 
increased peak broadening. C is the 
mass transfer between the stationary 
phase and the mobile phases. Ideally, 
this transfer is in equilibrium at any 
time and the exchange is fast enough 
to not cause peak broadening by 
retention of the fraction bound to the 
stationary phase 21. 
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to higher backpressure and reduces ionization efficiency 149. For many years, backpressure was the 
bottleneck for further improvements of chromatography. With the introduction of new ultrahigh 
pressure HPLC (up to 1,000 bar) and column heating devices, chromatographic performance has 
significantly improved 147,150,151. 
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2.3.3. The Leap of Charges – Electrospray Ionization 
In the 1980s, two new soft ionization techniques paved the way for MS based 
proteomics – electrospray ionization (ESI) and matrix assisted laser desorption ionization (MALDI). 
ESI is by far the most commonly employed ionization method in proteomics and is based on 
electrostatic dispersion and desolvation 124,152. A kilovolt potential is applied between the tip of the 
chromatographic column and the inlet orifice of the MS. In the positive mode, the column tip supplies 
the positive charge and tryptic peptides usually carry two or more 
protons. The solvent of the emitted analytes evaporates, increasing 
the positive charge density until the electrostatic repulsion releases 
charged analytes (coulomb explosion at the Rayleigh limit), 
ultimately transferring single peptide ions into the gas phase. ESI 
usually results in multiple charged peptide ions with roughly one 
charge per kDa. Therefore, even large masses can be recorded in a 
relatively narrow 𝑚 𝑧⁄  range 
153.
Two principle models are used to explain the generation of gas-phase ions. The ion evaporation 
model suggests that the increase in charge density at the surface cause jet-like ion desorption. The 
second model (charge residue model) postulates evaporation and fission cycles of the droplets until 
single desolvated analytes remain 154. These processes are not mutually exclusive. A growing body 
of evidence suggests that large molecules are released according to the charge residue model whereas 
smaller ions are released into gas-phase via ion evaporation 155. 
Figure 7 Gentle ionization techniques MALDI and ESI: In ESI ions are transferred into 
the gas phase by desolvation from electrically charged droplets. ESI can easily be 
coupled to liquid chromatography, which is very useful for the analysis of complex 
samples. MALDI is the other gentle ionization technique. It uses a pulsed laser to 
evaporate analytes incorporated into a matrix. MALDI primarily generates singly 
charged peptides. Compared to ESI, MALDI is more robust with respect to buffer 
conditions 10. 
Mass and Charge 
In a MS individual 𝑚 𝑧⁄  are
determined (see chapter 
2.24). From spacing of the 
isotope pattern the charge 
and mass can be 
calculated. 
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2.4. The Mass Spectrometer 
2.4.1. Mass Analyzer 
In proteomics different types of mass analyzers are employed (Figure 8). Two groups of mass 
analyzer can be distinguished. The trap based mass analyzers include 3D and 2D ion traps (linear ion 
trap quadrupole, LTQ), Fourier transform ion cyclotrons (FTICR) and the Orbitrap analyzer. The 
beam based mass analyzer are made up of the triple quadrupole and time of flight (TOF) instruments. 
In proteomic practice, hybrid mass spectrometer contain elements of each group. They consist of 
different segments for ion guidance, selection, fragmentation and detection, combining the strength 
of the individual technologies. The ion optics that enable ion guidance and the mass analyzers 
themselves rely on a set of physical principles that govern ion motion. The following parameters are 
used to describe the performance of mass analyzer. 
Mass resolution: High mass resolution allows to distinguish two peaks with very similar 𝑚 𝑧⁄ .
This is very important for both the mass accuracy and the quantification as it is necessary to 
sufficiently resolve the contributing components 156. The resolution is defined as the ratio between 
the 𝑚 𝑧⁄  of a peak and the delta 
𝑚
𝑧⁄  at the full width half maximum (FWHM) and is therefore a
dimensionless quantity 157. It varies between mass analyzers and is 𝑚 𝑧⁄  dependent for some of them.
In proteomics ‘high resolution’ usually refers to > 10,000  and has now become standard in the 
field 158. Mass accuracy: The molecular mass is the sum of the atomic masses. The exact mass 
measured by MS for each isotope is different from the chemical mass where the abundance weighted 
average isotope masses are used. The mass accuracy refers to the deviation between the theoretical 
mass and the experimentally determined mass and is expressed as the mass error in parts per million 
or billion (ppm, ppb). The mass accuracy depends on many parameters such as the resolution and 
signal to noise ratio 156. Systematic mass errors can be corrected by internal and external 
calibrations 159. In proteomics, unambiguously identified peptides can serve as internal calibration 
points 160. The dynamic range of an instrument is an important parameter as it indicates how well 
the mass analyzer detects low abundant ions in a mixture with very high abundant ions. Especially 
in very complex biological samples, the abundance differences of proteins is many orders of 
magnitude. Scan speed: This parameter describes how fast a certain 𝑚 𝑧⁄  range can be monitored
and for many instrument types, is roughly inversely correlated with the resolution. Sensitivity: The 
detection limit of a mass analyzer depends on the principle of detection and in the proteomic context, 
also on the sample complexity and therefore dynamic range. 
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Figure 6 Commonly used Mass Analyzers: Mass analyzer can be classified into beam type and trap type 
analyzers. TOF, FTICR and Orbitrap analyzers are usually referred to as high-resolution analyzers. The 
underlying technologies have various advantages for mass spectrometric applications (adapted 161,162). 
Different 𝑚 𝑧⁄  are discriminated via their trajectory. This is achieved by changing electrical fields (radio
frequency current (RF) and direct current (DC)) for Quadrupole and Linear Ion Trap, electrostatic fields for 
Orbitraps and TOFs or magnetic fields (B) and RF for the FTICR. A more detailed description of these 
technologies is provided in the following chapters. Parameters are provide for general guidance only.  
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2.4.2. Beam Type Mass Analyzers 
One of the oldest beam type mass analyzer combines the mass selection capacity of a quadrupole 
mass filter with an ion detection unit such as electron multiplier. The quadrupole consists of four 
parallel rods with two opposing rods having a positive and the other two rods having a negative 
potential on which a time dependent radio frequency 
potential (RF) is superimposed. The motion of ions in this 
quadrupole field is governed by the Mathieu equation, a 
second order differential equation derived from the 
Lorentz Force and Newton’s Law for this electrical field. 
The Mathieu equation features two parameters a and q, 
characterizing the amplitude of direct current (DC) and RF 
voltage, respectively. Plotting a against q provides a 
stability diagram for 𝑚 𝑧⁄ . While unselective ion guidance
can be achieved with a = 0 (RF only mode), 𝑎 ≠  0 is used 
to stabilize a specific  𝑚 𝑧⁄  range.
The second beam type instrument is the time of 
flight mass analyzer. Unlike the quadrupole, which 
separates different 𝑚 𝑧⁄  by path-stability, the TOF
separates 𝑚 𝑧⁄  by velocities in a field-free drift tube. Ions
are accelerated in an electric field providing ions of the 
same charge the same kinetic energy. Because this kinetic 
energy is determined by mass and velocity, the arrival 
times of ions increases with mass. Generally, the longer 
the drift field and the faster the detector, the better the 
resolution that can be achieved in a TOF. In addition, the 
spatial and energetic drift can be reduced by electrostatic 
mirrors pushing state of the art TOFs to medium or high 
resolution performance (>30,000) 163. 
Ion Motion 
From the ionization source (ESI or 
MALDI) charged peptides are 
introduced into the MS. Two physical 
principles govern ion motion. The 
Lorentz force and Newton’s second 
law. In an electric and / or magnetic 
field the force ?⃑? a charged particle 
experiences is determined by 
?⃑? = 𝑧(?⃑? + ?⃑? × ?⃑⃑?)
Where z is the electric charge of the 
particle that experiences the electric 
field ?⃑? as well as the vector-cross 
product of the velocity ?⃑? and the 
magnetic field ?⃑⃑?. The acceleration ?⃑? 
is given by 
?⃑? = 𝑚 ∗ ?⃑? 
and the trajectory of ions therefore 
depends on the mass-over-charge 
ratio 𝑚 𝑧⁄ .
?⃑? =
(?⃑? + ?⃑? × ?⃑⃑? )
𝑚
𝑧⁄
The 𝑚 𝑧⁄  dependency allows to
selectively manipulate trajectories of 
ion species applying specific electric 
or magnetic field combinations.
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2.4.3. Trap Type Mass Analyzer 
In contrast to beam type analyzers, ion traps can store and accumulate ions over a period of time. A 
3D ion trap conceived in 1953 by Paul and Steinwedel was a basis for MS based proteomics for many 
years. The 3D ion trap consists of three electrodes, a hyperbolic ring electrode and two end-cap 
electrodes. Ions entering this trap are slowed down by collisional cooling with an inert gas and are 
confined in a 3-dimensional quadrupole field created by a time varying potential applied to the end 
caps (RF) 164-166. The 3D ion trap was superseded by the 2D ion trap, which stores ions in two 
dimensions along the z-axis of a quadrupole. The 2D ion trap is very similar to the quadrupole mass 
filter but it contains the ions by DC potentials at its entrance and exit (Figure 8). The different 
geometry of a 2D trap offers a longer trapping path, which increases ion-storage capacity more than 
tenfold. Decreased space charge effects in 2D ion traps lead to higher resolution and mass 
accuracy 167-169. 
Typically, a 2D ion trap is employed for ion accumulation and storage in hybrid mass 
spectrometers, whereas its use as stand alone mass analyzer is compromised by relatively low 
resolution and mass accuracy. The breakthrough for high-resolution mass analyzers in proteomics 
was achieved with the introduction of the hybrid linear ion trap – FTICR. In the LTQ FT the linear 
ion trap is coupled to an ion cyclotron resonance (ICR) cell, which confines ions in a static electric 
field along the axial dimension and forces ions on an orbital trajectory with a strong magnetic field 
(typically 7 T or more). From this periodic rotation, the 𝑚 𝑧⁄  value is determined. Although the 
FTICR features very high resolution, it is very bulky, expensive and has a relatively low ion storage 
capacity. In proteomics, most of these limitations were addressed by exchanging the ICR with the 
introduction of hybrid Orbitrap mass analyzers. 
 
The Orbitrap Analyzer 
In 2000 a novel mass analyzer, the Orbitrap, was introduced by Makarov 170,171. This ion trap is 
derived from a simple design by Kingdon 172 and features dynamic trapping in an electrostatic field 
(not using any RF field in contrast to the quadrupoles or 3D or 2D ion traps) around a cone shaped 
electrode (Figure 9). The electrostatic field generates a quadro-logarithmic potential distribution and 
is composed of a quadrupole field generated by the ion trap outer barrel-like electrodes and the field 
of the spindle-like inner electrode 171. The axial field strength is zero at the spindle equator and 
gradually increases towards the outside. Ions are injected off-center and circulate around the central 
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electrode on stable trajectories and oscillate harmonically along the z-axis 13. The frequency of only 
the z-axis oscillation is completely independent of initial variables such as initial ion velocity and 
position and it is inversely proportional to √𝑚 𝑧⁄  
171. Injection within a time interval that is small in
relation to the oscillation frequency forces ions of the same 𝑚 𝑧⁄  to oscillate along the z-axis in phase
for hundreds of thousands of periods shaping a thin ion ring orthogonal to z after radial dephasing 
(20-100 µs) 13,159,173.  
Radial and rotational motions induced image 
currents cancel each other due to the symmetric shape of 
the ion ring 173. Meanwhile the axial oscillation of the ion 
ring from one-half of the outer electrode to the other 
induces opposing currents in the outer electrodes, which 
are composed of two electrically separated halves. In 
contrast to 2D and 3D ion traps, which detect ions 
sequentially, the Orbitrap therefore records an alternating 
image current induced in the outer electrode by all trapped 
ions over a certain time (transient time) 174.  
To deconvolute the information of all m/z in the Orbitrap, a Fourier transformation (FT) is 
applied. FT is a set of mathematical operations to approximate complex periodic functions (= signals) 
as an overlay of different sinusoid functions. The periodic nature of the monitored image current 
dictates the dependence of the resolution on the number of oscillations along the z-axis and therefore 
on 𝑚 𝑧⁄  
157,171,174. Compared to FTICR, the resolution in an Orbitrap analyzer decays with √𝑚 𝑧⁄
rather than with 𝑚 𝑧⁄  
156.
The maximum resolution in an Orbitrap is also affected by other factors. First, the time of the 
transient is limited by dephasing of the z-axis oscillation of the individual ions in the Orbitrap. 
Dephasing is promoted by space charge effects, imperfection in the electrostatic field and collision 
with other molecules. The latter makes dephasing dependent on the size of the molecule 159. All these 
factors contribute to axial broadening of the ion ring, which ultimately cancels out the image 
current 173. In current systems, an image current in the Orbitrap becomes indistinguishable from noise 
after one second 156.  
During a transient newly arriving ions cannot be analyzed. Therefore, long transients increase 
the chance to miss ions in complex mixtures. Because the resolution in an Orbitrap is inversely 
proportional to the speed of the instrument, one might choose a lower resolution for complex 
mixtures to detect and sequence more peptides eluting in a narrow time window 15. 
Detection Limit of the Orbitrap 
The image current detection of the 
Orbitrap initially had a noise-band 
equivalent to 20 ions at 1 s 
transients, which is less sensitive 
than the theoretical single ion 
detection capability of electron 
multipliers 13. However, a proof of 
principle study published in 2009 
showed single ion detection capacity 
of the Orbitrap for highly charged 
and purified ions 15. 
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Over the years Orbitrap performance has significantly improved by the development of enhanced 
Fourier transformation (eFT) and by implementing a smaller, high-field Orbitrap analyzer 175. The 
eFT takes phase information into account, which provides a roughly two fold increase in resolution 
for the same transient length 176. The smaller dimension and stronger electrostatic field of the high 
field Orbitrap analyzer increase the oscillation frequencies of ions and allows to boost either the 
speed or resolution roughly by a factor two. 
 
 
 
 
 
 
Figure 7 Orbitrap mass analyzer: This analyzer records the axial oscillation 
of trapped ions. The number of oscillations is directly proportional to the 
resolution. This frequency depends on the instruments parameters (k) and 
decreases with the square root of 𝑚 𝑧⁄ . The recorded image current 
contains the overlay induced image currents of all 𝑚 𝑧⁄  species in the 
Orbitrap. Signals for individual 𝑚 𝑧⁄  are extracted via enhanced Fourier 
Transformation 156. 
 
2.4.4. Ion Fragmentation 
Another central feature of modern hybrid MS is their ion fragmentation capability. Fragmentation of 
ions and determination of the fragment masses provides an additional layer of information beside the 
mass of the precursor ion, which is extracted from the mass spectra or MS1 spectra. The identification 
of proteins via their proteolytic peptides can be based on the MS1 (parent-ion mass) information 
alone, which is called “peptide fingerprinting”. However, this approach is accurate only for isolated 
proteins or simple protein mixtures and clearly not suitable for analyzing complex protein mixtures. 
This is because many peptides of different sequence have very similar masses and peptides with the 
same amino acid composition but different primary structure are indistinguishable even in principle 
by this approach. To increase the information on the sequence of individual peptides, mass 
spectrometric fragmentation is employed (this is termed MS/MS or MS2). Peptides of interest are 
isolated within a narrow window around the desired 𝑚 𝑧⁄ , are subjected to fragmentation and these 
fragments are measured in a subsequent mass spectrum 177,178. 
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A common fragmentation principle is to induce dissociation of the peptides by collision with an inert 
gas such as He or N2. In this process, the kinetic energy is partially converted into internal energy, 
which eventually breaks the chemical bonds (Figure 10). The collisional energy required for efficient 
fragmentation depends on peptide mass and charge state. Two commonly used fragmentation 
methods, higher energy C-trap dissociation (HCD) and collision-induced dissociation (CID), 
preferentially fragment peptides at the amide bond to series of b-and y-ions, the N- or C-terminus, 
respectively. If complete, each of those would independently provide the complete sequence 
information 179.  
Although HCD and ion trap CID are related, they have conceptual differences 180. When CID 
is performed in an ion trap, the parent ions are resonance-excited and fragmented. Due to activation 
of only a specific 𝑚 𝑧⁄ , further fragmentation of the fragments is rare. Fragmentation in the ion trap
is fast and efficient but can suffer from a predominance of only the lowest energy fragment as well 
as from its low-mass cutoff 181,182. This low-mass cutoff is due to unstable trajectories of fragments 
with less than 1/3 of the precursor 𝑚 𝑧⁄  
183. In contrast, HCD, which is very similar to triple
quadrupole CID, takes place in an RF multipole, which does not activate ions via resonance excitation 
but fragments via a beam type collision, allowing even very small fragments to be observed. HCD 
also often entails further fragmentation of the fragment ions, which can complicate spectra but also 
Figure 8 Fragmentation spectrum of a peptide: A typical HCD fragmentation spectrum shows the b-and 
y-ions series of the peptide. While the y-ion series is almost complete, only some b-ions were identified 
for this peptide. Higher coverage of the y-ions is characteristic for HCD. The cleaved bonds for y-ions 
(red) b-ions (blue) as well as for z- and c-ion (grey) which are generated in ECD / ETD fragmentation are 
shown in the lower panel. 
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help provide additional sequence information. For these reasons, the chemically less stable b-ions 
are often further fragmented, leading to prominent y-ion series in HCD 177,180. While ion trap CID 
fragmentation spectra are usually recorded at low resolution and low mass accuracy, HCD usually 
features high resolution and high mass accuracy analysis of the fragment ions in the Orbitrap 177,179. 
Apart from HCD and CID, several other fragmentation principles are used in mass 
spectrometry. A common orthogonal approach is the activation of peptides with electrons. Both 
electron capture dissociation (ECD), which is employed in FTICR instruments and electron transfer 
dissociation (ETD), which is used with ion traps, are based on this principle. In ECD peptides are 
directly bombarded with electrons while radical anions are used as electron carrier in ETD. Both 
methods break the N-C bond and generate series of c-and z-ions 184,185. ETD and ECD have 
advantages in the analysis of intact protein and of peptides carrying PTMs where it is desirable to 
avoid fragmentation of weak bonds 186. The orthogonality of ETD / ECD compared to CID / HCD 
can be very useful to increase the information about the parent ion, a critical aspect in some 
proteomics approaches such as de novo sequencing of peptides. HCD and ETD can also be combined 
at the same time for extensive sequence information 187.  
2.5. The Q Exactive High Field 
The analysis of complex proteomes containing thousands of peptides after tryptic digest greatly 
benefits from the highest performance hybrid mass spectrometers. The latest generation of hybrid 
Orbitrap MS is called Q Exactive and couples a quadrupole mass filter, rather than a linear ion trap, 
with an Orbitrap analyzer 188. This instrument features high resolution in both MS1 and MS2 modes 
as well as extremely fast MS2 performance. Its latest version, the Q Exactive high field (HF) consists 
of an advanced quadrupole and a high field Orbitrap analyzer making it especially well suited to 
complex proteome analysis and is discussed and evaluated in detail in article 6. Its mode of operation 
is briefly described with reference to Figure 11.  
Peptides ions from an electrospray source enter via the orifice and the S-lens, which is 
composed of a series of flat-ring electrodes with an alternating RF of opposite phase. It efficiently 
transfers ions from the atmospheric pressure of the ESI to the low pressure in the MS. The spacing 
progressively increases to confine ions in an increasing RF field 189. The optimal RF for focusing 
depends on the 𝑚 𝑧⁄  and is adjusted for the individual precursor or precursor range. The S-lens
increases the ion current by several fold compared to the previous set-up 177. Many of the background 
ions entering the MS are not of interest for the analysis but can cause problems by contaminating the 
ion path. Removing those as early as possible therefore ensures long-term performance and increases 
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cleaning intervals. For this purpose, the Q Exactive HF features two early filters. The injection 
flatapole has low-resolution ion selection capability and is located near the front end of the 
instrument. It allows removal of unwanted ions outside the 𝑚 𝑧⁄  range of interest prior to the more
sensitive parts of the MS. The bent flatapole excludes neutral molecules and droplets from the ion 
beam, because they cannot follow the bent trajectory. While older Orbitrap hybrid MS were equipped 
with a linear ion trap 13,175,177,189 the Q Exactive HF instrument features a quadrupole mass filter 
with excellent ion transmission and mass selection capacity. It filters ions within a specified 𝑚 𝑧⁄
window with nearly perfect isolation shape and passes them into the C-trap. The C-trap is situated 
between the Orbitrap analyzer and the HCD cell. The C-trap is a curved RF only quadrupole. It 
can accumulate and store ions prior to injecting them into the Orbitrap. These ions can either come 
directly from the ion source (MS1) or they can be fragments produced in the HCD cell, which are 
then injected into the Orbitrap (MS2). For accumulation, ions entering the C-trap are confined by the 
trap electrode, cooled by collisions with nitrogen and come to rest along the curved axis. Injection of 
the focused ion package into the Orbitrap is accomplished by applying a very sharp DC voltage spike. 
More than one million ions can be stored in the C-trap before space charge effects distort energy and 
spatial distributions, preventing further accumulation. To prevent over or under loading of the C-trap, 
the ion accumulation is regulated by automatic gain control (AGC). This AGC value is usually set 
between 1 and 3 million for MS1 and about 50,000 for MS/MS. Compared to 2D traps, the ion storage 
capacity is more than an order of magnitude higher 13,190.  
Figure 9 Q Exactive HF: Ions are injected and focused in the RF lens (S-lens). The injection flatapole is a low 
resolution mass filter. Neutral particles are removed from the ion beam in the bent flatapole. The segmented 
quadrupole acts as mass filter for ions to be subjected to direct mass analysis via the C-trap or via 
intermediate HCD fragmentation 5.  
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2.6. Acquisition Strategies 
In shotgun proteomics, data dependent acquisition (DDA) strategies have generally been used. The 
most used method is called topN because eluting peptides are measured in a survey scan (MS1 or full 
scan) followed by selection and fragmentation of the top N most abundant peptides that have not 
been fragmented before. On our instrumentation in particular, the survey scan usually covers a 𝑚 𝑧⁄
range between 300 to 1650 Th at a resolution of 60,000. Higher resolution (120,000) can improve 
the efficiency of match between runs algorithms (see Chapter 2.7) but will reduce the speed of the 
instrument. After each MS1, the 5 to 20 most intense features with a charge state higher than one are 
sequentially subjected to fragmentation and the fragment masses are recorded in separate MS2 
spectra. In the Q Exactive, fragmentation is performed in the HCD cell and spectra are obtained at a 
high resolution (for MS2 scans) of 15,000 in the Orbitrap as opposed resolution less than 1000 in 
older instruments that perform CID fragmentation and mass analysis in the linear ion trap 190. The 
two approaches are termed High-High and High-Low strategy, respectively. In the Q Exactive HF, 
an acquisition cycle, consisting of one MS1 and 15 MS2 scans, takes roughly one second. This is fast 
compared to the several second that it takes peptides to elute from the chromatographic column. To 
prevent resequencing of the same peptide, precursors with the same mass are excluded from selection 
for 20 to 40 seconds. If the samples are very complex, under-sampling can occur. This gives rise to 
the ‘missing value problem’ in DDA, where some peptides are sequenced in one but not the other 
identical sample. With this background, data independent acquisition (DIA) strategies like 
SWATH MS have been developed, in which the mass spectrometer selects a precursor range of about 
10 to 25 m/z units and cycles through the mass range 191,192. This has the advantage that in principle 
all precursors are sequenced, however, so far at the cost of diminished dynamic range. The complex 
nature of the resulting MS2 spectra for each isolation window and elution time requires a peptide 
fragmentation library to infer peptide identities. SWATH MS is not hypothesis driven and allows to 
screen the spectra for other information post acquisition providing a suitable library. However, data 
interpretation is much more complicated. For SWATH MS quadrupole-TOF instruments are 
generally used because they are fast enough to sample the mass range in a time window smaller than 
the average time for peptide elution 
A third mode of bottom-up proteomics is used in a ‘hypothesis driven’ or ‘targeted’ mode and 
is called single or multi reaction monitoring (SRM or MRM). Pre-defined precursor ions are 
subjected to fragmentation to monitor specific precursor / fragment ion pairs without scanning at the 
MS1 or MS2 level. Usually triple quadrupole instruments have been employed in targeted proteomics. 
In this setup, the first quadrupole serves as precursor ion selector, the second as the collision cell and 
the third as an ion selector, which passes a predefined fragmentation product to the detector. This 
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approach has a very high sensitivity but relies on prior knowledge on the exact mass and retention 
time and is so far limited to the detection of approximately 100 proteins per sample 161,193. 
Furthermore, specificity of detection can be a challenge in SRM or MRM. This is alleviated in 
‘parallel reaction monitoring’, in which the precursor ion is targeted but a full scan of the fragments 
at high resolution is taken 194.  
2.7. Protein Identification 
The interpretation of the spectra recorded in the MS is a complex procedure that is nowadays 
performed in an automated manner. Peptide identities often cannot be inferred unambiguously from 
their accurate masses as discussed in chapter 2.4.4. Ideally, each MS2 provides complete fragment 
ion series for each peptide, which would in principle allow to determine the exact sequence based on 
this information (de novo sequencing). In practice however, de novo sequencing is not feasible in 
routine workflows. MS2 spectra are contaminated with co-isolated precursors, contain internal and 
side-chain fragments, and are often incomplete. To infer the sequence identity from the MS2 and MS1 
spectra from a s sequence data base, search engines like Andromeda or Mascot are employed 160,195. 
These search engines perform an in silico digest of all possible proteins in the proteomes studied and 
calculate theoretical MS2 spectra. Constrained by the MS1 masses, spectra recorded in the MS2 are 
matched to these theoretical spectra. They are evaluated using a probability based scoring model. 
MaxQuant, for instance, calculates posterior error probability (PEP) for each peptide based on the 
identification score and length 196. The quality of this match strongly benefits from high resolution 
data with high mass accuracy as this decreases the search 
space. Apart from employing high performance 
instrumentation and workflows, the mass accuracy can be 
improved in silico by averaging masses obtained in 
consecutive surveys scans as well as by performing an in 
silico mass recalibration based on peptide charge pairs. 
These algorithms in combination with Orbitrap 
instrumentation achieve average absolute mass accuracies 
below 400 ppb in the MS1 197.  
A proteome dataset can contain hundreds of thousands of features that are scanned against the 
database as described above. For such large datasets, it is essential to evaluate the likelihood to obtain 
a good score for an identification purely by chance. To estimate the likelihood of those false positive 
hits, a ‘target decoy’ false discovery rate estimation is performed. The standard MaxQuant procedure 
Matching between runs 
The partially stochastic nature of the 
DDA leads to missing MS2 
identification. A robust workflow 
allows to transfer identification from 
one sample to another by aligning 
the retention times of MS1 features. 
This algorithm is called ‘match 
between runs’ in the MaxQuant 
software suite. 
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is to combine the protein reference database with a library containing the reversed amino acid 
sequences. In addition, in the reverse data base each lysine and arginine (for tryptic digests) is 
swapped with the preceding amino acid. This avoids having exactly the same mass for the reverse 
peptide as for the respective forward peptide while preserving the general context of each amino 
acid 197. Spectra are matched to this combined database and the number of hits in the reversed 
sequences and the corresponding score can be used to define the cutoff and ensure a desired false 
discovery rate (FDR) – usually 1 % 196,198.  
All peptides are assembled into individual proteins. Proteins that cannot be discriminated by 
unique peptides are combined in proteins groups. Some peptides are ambiguous regarding the 
corresponding protein. According to lex parsimonies these peptides can be attributed to the protein 
group that already has the highest number of peptides. Assembled proteins are also FDR controlled 
based on the ranked protein PEP, which is the product of the respective peptides PEPs 160,196. The 
protein FDR usually dominates the peptide FDR, so that proteins that are confidently identified have 
peptides with FDRs much less than 1 %. The importance of the protein FDR concept was illustrated 
by two publications that claimed to provide the most comprehensive draft of the human proteins so 
far, covering roughly 18,000 proteins 199,200. However, these did not employ conventional protein 
FDR calculations, raising the possibility that the overall number of identified proteins is boosted at 
the expense of data quality. This is suggested by the surprisingly high number of olfactory receptors, 
that these studies reported in various tissues in which they are not thought to be expressed 201. 
2.8. Protein Quantification 
The identification of peptide and protein species is only the first step in the process of gaining insight 
into the biological system studied by proteomics. Proteins in the cell cover an abundance range of 
more than six orders of magnitude and interpretation of biological phenomena require quantitative 
information. Article 1, for instance, illustrates how quantitative information is essential to rigorously 
evaluate the similarity between cellular systems. Two levels of quantitative information can be 
distinguished: First, ‘relative quantification’ measures the difference between the same proteins in 
two or more samples. Second, ‘absolute quantification’ determines the absolute amount of the 
proteins of interest in copy numbers per cell or as a concentration. This is currently done by correcting 
the measured peptide signals identifying one protein for physical difference of individual proteins 
(for instance number of possible peptides). This type of absolute quantification provides information 
about the dynamic range of the measured proteome and ranks every measured protein in the proteome 
by expression level. Over the years, various quantification strategies have been developed that differ 
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significantly with respect to the method, accuracy and the quantification level. One discriminating 
feature is whether they are based on isotope labeling or on label-free approaches. 
2.8.1. Label-based Quantification 
Labeling strategies are often applied to derive highly accurate relative quantitative information. 
Labeling with an isotope tag allows combining samples and processing them together, thereby 
reducing the variation introduced by separate sample preparation. These isotopes do not significantly 
change the chemical property (chromatography or ionizability) and they can be distinguished in the 
MS 202. Approaches can be divided into metabolic and chemical labeling. Metabolic labeling such as 
stable amino acid labeling in cell culture (SILAC) allows combination of samples right after the 
biological experiment, reducing variances due to sample preparation to a minimum 203. In SILAC, 
one set of cells incorporates a heavy isotope labeled version of an essential amino acid, whereas the 
other set of cells incorporates the normal amino acid. Heavy arginine and heavy lysine are commonly 
used allowing nearly all resulting tryptic peptides to be distinguished by the respective 𝑚 𝑧⁄  offset in
the MS1 spectrum and their corresponding intensity differences to be used for very robust and 
accurate quantification. SILAC labeling is also possible in whole organisms such as mouse and the 
technology allows monitoring protein turnover (pulsed SILAC) 204,205. Although unmatched in 
accuracy SILAC, has some limitations. One caveat of SILAC is that the MS1 spectra have twice the 
complexity. Furthermore, SILAC initially only allowed the comparison of two conditions and could 
not be used to make quantitative comparisons in every biological system, as it required the 
incorporation of at least one of the heavy amino acids without metabolic conversion. The 
introductions of super SILAC – which uses mixtures of SILAC labeled cell lines as a spike-in 
reference – extended the use of SILAC to various biological systems that cannot be metabolically 
labeled 206.  
Chemical labeling can be performed independently from the source of the material and allows 
to combine samples either before or after enzymatic digestion. Different chemical labeling strategies 
have been developed. Similar to SILAC, iCAT and dimethyl labels lead to peptide pairs in the MS1 
spectrum, however, iCAT only labels cysteins at the protein level, leading to decreased sample 
complexity 207,208. The label further contains an affinity handle (such as biotin), which allows 
enrichment. Unlike iCAT were quantification is solely based on the cysteine containing peptides, 
dimethyl labeling allows quantification on all peptides. It employs isotopically labeled formaldehyde 
to react via reductive amination with ε-aminogroup of lysine and the N-terminus. In contrast to iCAT 
and dimethyl labeling, isobaric labeling strategies such as TMT and iTRAQ use the MS2 level to 
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distinguish and quantify the different peptides 209,210. Isobaric tags have the same chemical properties 
and masses in the MS1, but result in distinct fragment ions in the MS2. This strategy has the advantage 
of not increasing the sample complexity on the MS1 level and allowing higher multiplexing, with 10-
plex kits now commercially available. However, unless special measures are taken, MS2 
quantification suffers from ratio compression due to coeluting peptides that contribute to the intensity 
of the tag-ion intensity 202. In addition, the reporter ions have relatively low masses (<150 Da), which 
tend to be unstable in conventional ion trap (1/3 rule) CID fragmentations. This stability problem 
however, was solved with the development of new technologies such as pulsed Q dissociation and 
ETD and is in any case not an issue when using HCD 202. 
2.8.2. Label-free Quantification 
Label-free comparison of proteomes has several practical and conceptual advantages, such as being 
applicable to any sample, avoiding increase in proteome complexity, being freely scalable to any 
number of comparisons and increasing accuracy for very high ratios. However, it entails completely 
separate processing and measurement of the samples, which reduces the accuracy and robustness of 
the quantitative information unless the workflow is very well controlled.  
Early label-free quantification methods were based on the correlation between the number of 
spectra recorded for a protein and its abundance. In spectral counting the abundance of proteins is 
estimated by the number of MS2 spectra recorded for each protein 211. However, this quantification 
method requires high numbers of fragmentation spectra for each protein to be at least moderately 
accurate. Alternatively, the number of identified unique peptides can be used as an estimator of 
protein abundance. The protein abundance index (PAI) normalizes the number of identified peptides 
by the number of theoretically observable peptides, providing a rough estimation of the abundance. 
Furthermore, 10PAI-1 empirically turns out to be roughly proportional to absolute protein 
abundance 212. APEX is another algorithm to estimate the abundance of proteins based on the number 
of observed peptides. In contrast to PAI, APEX uses a machine-learning algorithm to predict the 
observable peptides to estimate absolute abundances 213. Although relatively easy to implement, 
neither spectral counting nor the number of identified peptides comes close to the accuracy achieved 
in labeling approaches such as SILAC.  
More recently developed label-free strategies make use of high resolution data and employ the 
MS1 ion intensities of all the identified peptides (extracted ion current or XIC) to extract quantitative 
protein information. The MS1 intensity is directly proportional – within the linear dynamic range of 
the instrument – with the number of ions. The MaxQuant MaxLFQ algorithms calculate ratios of 
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normalized peptide intensity and uses those to obtain relative or absolute quantitative information 
from the MS data. These sophisticated algorithms, in combination with robust and simple workflows 
as well as high performance MS, often allow to quantify protein changes within a fold-change of 
two, which is almost in the range of SILAC accuracy 214.  
 
2.8.3. Copy Number Estimation 
The quantification strategies mentioned above provide limited information about the copy number 
of proteins. Apart from the number of cells, this level of information requires normalizing all proteins 
with respect to each other and usually requires a reference to a standard with known amount. Spike-in 
of isotopically labeled standard peptides, whose molarity has been determined for example by amino 
acid analysis can be a very accurate way to determine protein copy numbers of the respective 
proteins. The Protein Epitope Signature Tag (PrEST) strategy makes use of the Human Protein Atlas 
Project where parts of all human proteins had been produced for generating antibodies 215. PrESTs 
consist of unique sequence stretches of the proteins of interest, fused to a common Protein A derived 
solubility tag that has no equivalence in the proteome. PrEST can be isotopically labeled and 
quantitative information can be derived from the ratio of the endogenous protein to the PrEST in the 
MS1 spectrum. The exact amount of the spiked in PrEST can be determined via the solubility tag, 
which is repurposed as a quantification tag. In comparison to related approaches like AQUA or 
QconCAT, PrESTs have the advantage of a common reference tag (solubility tag) and a preexisting 
library 216-219. Even more importantly, PrEST correct for the unknown and varying efficiency of 
digestion of proteins to peptides. Other approaches rely on normalized summed peptide intensity in 
combination with a spike-in standard (iBAQ 220) or the summed intensity of the three most abundant 
peptides normalized with an internal standard (Top3 221). Finally, the total protein abundance (TPA) 
approach does not require any spike-in standard and allows estimating copy numbers purely based 
on XIC quantitative information, the molecular mass and the estimate protein amount per cell 222. In 
summary, copy number estimation is possible with different levels of accuracies depending on the 
method used. Highest accuracy is achieved by using spike-in standards. Normalizing all proteins with 
respect to each other allows to interpolate the abundance of proteins without a corresponding 
reference, however with reduced accuracy.  
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Figure 10 MS feature interpretation: MaxQuant fits a Gaussian curve to the three central data points of each 
MS1 peak and calculates the intensity weighted mass deviation and assembles 3D peaks of each eluting feature 
visible in the spectra. High mass accuracy significantly reduces the search space and improves data quality 223. 
For quantification, the apex intensity of the 3D peak is employed. In contrast to the integral of the MS1 peak, 
the apex is more robust towards background peaks and non-symmetrical peak shapes. On the basis of the MS1 
features and the corresponding MS2 spectra, peptides are identified, assembled to quantified proteins and 
quantitative difference are subjected to statistical testing. 
2.9. Optimized Experimental Designs 
Complex systems like a MS have many adjustable parameters that may or may not significantly affect 
their performance. For instance, as discussed in chapter 2.4.3 high mass resolution is a precondition 
of high mass accuracy but will inevitably reduce the sequencing speed of Orbitrap analyzers and 
eventually the number of identified peptides. Those dependencies are not necessarily linear and can 
depend on many other parameters such as the sample complexity or the length of a gradient. 
Knowledge about these dependencies is critical to optimize the performance of the instrument. The 
same goes for any biochemical experiment or biological system such as the isolation efficiency of 
proteins or the optimal growth condition for primary cells. The conventional optimization approach 
is to change one parameter at a time and monitor the response of the system to titrate the optimal 
condition such as the number of proteins or growth rate. However, this approach is tedious, and fails 
to identify higher order dependencies without sampling an exponentially growing condition space. 
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It is apparent that sampling all potential combinations of parameters and matching these to the system 
response would provide a complete but unnecessarily redundant description of the system. It would 
be sufficient to measure some but not all points to reliably model how the system responses to 
individual parameter settings. Mathematical designed and evaluated experiments offer efficient 
sampling of the parameter space and statistically meaningful interpretation of the results. So called 
Design of Experiment (DoE) approaches have been increasingly popular to optimize complex 
systems 224. In DoE, different mathematical models are used to approximate the real 
multidimensional parameter (or ‘factor’) space based on the evaluation of responses to defined factor 
settings. Different models are employed, which usually have an inverse correlation between the order 
of dependency that can be modeled (linear, quadratic, synergistic effects etc.) and the number of 
required experiments 224. The advantages of DoE is the substantially reduced experimental effort, 
while allowing to assess significance of the influencing factors and to quantify higher order 
dependencies like synergistic effects. Figure 13 shows an example of a response surface spanned by 
two dimensions (two factors) and the response. In that example, non-linearity of the response would 
render “one parameter at a time” approaches very inefficient and error prone. 
Figure 11 Comparison of conventional 
experimental approaches and Design of 
Experiment (DoE): A) A theoretical response 
with nonlinear dependencies on two factors. 
The goal is to find the parameter setting 
yielding the most robust and highest response. 
B) 2D projection of the response surface. The
conventional approach — ‘changing one 
parameter at time’ — is laborious and might 
not find the optimal factor settings. DoE 
sampling, here a central composite faced 
design, provides better insight into the global 
response landscape and is more likely to 
provide information on the global optimum. A 
second DoE in the area of the determined 
optimum might be advisable to provide even 
higher resolution around the optimal settings. 
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A DoE usually employs three steps: (1) Identifying potentially relevant factors that might influence 
the system and setting realistic factor ranges. (2) Performing a screen providing information which 
parameters have the strongest effects. (3) Probing a subset of the relevant parameters combinations 
and modelling individual effects and dependencies. The resulting empirical function is usually a 
polynomial that allows predicting the behavior of the system. The elegance of DoE is that the 
responses of almost any technical and biological system can be assessed. The only critical 
requirements are a well quantifiable readout and adjustable factors. We used DoE to model quadratic 
and synergistic effects of settings affecting the number of identified peptides from the newest 
generation of Orbitrap hybrid MS (article 6).
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Article 1 
Deep proteomic evaluation of primary and cell line motoneuron 
disease models delineates major differences in neuronal 
characteristics 
This study provides a paradigm example of how to use label-free quantitative proteomics to assess 
and compare properties of primary cells, tissues and cell culture systems. The fatal neurodegenerative 
disorder amyotrophic lateral sclerosis (ALS) primarily affects neurons of the motor system. Its 
cellular specificity and complex genetics (see chapter 1.3) make ALS a promising test case to 
investigate the network of factors contributing to neurodegeneration. To understand pathological 
changes, knowledge of the physiological properties of affected cells is imperative. Our collaborators 
have recently established a protocol to isolate and differentiate primary motoneurons from mouse 
embryos 225. In this study, we characterized primary motoneurons providing a resource for 
motoneuron disease research. In addition, we benchmarked two in vitro cell line model systems 
(NSC-34, N2a) that are widely used to investigate (moto)neuron diseases. We compared these to 
mouse embryonic spinal cord tissue as well as to non-neuronal cell lines (Hepa 1-6, Mef) in order to 
evaluate neuronal properties. With more than 10,000 identified proteins, we were able to ascertain 
properties of these cell-systems in depth. We observed substantial differences between 
motoneuron-like cell lines and primary motoneurons, especially for proteins involved in 
differentiation, the cytoskeleton, and receptor signaling. However, our data also indicate that both 
motoneuron-like cell lines retain neuronal properties in comparison to the non-neuronal cell lines. 
For future research, our quantitative data will allow choosing the appropriate model system 
depending on the biological question to be addressed. In addition, the dataset will enable researchers 
to better judge the reliability of previously obtained results using the motoneuronal model cell lines. 
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Molecular & Cellular Proteomics (2014) 226 
Hornburg D, Drepper C, Butter F, Meissner F, Sendtner M, Mann M. 
Contribution: This project was a collaboration between the department of Matthias Mann (MPI 
Biochemistry) and the group of Michael Sendtner (University of Wurzburg). To quantify proteomes 
of different model systems, I conceived the experimental setup, prepared the samples, acquired and 
analyzed the data and performed the follow up experiments. Our collaborators provided primary 
motoneurons and spinal cord tissue and contributed to data interpretation. 
Deep Proteomic Evaluation of Primary and Cell
Line Motoneuron Disease Models Delineates
Major Differences in Neuronal Characteristics*□S
Daniel Hornburg‡, Carsten Drepper§¶, Falk Butter‡, Felix Meissner‡**,
Michael Sendtner¶**, and Matthias Mann‡**
The fatal neurodegenerative disorders amyotrophic lat-
eral sclerosis and spinal muscular atrophy are, respec-
tively, the most common motoneuron disease and genetic
cause of infant death. Various in vitro model systems have
been established to investigate motoneuron disease
mechanisms, in particular immortalized cell lines and pri-
mary neurons. Using quantitative mass-spectrometry-
based proteomics, we compared the proteomes of pri-
mary motoneurons to motoneuron-like cell lines NSC-34
and N2a, as well as to non-neuronal control cells, at a
depth of 10,000 proteins. We used this resource to eval-
uate the suitability of murine in vitro model systems for
cell biological and biochemical analysis of motoneuron
disease mechanisms. Individual protein and pathway
analysis indicated substantial differences between mo-
toneuron-like cell lines and primary motoneurons, espe-
cially for proteins involved in differentiation, cytoskeleton,
and receptor signaling, whereas common metabolic path-
ways were more similar. The proteins associated with
amyotrophic lateral sclerosis also showed distinct differ-
ences between cell lines and primary motoneurons, pro-
viding a molecular basis for understanding fundamental
alterations between cell lines and neurons with respect to
neuronal pathways with relevance for disease mechanisms.
Our study provides a proteomics resource for motoneuron
research and presents a paradigm of how mass-spectrom-
etry-based proteomics can be used to evaluate disease
model systems. Molecular & Cellular Proteomics 13:
10.1074/mcp.M113.037291, 3410–3420, 2014.
Motoneurons are extremely extended neurons that mediate
the control of all muscle types by the central nervous system.
Therefore, diseases involving progressive motoneuron degen-
eration such as amyotrophic lateral sclerosis (ALS)1 (OMIM:
105400) or spinal muscle atrophy (OMIM: 253300) are partic-
ularly devastating and generally fatal disorders. Today, ALS is
believed to form a phenotypic continuum with the disease
entity frontotemporal lobe degeneration (OMIM: 600274) (1,
2). About 10% of ALS cases are known to be inherited, but the
vast majority are considered sporadic. The number of inher-
ited cases might be underestimated because of incomplete
family histories, non-paternity, early death of family members,
or incomplete penetrance (3).
Mutations in several genes have been reported for the
familial form, including in Sod1 (4), Als2 (5), Setx (6), Vapb (7),
Tardbp (8, 9), Fus/Tls (10, 11), Vcp (12), Pfn1 (13), and several
others (reviewed in Ref. 14). The most frequent genetic cause
of inherited ALS was recently shown to be a hexanucleotide
repeat expansion in an intron of a gene of unknown function
called C9orf72 (15–17). Based on the spectrum of known
mutations, several disease mechanisms for ALS have been
proposed, including dysfunction of protein folding, axonal
transport, RNA splicing, and metabolism (reviewed in Refs.
14, 18, and 19). Despite intensive research, it is still unclear
whether a main common molecular pathway or mechanism
underlies motoneuron degeneration in ALS and frontotempo-
ral lobe degeneration. Spinal muscle atrophy is caused by
homozygous mutations or deletions in the survival of motor
neuron gene (Smn1) that presumably impair the RNA metab-
olism through diminished functionality of the Smn1 gene
product (20). Over recent decades several model systems
have been established to investigate ALS (21). These include
transgenic animal models such as mouse (22), drosophila
(23), and zebrafish (24). In cell-based studies, primary mo-
toneurons cultured from rodent embryos (25) or motoneuron-
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like cell lines are employed. Primary cells are considered to
more closely mimic the in vivo situation, but they are more
challenging to establish and maintain. In contrast, the degree
of functional relevance of cell lines can be difficult to establish,
but they can be propagated without limitation and are well
suited for high-throughput analysis. In particular, the spinal
cord neuron–neuroblastoma hybrid cell line NSC-34 (26) and
the mouse neuroblastoma cell line N2a (27) are widely used
not only to assess motoneuron function, but also to study
disease mechanisms in motoneurons (28, 29).
As proteins are the functional actors in cells, proteomics
should be able to make important contributions to the char-
acterization and evaluation of cellular models. In particular, by
identifying and quantifying the expressed proteins and bioin-
formatically interpreting the results, one can obtain enough
information to infer functional differences. Our laboratory has
previously shown proof of concept of such an approach by
comparing the expression levels of about 4,000 proteins be-
tween primary hepatocytes and a hepatoma cell line (30). Very
recently, mass-spectrometry-based proteomics has achieved
sufficient depth and accuracy to quantify almost the entire
proteome of mammalian cell lines (31–33). Furthermore, new
instrumentation and algorithms now make it possible to per-
form label-free quantification between multiple cellular sys-
tems and with an accuracy previously associated only with
stable isotope labeling techniques (34, 35).
To evaluate the suitability of motoneuron-like cell lines as
cellular model systems for research on ALS and related dis-
orders, we characterized the proteomes of two widely used
cell lines, NSC-34 and N2a, and compared them with the
proteomes of mouse primary motoneurons and non-neuronal
control cell lines. To generate primary motoneurons, we em-
ployed a recently described culturing system that makes it
possible to isolate highly enriched motoneuron populations in
less than 8 h (25). We identified more than 10,000 proteins
and investigated differences in quantitative levels of individual
neuron-associated proteins and pathways related to mo-
toneuron function and disease mechanisms.
EXPERIMENTAL PROCEDURES
Cell Culture—N2a (CCL-131, American Type Culture Collection),
NSC-34 (CED-CLU140, Biozol, Eching, Germany), mouse embryonic
fibroblasts (MEFs) (American Type Culture Collection), and mouse
hepatoma (liver cancer; Hepa1–6) (CRL-1830, American Type Culture
Collection) cell lines were grown in high-glucose Dulbecco’s modified
Eagle’s medium with L-glutamine (PAA/GE, Freiburg, Germany), 10%
FCS (PAA), 1% penicillin/streptomycin (PAA). NSC-34 cells were
directly ordered from the supplier and kept in culture for up to six
passages. All other non-neuronal cell lines are maintained in cryo-
stocks in our laboratory. Cells were harvested with cold PBS. Washed
pellets were flash-frozen in liquid nitrogen for storage.
Primary Motoneurons—CD1 wild-type mice were directly pur-
chased from Charles River (Sulzfeld, Germany). Primary spinal cord
motoneurons from mice were cultured essentially as described pre-
viously (25). Briefly, spinal cords of E12.5 mouse embryos were
dissected and collected in 1.5-ml tubes containing Hank’s Balanced
Salt Solution, Life Technologies GmbH, Darmstadt Germany After
trypsin treatment and trituration, the suspension was enriched for
p75NTR-positive cells via an antibody-panning procedure (25). After
washing and depolarization to remove the cells from the panning dish,
the cells were collected via centrifugation at 400g for 5 min and
resuspended in full medium (Neurobasal (Invitrogen), 1 GlutaMax
(Invitrogen), supplemented with 1 B27 (Invitrogen), 2% horse serum
(Linaris, Dossenheim, Germany)). After counting with a hemocytom-
eter, 7  105 cells were plated on poly-ornithine- (Sigma) and laminin-
coated (Invitrogen) dishes (six-well format, Delta surface, Nunc/
Thermo Fisher Scientific Inc., Waltham, MA) and fed with full medium
supplemented with 5 ng/ml BDNF. 40% of the medium was replaced
after 24 h and every second day after that. In total, cells from 140
CD1 wild-type embryos were used in three experiments. After 7 days
in culture, cells were washed three times with PBS and harvested in
0.5 ml of lysis buffer (4% SDS, 0.1 M DTT, 10 mM Hepes, pH 8.0) per
well.
Sample Preparation for MS Analysis—Cell lysis was performed at
room temperature in lysis buffer (4% SDS, 10 mM Hepes, pH 8.0) with
15 min of sonication (level 5, Bioruptor, Diagenode, Seraing (Ougrée) -
Belgium). Proteins in the lysate were reduced with 10 mM DTT for 30
min and then subjected to 45 min of alkylation with 55 mM iodoacet-
amide. The protein concentration was determined with fluorescence
at 350 nm and compared with a bovine serum albumin standard.
To remove the detergent, we performed acetone precipitation.
Acetone (20 °C) was added to 100 g of proteins to a final concen-
tration of 80% v/v, and proteins were precipitated for at least 2 h at
20 °C. The supernatant was removed after 15 min of centrifugation
(4 °C, 16,000g) followed by washing with 80% acetone (20 °C). The
protein pellet was dissolved in 50 l of 6 M urea/2 M thiourea, 10 mM
Hepes, pH 8.0. After the addition of 1 g of LysC, digestion was
carried out for 3 h at room temperature. We diluted with 4 volumes of
50 mM ammonium bicarbonate and further digested the mixture with
1 g of trypsin overnight at room temperature. The resulting peptide
mixtures were either analyzed directly via a single-shot strategy (36)
or separated into six strong anion exchange fractionations as de-
scribed elsewhere (37). We desalted peptides on C18 StageTips (38).
LC-MS/MS—We separated peptides on a Thermo Scientific EASY-
nLC 1000 HPLC system (Thermo Fisher Scientific, Odense, Den-
mark). Columns (75-m inner diameter, 50-cm length) were in-house
packed with 1.9-m C18 particles (Dr. Maisch GmbH, Ammerbuch-
Entringen, Germany). Peptides were loaded in buffer A (0.5% formic
acid) and separated with a gradient from 7% to 60% buffer B (80%
acetonitrile, 0.5% formic acid) within 3.5 h at 200 nl/min. The column
temperature was set to 40 °C. A quadrupole Orbitrap mass spectrom-
eter (34) (Q Exactive, Thermo Fisher Scientific) was directly coupled to
the liquid chromatograph via a nano-electrospray source. The Q
Exactive was operated in a data-dependent mode. The survey scan
range was set to 300 to 1,650 m/z, with a resolution of 70,000 at m/z
200. Up to the 10 most abundant isotope patterns with a charge of 2
were subjected to Higher-energy collisional dissociation (39) with a
normalized collision energy of 25, an isolation window of 2 Th, and a
resolution of 17,500 at m/z 200. To limit repeated sequencing, dy-
namic exclusion of sequenced peptides was set to 30 s. Thresholds
for ion injection time and ion target value were set to 20 ms and 3 
106 for the survey scans and to 60 ms and 106 for the MS/MS scans.
Data were acquired using Xcalibur software (Thermo Scientific).
Data Analysis and Statistics—To process MS raw files, we em-
ployed MaxQuant software (v. 1.3.10.18) (40). We used Andromeda
(41), which is integrated into MaxQuant, to search MS/MS spectra
against the UniProtKB FASTA database (59,345 forward entries; ver-
sion from June 2012). Enzyme specificity was set to trypsin allowing
cleavage N-terminal to proline and up to two miscleavages. Peptides
had to have a minimum length of seven amino acids to be considered
for identification. Carbamidomethylation was set as a fixed modifica-
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tion, and acetylation (N terminus) and methionine oxidation were set
as variable modifications. A false discovery rate (FDR) cutoff of 1%
was applied at the peptide and protein levels. Initial precursor mass
deviation of up to 4.5 ppm and fragment mass deviation up to 20 ppm
were allowed. Precursor ion mass accuracy was improved by time-
dependent recalibration algorithms in MaxQuant. The cutoff score
(delta score) for accepting individual MS/MS spectra was 17.
Nonlinear retention time alignment of all measured samples was
performed in MaxQuant. “Match between runs,” which allows the
transfer of peptide identifications in the absence of sequencing, was
enabled with a maximum retention time window of 1 min. As a library
for “match between runs” in MaxQuant, we employed additional sets
of NSC-34, technical duplicates of E12.5 spinal cord, and technical
duplicates of strong anion exchange fractionated peptides from mo-
toneurons in addition to the biological samples analyzed here (bio-
logical triplicates of NSC-34, N2a, MEF, Hepa 1–6, motoneurons, and
E12.5 spinal cord) (supplemental Table S6). Added individual peptide
intensities are a rough proxy of each protein’s abundance. In order to
ensure improved quantification, we applied further normalization al-
gorithms built into MaxQuant before making quantitative compari-
sons of the cellular systems. Furthermore, we stringently filtered our
data by requiring a minimum peptide ratio count of 2 in MaxLFQ (42).
Protein identification required at least one razor peptide (40). Proteins
that could not be discriminated on the basis of unique peptides were
grouped into protein groups. Furthermore, proteins were filtered for
common contaminants (n  247 (41)) to which laminin sequences
were added to avoid bias resulting from the laminin-coating of plates
in the case of the primary motoneuron culture. Proteins identified only
by site modification were excluded from further analysis. Further-
more, we required a minimum of two valid MaxLFQ quantifications in
at least one group of triplicates. A flowchart describing the individual
steps of the data processing and filtering is presented in supplemen-
tal Table S5.
To quantify fold changes of proteins across samples, we used
MaxLFQ. To visualize these fold changes in the context of individual
protein abundances in the proteome, we projected them onto the
summed peptide intensities normalized by the number of theoretically
observable peptides (43).
Specifically, to compare relative protein abundances between and
within samples, the following transformations to the MaxQuant output
data were performed. First log 2 MaxLFQ differences to the mean log
2 MaxLFQ intensity of each protein group for each sample were
calculated, resulting in intensity-independent log 2 MaxLFQ differ-
ences. Then protein length normalized log 2 protein intensities
(termed iBAQ values in MaxQuant) were added to the MaxLFQ dif-
ferences. The first transformation provides highly accurate informa-
tion about the protein differences between samples, and the second
allows one to compare the abundances of different protein groups.
For statistical and bioinformatic analysis, as well as for visualiza-
tion, we used the open PERSEUS environment, which is part of
MaxQuant. For several calculations and plots we also used the R
framework (44). Pearson correlation was performed on filtered Max-
LFQ intensities omitting missing values (NaN). To identify the most
discriminating proteins in groupwise comparisons, first we performed
imputation of missing values with a normal distribution (width  0.3;
shift  1.8) as described elsewhere (45). Then, we applied the built-in
analysis-of-variance functions in PERSEUS using an FDR of 1% and
S0 of 4 (the S0 parameter sets a threshold for minimum fold change
(46)). For pairwise comparison of proteomes and determination of
significant differences in protein abundances, t test statistics were
applied with a permutation-based FDR of 2% and S0 of 4 (46). The
resulting significant outliers for each of the sample pairs were ana-
lyzed for annotation enrichments.
We used outlier populations derived by means of t test statistics in
order to determine Gene Ontology (GO) (47), KEGG (48), and UniProt
Keyword (49) enrichment of categorical annotations with an intersec-
tion size of at least 8. In Fig. 3 this was done by testing categorical
annotations in individual outlier populations for enrichments com-
pared with the complete dataset via Fisher’s exact test with a
Benjamini–Hochberg corrected FDR of 2% (Fig. 3C). In Fig. 4, no FDR
cutoff was used, but the FDR values are reported (supplemental Table
S3). In cases of identical annotation in both outlier populations, only
the enrichment with highest p value was depicted.
For comparison of the motoneuronal proteome to published tran-
scriptome data (50), we used normalized and filtered log 2 Affymetrix
intensities provided by the authors for transcripts and protein inten-
sities from MaxQuant, which were normalized by protein sequence
length. Transcriptome data were matched in PERSEUS to proteome
data on the basis of gene names, and the median of replicates was
used for comparison.
RESULTS
Deep Proteome Analysis of Motoneuronal Model Sys-
tems—We set out to characterize the proteomes of different
cellular model systems employed in the study of motoneuron
disease mechanisms. Primary motoneurons were isolated
from 12.5-day-old mouse embryos, enriched and differenti-
ated using a recently developed protocol (25), and compared
with two commonly used motoneuron-like cell lines (NSC-34
and N2a) and spinal cord from 12.5-day-old mouse embryos.
As non-neuronal control cells, we employed mouse hepatoma
cells (Hepa 1–6) and MEF cells. To ensure optimal recovery of
membrane proteins such as receptors, which are crucial for
neuronal function, we extracted proteins from cells via lysis in
SDS followed by acetone precipitation. After enzymatic diges-
tion, tryptic peptides were separated by means of reverse
phase liquid chromatography in 4 h gradients and analyzed
on a quadrupole Orbitrap mass spectrometer in single shots
(Fig. 1A). Label-free quantification between biological repli-
cates was highly reproducible, as evidenced by a Pearson
correlation of more than 0.93 (Fig. 1B). Overall we quantified
more than 10,000 proteins and 7,000 to 8,100 proteins in the
individual cellular systems (Fig. 1C, supplemental Tables S1
and S2).
About 75% of all quantified proteins were present in all
analyzed cellular systems (primary cells, motoneuronal cell
lines, and non-neuronal controls). We observed the most pair-
wise overlap of detected proteins between primary neuronal
cells and motoneuronal cell lines (Fig. 1D). However, on a
quantitative level, motoneuronal cell lines correlated more
tightly to the non-neuronal controls than to the primary cells.
This unexpected observation highlights the value of quantita-
tive data (Fig. 1B). Measured protein abundance values
(summed, normalized intensities of the peptides identifying
each protein) covered over 6 orders of magnitude (Fig. 1E). In
all cell systems, some of the most abundant proteins were
histones and ribosomal proteins, in accordance with previous
studies (43, 51, 52). Proteins of housekeeping metabolic pro-
cesses such as spliceosomes or oxidative phosphorylation
were also generally highly abundant. In contrast, neuronal
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proteins involved in receptor signaling or axonal guidance
were relatively low abundant. Because ALS-associated pro-
teins are involved in a variety of cellular processes, they span
almost the entire dynamic range (supplemental Table S2).
For selected gene products—Dctn1, Vcp, Fus, Syp, and
Sox2—we performed Western blot analysis on motoneuron
primary culture, NSC-34, and Hepa 1–6 cell lines. Although
Western blot staining was less easy to interpret than the MS
signals, trends in protein abundance were the same (supple-
mental Figs. S1A–S1C). We also compared our motoneuronal
dataset to a published transcriptome of murine motoneurons
that were differentiated from stem cells with retinoic acid and
sonic hedgehog for 5 days (50) (supplemental Fig. S1E, sup-
plemental Table S4). We observed a moderate and highly
significant correlation (Pearson correlation, 0.49; Pearson p
value, 10e-15) between transcriptome and proteome; how-
ever, many proteins differed strongly between the two data-
sets (supplemental Table S4).
Global Comparison of the Proteomes of Primary Motoneu-
rons, Cell Lines, and Mouse Spinal Cord—After stringent fil-
tering as described in “Experimental Procedures” and sup-
plemental Table S5, we quantitatively compared 7,950
proteins between the model systems on the level of individual
protein expression as well as annotation levels (supplemental
Table S2). The mean standard deviation within biological rep-
licates was less than 2-fold for 95% of the quantified proteins,
demonstrating the quantitative robustness of our measure-
ments (Fig. 2A). Even for the least abundant proteins, the
mean standard deviation was less than 2-fold for more than
99.5% of these proteins (Fig. 2B). As an example, for spinal
cord tissue, the variation between one biological sample
measured twice (technical replicate) was moderately but sig-
FIG. 1. Deep proteome analysis of motoneuronal model systems. A, spinal cord from E12.5 mouse embryo was dissected, and cells were
isolated. P75NTR-positive cells were enriched in an antibody-panning step and grown in culture for 7 days. Motoneuron-like cell lines (N2a,
NSC-34) and control cell lines (MEF, Hepa 1–6) were grown under standard culture conditions. All investigated cellular systems were analyzed
via liquid chromatography coupled to high-resolution mass spectrometry following a single-shot strategy. B, Pearson correlation for MS-
determined protein abundances (MaxLFQ intensities) from single-shot MS measurements. All replicate correlation values were greater than
0.93, and Pearson correlation between different cellular systems was at least 0.7. C, total number of quantified proteins (summed peptide
intensities) in all measurements, including additional replicates of cell lines and spinal cord (“library”) and in individual systems. Between 7,000
and 8,100 proteins were quantified in the individual cellular systems. D, Venn diagram of the distribution of quantified proteins in the
investigated cellular systems, grouped by primary cells, motoneuron-like cell lines, and non-neuronal cell lines. E, ranked MaxLFQ normalized
protein abundances for motoneurons. Indicated are approximated abundance ranges for proteins involved in neuron-specific and general
metabolic processes and in ALS pathology.
FIG. 2. Standard deviation of MaxLFQ quantifications in protein groups within replicates. A, standard deviation of MaxLFQ quantifi-
cations in protein groups for triplicates. B, intensity dependence of MaxLFQ standard deviations for all triplicates. The number of data points
contributing to each bin is depicted above the bins. C, comparison of standard deviations from technical duplicates and biological triplicates
of spinal cord throughout the whole abundance range. Differences between technical and biological replicates are significant (p  0.0001) for
protein intensities of bins 25–30, 30–35, and 35. The number of protein groups for which standard deviations were calculated is depicted
above the bins. Data are plotted as median with 5%–95% percentile.
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nificantly smaller than the variation between biological repli-
cates (Fig. 2C).
We applied principal component analysis (PCA) to evaluate
similarities and dissimilarities on a global scale. Biological
replicates clustered tightly in the PCA space, indicating high
quantitative reproducibility of the experimental setup and the
label-free quantification (Fig. 3A). Motoneurons, spinal cord,
Hepa 1–6, MEFs, and motoneuronal cell lines were clearly
separated in the first two components of PCA. NSC-34 and
N2a together formed a close pair of clusters that was approx-
imately equidistant from the primary cells and the control cell
lines. Although derived from completely different tissues, the
latter are co-located and widely separated from the other
systems. As the difference between them is not profound, we
focused on Hepa 1–6 as a non-neuronal cell line control for
further analysis. Interestingly, the motoneuron primary culture
and the E12.5 spinal cord tissue, although clearly separated,
clustered much closer to each other than to the neuronal and
non-neuronal cell lines.
To assess individual, discriminating proteins in motoneu-
rons, spinal cord, N2a, NSC-34, and Hepa 1–6 cells, we
plotted the “loadings” of the PCA (loadings are the proteins
driving, or responsible for, the separation of the proteomes).
In Fig. 3B, those loadings that also passed a stringent analysis
of variance and fold change (“Experimental Procedures”) are
colored. Within this selection we can distinguish groups of
proteins on the basis of neuronal properties. Proteins that
function in neurite growth, such as Gap43 and Syn2, or in
vesicle release, such as the neuro-secretory protein Vgf, were
shared outliers for both neuron-like cell lines and motoneu-
rons/spinal cord (orange population in Fig. 3B). In contrast,
another group of proteins—such as medium and light chains
of neurofilaments (Nefm and Nefl)—proved to be distinctive
for motoneuronal systems relative to all other systems (green
population in Fig. 3B).
We employed PERSEUS to bioinformatically determine ma-
jor physiological differences among the cellular model sys-
tems via enriched annotations (GO, UniProt Keyword, and
KEGG) (Fig. 3C, supplemental Fig. S3, supplemental Table
S3). E12.5 spinal cord consists of a mixed population of
undifferentiated cells. Consistent with this, annotation enrich-
Fig. 3. Global proteomic comparison of motoneuron-like cell
lines, embryonic spinal cord, unrelated cell lines, and primary
motoneurons. A, PCA of protein expression values of the different
systems. Component 1 and component 2 account for 54.8% of the
data variation. B, significant outliers from analysis of variance (FDR
cutoff  1%, S0 fold-change cutoff  4) are depicted in red in the PCA
loading distribution (gray dots). Proteins driving the separation are
colored according to the PCA plot in A. C, analyses of enriched
annotation (Fisher’s exact test) for t test significant (FDR cutoff  2%,
S0 fold-change cutoff  4) outlier populations. The six most enriched
(log 2) annotations from UniProt Keywords (Key), GO biological pro-
cess (GOBP), GO cellular compartment (GOCC), and KEGG are
depicted.
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ments for primary motoneurons demonstrated a stronger neu-
ronal character relative to spinal cord (supplemental Fig. S3).
NSC-34 and N2a cells differed even more from primary mo-
toneurons with respect to neuron-specific proteins. For in-
stance, neuron-associated annotations such as GO biological
process “neurotransmitter transport” were enriched more
than four times in motoneurons relative to NSC-34 and N2a
(Fig. 3C). Functions that were enriched for these neuronal cell
lines were mainly related to DNA metabolism, presumably as
a consequence of the fact that they are proliferating whereas
the primary motoneurons are terminally differentiated.
Although they are derived from neuroblastoma, the overall
neuronal characteristics of NSC-34 and N2a are not profound.
Nevertheless, comparison of NSC-34 and N2a cells to non-
neuronal cell lines revealed some patterns that are character-
istic for neurons—for instance, enrichment of proteins in-
volved in neuron projection and the neuronal cytoskeleton.
These observations based on proteomic quantification high-
light fundamental differences between neuronal cell lines and
primary motoneurons with respect to their protein repertoire
for neuronal differentiation and function.
To characterize differences in protein patterns among pri-
mary motoneurons, motoneuronal cell lines, and non-neuro-
nal cell lines in more detail, we computed enrichment values
and p values for annotation categories for binary comparisons
of the cellular systems (Fig. 4, supplemental Table S3). Com-
parison of primary motoneurons to NSC-34 and N2a cells
revealed striking differences for neuronal categories, with a
large overrepresentation in the motoneurons.
Evaluation of Axon Growth, Guidance, and Polarity—Im-
paired establishment and maintenance of neuronal morphol-
ogy is a central pathological aspect in neurodegenerative
disorders (53). We had observed the corresponding annota-
tions such as neuron projection (GO cellular component) and
axon guidance (KEGG) to be de-enriched in the motoneuronal
cell lines, and we next wished to extract the expression level
of key factors in these processes (Fig. 5A). Illustrating the use
of the dataset as a resource, we observed that proteins im-
portant for axonal outgrowth like Slits/Robos, Semaphorins,
Netrins, or Ephrins or proteins involved in morphological
maintenance such as Mapt were either missing or underrep-
resented in NSC-34 and N2a.
Evaluation of Excitability and Synaptic Function—Neu-
rotransmitter-receptor signaling and excitability are main fea-
tures of neuronal cell types that differ according to cellular
functionality. We assessed the abundance of proteins in-
volved in receptor signaling (KEGG “neuroactive receptor-
ligand interaction,” voltage-gated channel (UniProt Keyword),
and ligand-gated ion channel (UniProt Keyword); Fig. 5). Strik-
ingly, many receptors were underrepresented or even not
detected in the NSC-34 and N2a cells. In particular, glutamate
receptors were present almost exclusively in isolated mo-
toneurons, and to a lesser extent in spinal cord, but not in the
neuronal cell lines. The serotonin receptor functions in fast
depolarization of neurons and is not expected to be present in
motoneurons. Accordingly, we did not detect it in motoneu-
rons. It was, however, identified in NSC-34 and N2a cells,
suggesting that they do not faithfully represent motoneuronal
characteristics in this respect. Overall, slightly more receptor
proteins were present in N2a than in NSC-34 cells. Despite
the striking differences of both neuronal cell lines relative to
primary motoneurons, their protein abundance patterns
FIG. 4. Evaluation of neuronal pathway enrichments and neu-
ron-specific protein abundances. A–C, pairwise comparison of en-
riched annotations in different cellular model systems. Annotations
are depicted by their enrichment factor and statistical significance,
similar to volcano plots for protein populations.
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clearly indicated a neuronal inheritance compared with Hepa
1–6.
Evaluation of ALS-associated Proteins—As mentioned
above, ALS-associated proteins span a wide range of cellular
functions and are not generally neuron specific. The presence
and abundance of these ALS-associated proteins are impor-
tant aspects for studying disease mechanisms and therefore
for evaluating the suitability of disease models. We found that
most ALS-associated proteins were indeed present in the
proteomes of NSC-34 and N2a cell lines (Fig. 6). Compared
with neuronal proteins, the differences between the cellular
systems were smaller but still distinct. For example, whereas
we observed major expression-level differences for ALS-as-
sociated neuron-specific proteins such as the Eph4 receptor,
the neurofilament protein Nefl, and the microtubule-associ-
ated Mapt, levels were similar for proteins that are not neuron
specific, such as Sod1.
DISCUSSION
Motoneuron diseases such as ALS or spinal muscle atrophy
are incurable, and no effective symptomatic treatments are
available. Researchers make use of a variety of different cell
culture model systems to unravel disease pathways and to
understand pathological mechanisms (19, 21, 54). However,
the proteomics properties of these systems have never been
assessed on a global level. Here we provide a large-scale and
quantitative analysis comparing the proteomes of primary
motoneurons to the neuroblastoma cell lines NSC-34 and
N2a, as well as to unrelated cell lines. The quantitative inven-
tory of expressed proteins in these systems should serve as a
valuable resource for the community. We have made these
data easily accessible in the MaxQB database (55). Users can
query the expression rank order of proteins of interest, se-
quence coverage, high-resolution MS/MS spectra of pep-
tides, and many other features of the proteome. Moreover,
our study presents a generic approach with which to evaluate
model systems using high-resolution quantitative mass-spec-
trometry-based proteomics.
Unexpectedly, our proteomics results at both global and
individual protein levels only place the neuronal cell line mod-
els halfway between the actual target tissue (in vivo motoneu-
rons) and completely unrelated cell lines derived from mouse
liver cancer or mouse embryos. We found proteins with high
relevance for neuronal function, in particular neurotransmitter
receptors and proteins involved in neuronal excitability and
neurotransmitter release, to be strongly underrepresented in
NSC-34 and N2a. The abundances of glutamate receptors
were considerably lower as well, suggesting nonexistent or at
least significantly diminished neuronal excitability. Because
disease pathways associated with excitotoxicity, in particular
glutamate toxicity, are frequent areas of focus in ALS research
(19, 56), this leads us to question the suitability of these cell
lines for such studies. The nerve growth factor receptor is
highly abundant during development and when neurons are
lesioned or degenerating (57–60). In accordance with this,
we found nerve growth factor receptor to be highly abun-
dant in E12.5 spinal cord, whereas it was down-regulated in
primary motoneurons, which are terminally differentiated.
This receptor also showed relatively high abundance in
NSC-34 and N2a cell lines, further suggesting differences
relative to motoneurons.
Mechanisms that destabilize axons are a major focus of
research in neurodegeneration (53). In this regard it is impor-
FIG. 5. Evaluation of neuron-specific protein abundances. A, B,
abundances of selected proteins that are members of the neuronal
annotation classes in Fig. 3. The normalized MS-derived abundance
values allow comparisons within and between cellular systems.
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tant to take the observed differences for cytoskeleton-asso-
ciated proteins—for instance, for Mapt and Nefl, which were
much lower in N2a and NSC-34 cells than in primary mo-
toneurons—into account. In addition, various members of the
axon guidance family such as Slits/Robos, Semaphorins, Ne-
trins, or Ephrins showed altered abundance patterns in
NSC-34 and N2a. Together, these observations raise the
question of whether N2a and NSC-34 cells are reliable models
regarding motoneuronal structure, in particular axon growth
and maintenance. Although both cell lines certainly exhibit
aspects of neuronal morphology, at the proteomics level,
neuronal features mainly become apparent in comparison to
unrelated, non-neuronal cell lines. Our data thus indicate that
the morphological tendency toward motoneurons does not
correspond directly to the protein level. This also suggests
that morphological comparisons can usefully be comple-
mented by quantitative proteomic data.
In contrast to these motoneuron-specific pathways, univer-
sal metabolic and housekeeping pathways were less altered
between cell lines and primary cells. The main difference
highlighted by bioinformatic analysis of the proteomic data
was an up-regulation of DNA metabolism (Fig. 3). This is
because cell culture favors rapidly dividing cells, and any
non-essential metabolic pathways are counter-selected. The
same reasoning might also explain the down-regulation of
pathways such as receptor signaling and of proteins impor-
tant for the maintenance of complex cellular morphologies
noted above.
We further found differences in the expression levels of
some, but not all, ALS-associated proteins in the analyzed
cellular systems. For many of them, such as mutant Sod1 or
wild-type Tdp-43 (61), even relatively small expression levels
(2-fold overexpression relative to wild-type levels, for instance
(62)) are known to have severe effects on the pathogenic
cascade and the onset of symptoms (63). Furthermore, mo-
toneuron diseases are highly cell-type specific, suggesting a
narrow physiological niche for manifestation of a pathological
phenotype. Therefore, in addition to the fact that moderate
differences in ALS protein abundances may be very impor-
tant, the general motoneuronal characteristics as evidenced
by quantitative proteomics need to be taken into account.
Thus neuroblastoma cell lines are limited in terms of their
suitability to serve as model systems for motoneurons for the
study of ALS-relevant functional mechanisms, as they neither
reconstitute global motoneuronal properties nor faithfully
mimic motoneurons on the individual protein level. However,
they still retain neuronal character in comparison to other cell
lines, rendering them a valid choice for some biological inves-
tigations and high-throughput screens.
In conclusion, we here present a resource for motoneuron
disease research. Because of the high protein coverage in
cell lines and primary motoneurons, our data highlight im-
portant cellular pathways unique to or enriched in neurons
and functionally relevant in motoneurons. Our study exem-
plifies how quantitative proteomics can be used to critically
evaluate the suitability of model systems in general. De-
FIG. 6. Evaluation of ALS-associated protein abundances. A, ranked abundances of ALS-associated proteins in the context of the entire
proteome. B, normalized MS-derived expression values of the same proteins as in A, depicted as a heat map for motoneurons, NSC-34, N2a,
Hepa 1–6, and E12.5 spinal cord.
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pending on the intended experiments, the best cellular
model system can be chosen according to the presence or
abundance of the involved receptors or neuronal pathways
(such as ALS or signaling studies). In the current context, for
instance, it would be interesting to compare the proteome
of primary motoneurons to in vitro differentiated motoneu-
rons derived from induced patient-derived pluripotent stem
cells with a view to evaluate these exciting and promising
new model systems.
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Article 2 
C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins 
cause neuronal toxicity and Unc119 sequestration 
Misfolded and aggregated proteins are cardinal features of neurodegenerative disorders. Our 
collaborators have recently discovered that the hexanucleotide repeat expansion in C9orf72, which 
marks the most common pathogenic mutation in patients with ALS and FTD, is translated in an ATG 
start codon independent manner 48. The resulting poly-dipeptide repeat (pDPR) forms insoluble 
aggregates in the cytosol. To better understand the pathological mechanism of these insoluble 
aggregates we investigated their proteome composition. We optimized the sample preparation to 
break down pDPR associate proteins and were able to determine the corresponding “aggregatome” 
in primary cortical neurons. As expected, these aggregates are associated with components of the 
ubiquitin / proteasome machinery like the sequestosome. To identify novel pathological mechanisms, 
we were specifically interested in proteins that are not associated with protein degradation. Among 
those, the transport adapter UNC119 showed a complete sequestration into the aggregates. Biological 
follow up on UNC119 revealed that this sequestration is at least partially responsible for the 
neurotoxic effects of the aggregates. Moreover, histological analysis of postmortem brain tissue 
confirmed the sequestration of UNC119 in ALS patients. This article provides a proof of concept for 
identification of novel disease players by proteomics-based research on toxic aggregates, and makes 
a significant contribution to the understanding of the general toxic mechanism of protein aggregates 
in ALS / FTD and neurodegeneration. The paper has been cited 14 times (Google Scholar) within 
less than a year, illustrating the interest in our findings.  
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protein aggregates. I developed a sample preparation workflow that allows to breakdown the 
proteolytic resistant aggregates. Further, I measured and analyzed the data and identified several 
novel disease relevant proteins such as Unc119. 
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to identify poly-GA co-aggregating proteins revealed a sig-
nificant enrichment of proteins of the ubiquitin–proteasome 
system. Among the other interacting proteins, we identified 
the transport factor Unc119, which has been previously 
linked to neuromuscular and axonal function, as a poly-
GA co-aggregating protein. Strikingly, the levels of soluble 
Unc119 are strongly reduced upon poly-GA expression in 
neurons, suggesting a loss of function mechanism. Similar 
to poly-GA expression, Unc119 knockdown inhibits den-
dritic branching and causes neurotoxicity. Unc119 over-
expression partially rescues poly-GA toxicity suggesting 
that poly-GA expression causes Unc119 loss of function. 
In C9orf72 patients, Unc119 is detectable in 9.5 % of GA 
inclusions in the frontal cortex, but only in 1.6 % of GA 
inclusions in the cerebellum, an area largely spared of neu-
rodegeneration. A fraction of neurons with Unc119 inclu-
sions shows loss of cytosolic staining. Poly-GA-induced 
Unc119 loss of function may thereby contribute to selective 
Abstract Hexanucleotide repeat expansion in C9orf72 
is the most common pathogenic mutation in patients with 
amyotrophic lateral sclerosis (ALS) and frontotemporal 
lobar degeneration (FTLD). Despite the lack of an ATG 
start codon, the repeat expansion is translated in all read-
ing frames into dipeptide repeat (DPR) proteins, which 
form insoluble, ubiquitinated, p62-positive aggregates that 
are most abundant in the cerebral cortex and cerebellum. 
To specifically analyze DPR toxicity and aggregation, we 
expressed DPR proteins from synthetic genes containing a 
start codon but lacking extensive GGGGCC repeats. Poly-
Gly-Ala (GA) formed p62-positive cytoplasmic aggregates, 
inhibited dendritic arborization and induced apoptosis in 
primary neurons. Quantitative mass spectrometry analysis 
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vulnerability of neurons with DPR protein inclusions in the 
pathogenesis of C9orf72 FTLD/ALS.
Keywords Neurodegeneration · C9orf72 · FTLD · ALS · 
Unc119 · Proteomics
Introduction
Amyotrophic lateral sclerosis (ALS) and frontotemporal 
lobar degeneration (FTLD) are severe neurodegenerative 
diseases with no effective treatment. Degeneration of the 
upper and lower motor neurons in ALS leads to progressive 
paralysis [42]. Depending on the affected regions, FTLD 
patients suffer from dementia, behavioral abnormalities, 
language impairment and personality changes [21]. Both 
diseases have overlapping clinical, neuropathological and 
genetic features and are often described as extreme ends of 
a disease spectrum [22].
Recently, a mutation in the non-coding region of the 
C9orf72 gene has been identified as the most common 
genetic cause of both ALS and FTLD [12, 20, 41]. Muta-
tion carriers have a GGGGCC hexanucleotide repeat 
expansion either in the first intron or the promoter region, 
depending on the isoform of the C9orf72 transcript [5]. 
Patients typically have several hundred or thousand repeats, 
whereas healthy controls show <33 repeats [5, 51]. C9orf72 
patients exhibit clinical symptoms similar to other FTLD or 
ALS subtypes, but suffer from an unusually high incidence 
of psychosis [13].
In addition to the common TDP-43 aggregates in FTLD 
and ALS, C9orf72 mutation carriers have abundant star-
shaped, TDP-43-negative neuronal cytoplasmic inclu-
sions (NCI) particularly in the cerebellum, hippocampus 
and frontal neocortex that stain positive for markers of 
the proteasome system (UPS) such as p62 or ubiquitin [1, 
7]. We and others discovered that these TDP-43-negative 
inclusions contain dipeptide repeat proteins (DPR) that are 
translated ATG-independent from both sense and antisense 
transcripts of the C9orf72 repeat in all reading frames [4, 
19, 33, 35, 36, 55]. Repeat translation results in five DPR 
species, poly-GA, poly-GR, poly-GP, poly-PR and poly-
PA. Nearly all TDP-43-negative inclusions contain poly-
GA, while the other DPR species co-aggregate to a lesser 
extent. The translation of the DPR proteins is initiated 
without an ATG start codon, a phenomenon that was ini-
tially discovered in other repeat expansion disorders such 
as myotonic dystrophy 1 and spinocerebellar ataxia type 8 
and was recently also found in fragile X-associated tremor/
ataxia syndrome (FXTAS) [48, 54].
Several possible disease mechanisms are discussed 
(reviewed in [18, 32]). First, DPR protein aggregates, 
or their precursors, may be toxic through binding or 
sequestration of cellular proteins. Second, both sense and 
antisense repeat transcripts accumulate in nuclear RNA foci 
and may cause the sequestration of specific RNA-binding 
proteins, which potentially impairs the physiological func-
tion of those proteins [15, 26, 43]. Third, C9orf72 mRNA 
expression is downregulated in patients with a hexanucleo-
tide repeat expansion, which may indicate a loss of func-
tion pathomechanism [12, 20]. Currently, the physiological 
function of C9orf72 and the relative importance of the three 
proposed disease mechanisms are still unclear.
The investigation of aggregation and toxicity of DPR 
proteins is essential to further elucidate their role in disease 
progression. Therefore, we developed a primary neuronal 
cell culture model to test the toxicity and aggregation prop-
erties of poly-GA, the most abundant of the five DPR spe-
cies in patient brain [35]. Our cell-based model reproduces 
key disease features, including formation of insoluble poly-
GA aggregates and co-aggregation with p62. Strikingly, 
poly-GA expression caused neurotoxicity, suggesting that 
our cell culture model is a valuable tool to study DPR pro-
teins in vitro. To elucidate the mechanism of GA-mediated 
neurotoxicity, we analyzed the proteome composition of 
poly-GA aggregates in our model using mass spectrometry-
based proteomics. Recently, we have developed a label-free 
workflow which allows multiple quantitative comparisons 
of cellular systems [9, 28] and enables an unbiased analy-
sis of protein aggregates from primary cells. Using this 
approach, we identified Unc119 as a potential new disease-
relevant protein, which is co-aggregating in DPR protein 
inclusions of C9orf72 patients.
Materials and methods
Antibodies and reagents
The following antibodies were used: Anti-GFP (mouse 
N86/8, Neuromab, Davis, CA, USA and rabbit, Clontech, 
Mountainview, CA, USA), anti-β-actin (Sigma Aldrich, St. 
Louis, MO, USA), anti-myc (mouse 9E10 and rabbit A-14, 
Santa Cruz biotechnology, Dallas, TX, USA), anti-p62 for 
immunoblotting (Cell Signaling, Danvers, MA, USA), anti-
p62 for immunofluorescence (MBL, Nagoya, Japan), anti-
HA (Sigma Aldrich), anti-V5 (Life technologies, Carlsbad, 
CA, USA), anti-TDP43 (Sigma Aldrich), anti-phospho-
TDP-43 (Ser409/Ser410, rat, clone 1D3) [38], anti-PSD-95 
(K28/43, Neuromab), anti-Unc119 (termed Unc119#2, 
ThermoFisher scientific, Pierce Biotechnology, Rockford, 
IL, USA), anti-poly-GA [29], anti-PSMC2 (Bethyl labo-
ratories, Montgomery, TX, USA), anti-PSMC4 (Bethyl 
laboratories), anti-MAP2 (AP-20, Sigma Aldrich), DAPI 
(Roche Applied Science, Penzberg, Germany). An Unc119 
specific antibody (Unc119#1) was raised and affinity 
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purified against full-length human Unc119 fused to GST 
in rabbits (Eurogentec, Seraing, Belgium) as described 
previously [36]. For competition experiments, the diluted 
Unc119 antibodies were preincubated with native or dena-
tured GST or GST-Unc119 (25 μg/ml) for 2 h at 37 °C. For 
denaturation, the concentrated GST fusion proteins were 
heated in 1 % SDS 50 mM Tris pH 8.0 at 95 °C for 5 min. 
We raised a poly-AP specific monoclonal antibody (clone 
14E2 of isotype IgG1) by immunizing rats with synthetic 
AP10 peptide as described previously [29].
DNA constructs and lentivirus production
Synthetic genes for DPR sequences with ATG start codon, 
reduced GC content and very few remaining GGGGCC 
repeats were made to order with C-terminal epitope tags 
(Life technologies, Geneart, Regensburg, Germany). For 
details and design rational see Fig. S1a. The full sequence 
information is available in the supplemental methods. Syn-
thetic genes and the original GGGCCG-based poly-GP con-
struct with an ATG start codon were subcloned into pEF6/
V5-His vector (Life technologies) or a lentiviral vector 
driven by human synapsin promoter (FhSynW2). To replace 
the ATG start codon in the GA149-myc construct with a TAG 
stop codon we cloned annealed oligonucleotides between 
an SgrAI site at the 5′ end of the open reading frame and 
the EcoRI site in the vector. As a negative control GFP from 
pEGFP-N1 (Clontech) was subcloned into pEF6/V5-His 
and FhSynW2. The GGGGCC repeat constructs without 
ATG start codon had been described previously [36]. Rat 
and human Unc119 cDNA was expressed from a lentiviral 
vector driven by human ubiquitin promoter containing an 
N-terminal HA-tag (FUW2-HA). We used shRNA targeting 
rat Unc119 (GAGAGGCACTACTTTCGAA) or a control 
targeting firefly luciferase (CGTACGCGGAATACTTCGA) 
driven by the H1 promoter in the vector FUW coexpressing 
TagRFP both for transfection and transduction. Lentivirus 
was produced in HEK293FT cells (Life Technologies) as 
described previously [17]. The Q102-GFP construct in pCS2 
vector was a gift from B. Schmid [44].
Cell culture, immunoblotting and immunofluorescence
HEK293FT cells were transfected using Lipofectamine 
2000 according to the manufacturer’s instructions. For 
immunoblotting, cells were harvested in RIPA buffer 
(137 mM NaCl, 20 mM Tris pH 7.5, 0.1 % SDS, 10 % 
Glycerol, 1 % Triton X-100, 0.5 % Deoxycholate, 2 mM 
EDTA) containing protease and phosphatase inhibitor cock-
tails (Sigma). Cells were lysed on ice for 20 min and cen-
trifuged at low speed to avoid pelleting of the DPR protein 
aggregates (1,000g for 10 min at 4 °C). The supernatant was 
mixed with 4 × loading buffer (0.4 M sodium phosphate 
pH 7.5, 8 % SDS, 40 % glycerol, 10 % 2-mercaptoethanol, 
bromphenol blue) and incubated at 95 °C for 5 min. Primary 
hippocampal or cortical neurons were cultured from embry-
onic day 19 rats and infected with lentiviruses as described 
previously [17, 47]. Primary cortical neurons infected with 
indicated lentiviruses were harvested with 2x loading buffer. 
Samples were run on 12.5 % SDS-PAGE gels or Novex 10–
20 % Tris-Tricine gels (Life technologies).
HEK293FT cells and primary neurons were fixed for 
10 min with 4 % paraformaldehyde and 4 % sucrose. 
Primary and secondary antibodies were diluted in GDB 
buffer (0.1 % gelatine, 0.3 % Triton X-100, 450 mM NaCl, 
16 mM sodium phosphate pH 7.4). Confocal images were 
obtained on a confocal laser scanning LSM710 system 
(Carl Zeiss, Jena) with a 40 × oil immersion objective. 
Sholl analysis was performed manually and blinded to 
the experimental conditions using MetaMorph software as 
described before [47].
Filter trap assay
To detect DPR aggregates, transfected HEK293FT cells or 
transduced neurons were harvested with 1 % Triton X-100, 
50 mM MgCl2 and 0.2 mg/ml DNase I in PBS. After cen-
trifugation (18,000g for 30 min at 4 °C) the pellet was 
resuspended in 2 % SDS in 100 mM Tris (pH 7.0). After 
1 h incubation at room temperature the homogenates were 
filtered through a Whatman cellulose acetate membrane 
with 0.2 μm pore size (Sigma Aldrich).
To detect Unc119 aggregates, brain samples were resus-
pended in RIPA buffer containing 0.2 mg/ml DNase I. 
After centrifugation (186,000g for 30 min at 4 °C) the pel-
let was resuspended in 1 % SDS in 100 mM Tris (pH 7.0) 
and treated as above.
Cellular assays
Viability of HEK293FT cells and primary neurons was 
analyzed according to the manufacturer’s instructions 
in 96 well plates: LDH Cytotox Non-Radioactive cyto-
toxicity assay (Promega), Caspase-glo 3/7 assay (Pro-
mega), TUNEL in situ cell death detection TMR red assay 
(Roche). For the TUNEL assay dead and living cells were 
counted manually with the Fiji cell counter plugin. At least 
400 cells per condition were counted per experiment in a 
total of three independent experiments. Proteasome activity 
was measured using the Proteasome-Glo kit according to 
the manufacturer’s instructions (Promega).
qPCR
RT-qPCR of primary cortical neurons was performed as 
described previously [39]. The following primers were 
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used for analysis of rat Unc119: GCGCTTTGTTCGATAC-
CAGT and TGTTCTTGCTGCTGGGAATG. GAPDH was 
used as a reference gene: CCGCATCTTCTTGTGCAGT-
GCC and AGACTCCACGACATACTCAGCACC.
Immunoprecipitation of poly-GA aggregates
Transduced cortical neurons or transfected HEK293FT 
cells were harvested in RIPA buffer as described above, 
additionally adding Benzonase (67 U/ml). Samples were 
rotated for 30 min at 4 °C prior to centrifugation (1,000g 
for 15 min at 4 °C). 2 % of the input was kept and the rest 
of the supernatant was added to 50 μl protein G dynabeads 
(Life Technologies), that were preincubated with 10 μg 
GFP antibody. After incubation (3 h at 4 °C) the magnetic 
beads were washed three times (150 mM NaCl, 50 mM 
Tris pH 7.5, 5 % Glycerol). One-fifth of the bead-mix was 
denatured in 4× loading buffer (95 °C, 5 min) for western 
blot analysis and the rest was kept for mass spectrometry 
(MS) analysis. For co-immunoprecipitations from trans-
fected HEK293FT cells the whole samples were analyzed 
by western blot.
Sample preparation for MS
The bead-mix was resuspended in 50 μl 8 M Urea, 10 mM 
Hepes pH 8.0. Protein cysteines were reduced with DTT 
and alkylated with iodoacetamide (IAA), followed by 
quenching of IAA with thiourea. Proteins were digested 
with LysC for 4 h and the bead-mix was centrifuged for 
5 min at 16,000g. The supernatant was removed and diluted 
with 4 volumes of 50 mM ammonium bicarbonate. The 
pellet was resuspended in 1 volume 6 M urea, 2 M thio-
urea, 10 mM Hepes pH 8.0, 4 volumes 50 mM ammonium 
bicarbonate and LysC. Trypsin was added to both fractions 
and the final digest was carried out for 16 h. The resulting 
peptide mix was desalted on C18 StageTips [40] and ana-
lyzed in single shots. Notably, in the supernatant we quanti-
fied only 50 proteins (data not shown) whereas over-night 
digestion of the pellet with LysC and trypsin resulted in 
over 450 quantifications.
LC–MS/MS
Peptides were separated on a Thermo Scientific EASY-nLC 
1000 HPLC system (Thermo Fisher Scientific, Odense, 
Denmark) via in-house packed columns (75 μm inner 
diameter, 20 cm length, 1.9 μm C18 particles (Dr. Maisch 
GmbH, Germany)) in a 100 min gradient from 2 % ace-
tonitrile, 0.5 % formic acid to 80 % acetonitrile, 0.5 % for-
mic acid at 400 nl/min. The column temperature was set to 
50 °C. An Orbitrap mass spectrometer [34] (Orbitrap Elite, 
Thermo Fisher Scientific) was directly coupled to the LC 
via nano electrospray source. The Orbitrap Elite was oper-
ated in a data-dependent mode. The survey scan range was 
set from 300 to 1,650 m/z, with a resolution of 120,000. 
Up to the five most abundant isotope patterns with a charge 
≥2 were subjected to collision-induced dissociation frag-
mentation at a normalized collision energy of 35, an isola-
tion window of 2 Th and a resolution of 15,000 at m/z 200. 
Data was acquired using the Xcalibur software (Thermo 
Scientific).
MS data analysis and statistics
To process MS raw files, we employed the MaxQuant soft-
ware (v 1.4.0.4) [9] and Andromeda search engine [11], 
against the UniProtKB Rat FASTA database (06/2012) 
using default settings. Enzyme specificity was set to trypsin 
allowing cleavage N-terminally to proline and up to 2 mis-
cleavages. Carbamidomethylation was set as fixed modifi-
cation, acetylation (N-terminus) and methionine oxidation 
were set as variable modifications. A false discovery rate 
(FDR) cutoff of 1 % was applied at the peptide and pro-
tein level. ‘Match between runs’, which allows the trans-
fer of peptide identifications in the absence of sequenc-
ing, was enabled with a maximum retention time window 
of 1 min. Protein identification required at least one razor 
peptide. Data were filtered for common contaminants 
(n = 247). Peptides only identified by site modification 
were excluded from further analysis. A minimum of two 
valid quantifications was required in either GA149-GFP or 
GFP quadruplicates.
For bioinformatic analysis as well as visualization, we 
used the open PERSEUS environment, which is part of 
MaxQuant and the R framework (Team, R Development 
Core, 2008). Imputation of missing values was performed 
with a normal distribution (width = 0.3; shift = 1.8). For 
pairwise comparison of proteomes and determination of 
significant differences in protein abundances, t test statis-
tics were applied with a permutation-based FDR of 2 % 
and S0 of 2 [50]. For GA-aggregate interacting proteins 1D 
annotation enrichment on the Welch-test difference using 
Uniprot Keywords with a Benjamini–Hochberg corrected 
FDR of 2 % showed a significant enrichment of the annota-
tions for the ubiquitin–proteasome system (gene ontology 
molecular function: “ubiquitin binding”, pfam: “ubiqui-
tin”, uniprot keywords: “proteasome”) (p value = 8.7−11, 
score = 0.77, 5.7-fold enrichment) [10].
Patient samples
All patient materials were provided by the Neurobiobank 
Munich, Ludwig-Maximilians-University (LMU) 
Munich and were collected and distributed accord-
ing to the guidelines of the local ethical committee. 
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Clinical data are listed in Table S1. Immunohistochemis-
try and immunofluorescence stainings were performed as 
described previously [35]. For competition experiments 
the Unc119#1 antibody was preincubated with 0.25 μg/μl 
native GST or GST-Unc119 for 2 h at 37 °C. To compare 
poly-GA aggregates from patient tissue with aggregates 
from neuronal culture, non-fixed brain-tissue sample of 
1 mm in diameter was smeared between two slides and 
fixed and stained like cultured neurons. For quantifica-
tion of Unc119 and GA co-aggregation in the different 
brain regions three patients were manually analyzed. In 
each region at least 300 GA aggregates were counted per 
patient.
Results
Poly-GA forms p62-positive SDS-resistant aggregates 
in HEK293 cells
To investigate the characteristics of the five different DPR 
species in cell culture, we generated ATG-initiated epitope-
tagged expression constructs for all reading frames of the 
GGGGCC repeat (Fig. S1a). These synthetic constructs, 
encoding 149–175 repeats, contain a mixture of alterna-
tive codons with reduced GC content to prevent instabil-
ity observed with repetitive GGGGCC-based constructs in 
E. coli, while allowing for high expression in mammalian 
cells (Fig. 1). Moreover, changing the original hexanu-
cleotide repeat sequence, but maintaining the DPR protein 
sequence, allowed us to focus on protein toxicity rather 
than GGGGCC or CCCCGG RNA toxicity. Unfortunately, 
gene synthesis for poly-GP constructs repeatedly failed. 
Thus, we generated an ATG-initiated construct from the 
endogenous repeat sequence encoding about 80 GP repeats. 
Importantly, without an ATG start codon GGGGCC repeat 
constructs did not impair cell viability in HEK293 cells 
excluding overt RNA toxicity of the utilized constructs 
(Fig. S1b).
To verify protein expression, we transfected HEK293 
cells with the DPR constructs (Fig. S1c). We observed pro-
tein products of the expected size for GP80-V5 (21 kDa), 
but not for GA175-GFP (50 kDa), GFP-GR149 (68 kDa), 
PR175-GFP (71 kDa) and PA175-myc (31 kDa). Similar to 
immunoblots from patient brains [36], specific bands at the 
top of the gel for GA175-GFP, GFP-GR149, PR175-GFP and 
PA175-myc indicate formation of insoluble aggregates for 
these species (Fig. S1c).
To compare the localization and aggregation of the dif-
ferent DPR species we analyzed transfected HEK293 cells 
by immunofluorescence (Fig. 1, S2a/b). Strikingly, poly-
GA, the most abundant DPR species in patients [35, 36], 
predominantly formed distinct dot-like or star-shaped 
inclusions in the cytosol (Fig. 1) and occasionally in the 
nucleus (Fig. S2a). In contrast, GFP-GR149 showed mainly 
cytoplasmic staining. PR175-GFP was diffusely local-
ized, both in the cytosol and nucleus. Additionally, GFP-
GR149 and PR175-GFP expressing cells often showed large 
dot-like intranuclear inclusions and occasionally smaller 
cytoplasmic inclusions. In contrast, poly-PA was evenly 
distributed throughout the nucleus and cytoplasm without 
apparent aggregation. GP80-V5 was distributed through-
out the cytoplasm without forming compact inclusions 
(Fig. 1).
The poly-GA inclusions were strongly positive for p62 
(Fig. 1), suggesting that cytoplasmic poly-GA forms ubiq-
uitinated aggregates similar to the abundant poly-GA inclu-
sions found in C9orf72 FTLD/ALS [36]. Some GP80-V5 
expressing cells also showed increased p62 levels and co-
localization with GP80-V5. For the other DPR species no 
such co-localization was detected. Moreover, immunofluo-
rescence and immunoblotting showed overall increased p62 
levels only in GA175-GFP expressing cells (Fig. 1, S1c). In 
HEK293 none of the constructs induced cell death in an 
LDH release assay (Fig. S2c).
To confirm aggregation of the DPR proteins, we per-
formed a filter trap assay with HEK293 extracts in the 
presence of 2 % SDS. Insoluble GA175-GFP and GFP-
GR149 aggregates were readily detectable on the cellulose 
acetate filter even upon 125-fold dilution, but no signal was 
detected for GP80-V5, PR175-GFP and AP175-myc with spe-
cific antibodies under these conditions suggesting that they 
are less aggregation prone and can be solubilized at 2 % 
SDS in the filter trap assay, but not at 0.1 % SDS in poly-
acrylamide gels (compare Fig. S1c and S2d).
Taken together, GA175-GFP, GFP-GR 149 and PR175-GFP 
DPR proteins formed cytoplasmic or nuclear inclusions in 
HEK293 cells. Although the number of repeats was differ-
ent for the individual constructs, these data suggest differ-
ential solubility of the five DPR species, since AP175-myc, 
one of the longest constructs, apparently, remained soluble 
under these conditions even when omitting the GFP tag. 
However, we cannot exclude that longer repeats (on aver-
age 1,000–2,000) observed in patients may promote aggre-
gation of all DPR species. Importantly, poly-GA mimicked 
most closely the pathology in patient brain by forming com-
pact p62-positive cytoplasmic inclusions and SDS-resist-
ant aggregates and was therefore used for all subsequent 
experiments.
Poly-GA forms inclusion in primary hippocampal 
and cortical neurons
Poly-GA expression in HEK293 cells recapitulates all 
known features of DPR inclusions seen in C9orf72 patients, 
without causing toxicity (Fig. S2c). However, DPR proteins 
490 Acta Neuropathol (2014) 128:485–503
1 3
p62GFP merge DAPI
GA175-GFP
GFP-GR149
GP80-V5
PA175-myc
PR175-GFP
GFP
GA
GR
GP
PA
PR
491Acta Neuropathol (2014) 128:485–503 
1 3
are almost exclusively expressed in neurons [4, 36] and the 
C9orf72 mutation leads to selective degeneration of neu-
rons. Thus, we analyzed the effects of long-term expres-
sion of poly-GA in post-mitotic neurons using lentiviral 
transduction.
Lentiviral expression of GA149-GFP in primary rat hip-
pocampal neuron cultures resulted in compact p62-pos-
itive poly-GA inclusions (Fig. 2a) similar to the results 
in HEK293 cells (Fig. 1) and patients [36]. Poly-GA/
p62-positive dot-like structures were most common in the 
cell soma, but were also detectable within dendrites. This 
finding is reminiscent of the poly-GA-positive dystrophic 
neurites seen in patient brains [29, 36]. Importantly, the 
DPR inclusions in transduced neurons and patient neurons 
showed comparable poly-GA staining intensities suggest-
ing that ATG-driven expression in neurons is a valid model 
to study DPR toxicity in vitro (Fig. S3). In immunoblots of 
neuronal extracts all poly-GA protein was retained at the 
top of the gel indicative of high molecular weight aggre-
gates (Fig. 2b). Consistent with the data in HEK293 cells 
(Fig. 1, S1c) and patient data [2, 49], p62 levels were 
strongly increased in poly-GA expressing cells. In contrast, 
TDP-43 levels were unaffected by GA149-myc expression 
(Fig. 2b) and pathological TDP-43 phosphorylation could 
not be detected (data not shown). Filter trap analysis fur-
ther corroborated the formation of SDS-resistant poly-GA 
aggregates in primary neurons (Fig. 2c).
Poly GA is toxic in primary hippocampal and cortical 
neurons
Whether DPR proteins contribute to neurodegeneration in 
C9orf72 patients is still unclear. In GA149-GFP express-
ing cultures, the neuron density appeared lower although 
the remaining cells maintained the typical neuronal mor-
phology. However, neurite branching as judged by MAP2 
staining appeared less complex (Fig. 2a). Therefore, we 
quantified dendritic complexity by Sholl analysis, which 
confirmed reduced branching in GA149-myc transfected 
neurons (Fig. 3a, b).
Furthermore, we quantified neuronal apoptosis in len-
tivirus transduced cells using several different methods. 
Compared to controls, GA149-myc expressing cortical neu-
rons showed a highly significant 2.0-fold increase in Cas-
pase 3/7 activity (Fig. 3c). Moreover, by analyzing apop-
totic DNA fragmentation in primary hippocampal neurons 
using TUNEL labeling, we detected a highly significant 
2.5-fold increase in the number of apoptotic cells (Fig. 3c, 
compare Fig. S4). Neurotoxicity was also associated with 
enhanced LDH release in GA149-myc expressing cells 
(Fig. 3e).
To exclude that the synthetic non-GGGGCC repeat 
sequence encoding GA149-myc in our constructs causes 
RNA-mediated toxicity we replace the ATG start codon 
with a stop codon (TAG-GA149-myc, compare Fig. S1a). 
Without a start codon we detected no poly-GA expres-
sion from the synthetic GA149-myc gene upon transduc-
tion of primary neurons (Fig. 3d) indicating that this non-
GGGGCC construct does not support RAN translation. 
Importantly, TAG-GA149-myc did not impair viability 
suggesting that the ATG-GA149-myc construct causes neu-
rotoxicity due to poly-GA expression and not due to RNA 
toxicity (Fig. 3e). Therefore, ATG-driven poly-GA expres-
sion constructs were used for the remainder of this study.
In summary, poly-GA formed p62-positive inclusions 
as seen in neurons of patients with C9orf72 mutation and 
induced apoptosis in primary cortical and hippocampal 
neurons, suggesting an important role of poly-GA in the 
pathogenesis of C9orf72 FTLD/ALS.
Poly-GA co-aggregates with components of the ubiquitin–
proteasome system and the cargo adaptor Unc119
Since DPRs are highly unusual proteins, we wondered if 
DPR inclusions sequester endogenous proteins and could 
thereby contribute to disease progression. To this end, 
we transduced primary cortical neurons with a lentivirus 
expressing GA149-GFP or GFP alone and immunoprecipi-
tated the interacting proteins with anti-GFP in quadrupli-
cates (Fig. S5a). To identify co-aggregating proteins by 
an unbiased approach we applied label-free quantitative 
proteomics. By comparing relative protein abundances in 
GA149-GFP and GFP samples we quantified 450 proteins, 
20 of which were strongly enriched in poly-GA aggregates 
(Fig. 4a, Table 1).
Importantly, p62/Sqstm1, a marker protein for DPR inclu-
sions [4, 33, 36, 55], showed strongest enrichment (Fig. 4a), 
which is consistent with p62 upregulation (Fig. 2b) and p62/
GA co-localization (Fig. 2a). Proteasomal subunits (e.g., 
PSMB6) and other ubiquitin-related proteins (e.g., Ubiqui-
lin 1 and 2) were 5.7-fold enriched in the poly-GA interac-
tome (p value = 8.7 × 10−11) (Fig. 4a; Table 1). However, 
chymotrypsin-like, trypsin-like and caspase-like protease 
Fig. 1  DPR species show differential aggregation properties in 
HEK293 cells. HEK293 cells were transfected with the five differ-
ent DPR constructs (GA175-GFP, GFP-GR149, PR175-GFP, PA175-
myc and GP80-V5) or GFP as a control and analyzed 2 days later 
by GFP fluorescence or in case of PA175-myc and GP80-V5 by 
immunofluorescence using specific antibodies. DAPI was used as a 
nuclear marker. Cytoplasmic inclusions (white arrows) and nuclear 
inclusions (magenta arrows) are seen for GA175-GFP, GFP-GR149 
and PR175-GFP. Many dot-like and star-shaped GA175-GFP inclu-
sions co-localize with p62 (second column from the left). Right pan-
els show close-ups of areas indicated in the merge column. Magnifi-
cations of intranuclear GA175-GFP inclusions are shown in Fig. S2a. 
Negative control stainings are shown in Fig. S2b. Scale bar repre-
sents 15 μm for overview and 5 μm for close-up
◂
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activities associated with the proteasome was not impaired 
in HEK293 cells expressing poly-GA (Fig. S5b). Moreover, 
the levels of two proteasomal proteins, PSMC2 and PSCM4, 
were unaffected by poly-GA expression in HEK293 cells 
and neurons (Fig. S5c/d). TDP-43 was not identified as poly-
GA co-aggregating protein which is in line with the lack of 
significant co-localization in patients [4, 33, 35, 36, 55]. Inter-
estingly, one of the interaction partners, Unc119, which was 
7.5-fold enriched in the GA149-GFP immunoprecipitates, was 
previously identified through severely impaired locomotion in 
a C. elegans mutant and is required for axon development and 
maintenance [23, 30], which warranted further analysis in the 
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Fig. 2  Poly-GA forms p62-positive aggregates in neurons. a Immu-
nofluorescence of primary hippocampal neurons transduced with 
GA149-GFP or GFP control lentivirus at day 6 in vitro for 15 days 
(DIV6 + 15). Immunostaining for p62 and the dendritic marker 
protein MAP2. DAPI was used a nuclear marker. Poly-GA forms 
p62-positive inclusions (arrow) in the soma and dendrites. Scale 
bar 15 μm. b Immunoblotting of primary cortical neurons trans-
duced with GA149-myc or GFP control lentivirus (DIV6 + 17) with 
the indicated antibodies. Poly-GA aggregates are stuck at the top of 
the gel (arrow). GA149-myc induces upregulation of p62, but levels 
of TDP-43 and the synaptic marker protein PSD-95 are not affected. 
Three separate transductions are shown. c Filter trap assay of primary 
cortical neurons transduced with GA149-myc or GFP (DIV6 + 17). 
Poly-GA aggregates are detected in the serial dilution of homogen-
ates using anti-GA
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context of ALS. Moreover, Unc119 binds to a myristoylated 
GAGASA motif of Transducin α (GNAT1), which bears 
strong resemblance to poly-GA [53]. To confirm that Unc119 
interacts and co-aggregates with poly-GA, we co-expressed 
HA-tagged Unc119 with GA175-GFP in HEK293 cells. This 
resulted in pronounced co-localization of HA-Unc119 with 
GA175-GFP inclusions, which is in contrast to the diffuse 
cytoplasmic localization of HA-Unc119 in GFP expressing 
cells (Fig. 4b, S6). Co-immunoprecipitation of HA-Unc119 
with both GA175-GFP and GA149-myc, but not GFP attests 
that the interaction is indeed mediated by poly-GA (Fig. S5e). 
In addition, upon co-expression in HEK293 cells, Unc119 did 
not co-aggregate with the other DPR species (GFP-GR149, 
PR175-GFP, GP80-V5 and PA175-myc) or Q102-GFP, an unre-
lated aggregating protein [44], supporting a specific interac-
tion of Unc119 and poly-GA (Fig. 4c).
Lentiviral co-expression of Unc119 with GA149-GFP in 
hippocampal neurons further corroborated the specific co-
aggregation of Unc119 with poly-GA (Fig. 5a). Neurons 
with poly-GA aggregates showed bright Unc119 inclusions, 
suggesting that a large fraction of cellular Unc119 becomes 
sequestered in poly-GA inclusions.
In summary, identification of the poly-GA interactome pro-
vides proteomic evidence for involvement of the ubiquitin–
proteasome system and suggests additional molecular targets 
of poly-GA toxicity through co-aggregation or sequestration.
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Fig. 3  Poly-GA causes dendrite loss and induces apoptosis in pri-
mary neurons. a Cortical neurons were co-transfected with empty 
vector as control (Ctrl) or GA149-myc together with GFP to outline 
cell morphology (DIV7 + 4). Scale bars represent 40 μm. b Den-
dritic complexity was measured using Sholl analysis by manually 
counting the number of dendrites crossing concentric circles around 
the soma. Poly-GA expression leads to significant reduction of den-
dritic branching. N = 3 with 40 cells analyzed per condition in each 
experiment, mean ± SEM. p < 0.001 for 12.5 μm radius, p < 0.0001 
from 25 to 50 μm radius, p < 0.001 for 62.5 μm radius, p < 0.01 for 
75 μm radius and p < 0.05 from 87.5 to 112.5 μm radius (two-way 
ANOVA). c Apoptosis in transduced neurons was analyzed using 
a fluorogenic assay to detect caspase 3/7 activation and a TUNEL 
assay to detect apoptotic DNA fragmentation (DIV6 + 17). Caspase 
3/7 activity was increased 2.0-fold in GA149-myc transduced cortical 
neurons. TUNEL-positive apoptotic cells (manually counted using 
the Fiji cell count plug-in) were increased by 2.5-fold in GA149-
myc transduced hippocampal neurons compared to control cells. 
Representative images of TUNEL stainings are shown in Fig. S2. 
DIV6 + 17. n = 3 experiments with 6 replicates each; mean ± SD, 
Student’s t test, ***p < 0.001. d Immunoblots of cortical neurons 
transduced with GA149-myc constructs with or without start codon 
(DIV8 + 10). Replacing the ATG start codon in the synthetic GA149-
myc gene with a TAG stop codon prevents poly-GA expression and 
aggregation. Arrow indicates top of the gel. e LDH release assay 
detected neurotoxicity of GA149-myc only in the presence of an ATG 
start codon in transduced cortical neurons (DIV8 + 14). One-way 
ANOVA with Tukey’s post-test. ***p < 0.001, n = 3 with six repli-
cates in each experiment
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Unc119 sequestration contributes to poly-GA toxicity
To analyze how poly-GA inclusions affect endogenous 
Unc119 we raised a polyclonal antibody against full-length 
human Unc119 (termed Unc119#1) and tested a commer-
cially available antibody (termed Unc119#2). Both antibod-
ies detected overexpressed rat and human Unc119 (Fig. S7a). 
To validate both antibodies on endogenous protein, we used 
RNAi to knockdown Unc119. Lentiviral expression of an 
Unc119 specific shRNA in neurons strongly reduced Unc119 
mRNA levels compared to control cells (Fig. S7b). Both 
Unc119 antibodies detected robust knockdown of endoge-
nous Unc119 protein by immunoblotting and immunofluores-
cence, thus confirming their specificity (Fig. S7c–e).
Although Unc119 was enriched in the poly-GA immu-
noprecipitation (Fig. 4a), almost no Unc119 could be 
detected at the regular size (27 kDa) in extracts of GA149-
myc expressing neurons by immunoblotting compared to 
C
GFP/GA HA-Unc119  DAPI
GFP+Unc119
GA+Unc119
B
GFP+ctrl
GA+ctrl
GA Unc119 GP Unc119
PA Unc119 PR Unc119 Q Unc119
GR Unc119
0
1
2
3
−2 0 2 4 6 8
Un 9
enrichment ubiquitin/proteasome
FDR: 2%, S0: 2
A
enrichment GA149-GFP vs GFP [log2]
C
ou
nt
 [l
n]
p-
va
lu
e
[-
lo
g1
0]
p62/Sqstm1
c119
Fig. 4  Unc119 specifically co-aggregates with poly-GA. a Quan-
titative proteomics of GFP immunoprecipitations from primary cor-
tical neurons transduced with GFP or GA149-GFP (DIV6 + 17). 
p62/Sqstm1 shows highest enrichment and statistical significance. 
Unc119 was identified by two unique peptides (GGGGTGP-
GAEPVPGASNR and LGPLQGK) and one peptide (YQFTPAFLR) 
shared with its homolog Unc119b. Full protein names are listed in 
Table 1. Upper panel illustrates distribution of quantified protein 
abundances binned for enrichment factors (x-axis below). Enrich-
ment of ubiquitin-related and proteasomal proteins in the poly-GA 
interactome is highlighted in green. Lower panel depicts volcano plot 
showing poly-GA interacting proteins. False discovery rate (FDR) 
controlled statistical analysis identified 20 poly-GA interacting pro-
teins compared to control (red dots). Dotted line depicts threshold for 
statistical significance. b Immunofluorescence of HEK293 cells co-
transfected with GFP or GA175-GFP and HA-Unc119 or empty vec-
tor control (ctrl). Staining with HA and GFP antibodies and DAPI as 
nuclear marker. Many GA175-GFP inclusions show co-aggregation 
of HA-Unc119 (examples marked with arrows). Separate channels 
of these images are shown in Fig. S6. Scale bar 30 μm. c HEK293 
cells were transfected with the five different poly-DPR constructs 
(GA175-GFP, GFP-GR149, PR175-GFP, PA175-myc and GP80-V5) or 
Q102-GFP and analyzed using GFP fluorescence and immunostain-
ing of HA-Unc119, PA175-myc and GP80-V5 using specific antibod-
ies 2 days later. HA-Unc119 co-aggregates only with GA175-GFP 
(white arrows). DAPI (in blue) was used as a nuclear marker. Scale 
bar 20 μm
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the GFP expressing control (Fig. 5b). Since the Unc119 
mRNA levels remained unchanged (Fig. 5c), this indicates 
that Unc119 sequestered in poly-GA aggregates becomes 
insoluble.
To analyze the effect of Unc119 loss of function in neu-
rons we transfected hippocampal neurons with specific 
shRNAs and analyzed neuron morphology. Unc119 knock-
down led to dendrite withering similar to poly-GA expres-
sion (Fig. 5d, e). Moreover, compared to a control shRNA, 
lentiviral Unc119 knockdown induced neuronal death 
as quantified by increased LDH release (Fig. 5f). While 
overexpression of HA-Unc119 alone had no effect on cell 
viability, HA-Unc119 overexpression reduced toxicity in 
GA149-myc expressing neurons suggesting that Unc119 
loss of function contributes to poly-GA toxicity in neurons. 
In contrast, Unc119 knockdown in GA149-myc expressing 
neurons did not increase toxicity, which also indicates that 
Unc119 loss of function is a major source of poly-GA tox-
icity (Fig. 5f).
In summary, sequestration of Unc119 in poly-GA aggre-
gates may cause Unc119 loss of function and contribute to 
FTLD/ALS pathogenesis.
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Fig. 5  Unc119 sequestration in neurons contributes to poly-GA 
toxicity. a Immunofluorescence of primary hippocampal neurons 
co-transduced with HA-Unc119 and either GFP or GA149-GFP 
(DIV6 + 17). Arrows indicate examples of poly-GA inclusions show-
ing co-aggregation of HA-Unc119. Scale bar 15 μm. b Immunoblot 
with the indicated antibodies in GFP or GA149-myc transduced cor-
tical neurons shows decreased levels of soluble Unc119 running at 
27 kDa. Two separate transductions are shown (DIV6 + 17). c qPCR 
analysis of neurons transduced as in (b) shows no significant changes 
in Unc119 mRNA levels (mean ± SD, Student’s t test, DIV7 + 10). 
(d, e) Hippocampal neurons transfected with shRNA targeting 
Unc119 (shUnc) or a non-targeting control (shCtrl) together with 
GFP to outline cell morphology (DIV7 + 5). Dendritic branching 
was quantified by Sholl analysis. Unc119 knockdown reduced den-
drite complexity significantly (p < 0.0001 for 12.5–62.5 μm radius 
and p < 0.001 for 75 μm radius, two-way ANOVA, n = 40 neurons 
per condition). Scale bar depicts 40 μm. f LDH release assay from 
cortical neurons co-transduced with either GFP or GA149-GFP (GA) 
together with HA-Unc119 (Unc), shRNA targeting Unc119 (shUnc) 
or non-targeting shRNA (shCtrl) (DIV6 + 17). Note that Unc119 
knockdown causes toxicity in GFP-transduced neurons, but does 
not increase poly-GA toxicity further. HA-Unc119 expression res-
cues GA149-GFP toxicity. One-way ANOVA with Tukey’s post-test. 
**p < 0.01, ***p < 0.001, n = 3 with six replicates in each experi-
ment
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Unc119 is a component of DPR inclusions in C9orf72 
patients
Next, we analyzed Unc119 localization in C9orf72 patients 
by immunohistochemistry using antibody Unc119#1 to 
validate co-aggregation with poly-GA found in vitro. In 
CA3/4 of the hippocampus Unc119 was mainly local-
ized in the cytoplasm (Fig. 6a). Moreover, in all analyzed 
C9orf72 FTLD/ALS patients Unc119-positive NCIs were 
detected, but no Unc119 NCIs were seen in healthy con-
trols (Fig. 6, S8d). In the hippocampus of C9orf72 patients, 
Unc119 formed star-shaped NCIs that appeared similar to 
poly-GA inclusions (Fig. 6b).
Further Unc119 NCIs were detectable in frontal cortex 
(Fig. 6c, d), occipital cortex (Fig. 6e) and the hippocampal 
dentate gyrus (Fig. 6f). Importantly, in a fraction of neurons 
nearly all Unc119 was sequestered into aggregates (Fig. 6b, 
d, f). Despite abundant DPR pathology only one of the five 
C9orf72 cases showed prominent Unc119 NCIs in the cere-
bellum (Fig. 6g). The second Unc119 antibody (Unc119#2) 
appeared less sensitive but showed robust NCI pathology 
in the frontal cortex and in the dentate gyrus (Fig. S8a/b). 
With both antibodies no Unc119 inclusions were detected 
in control cases (Fig. 6a, S8c/d).
To further validate antibody specificity we performed 
competition experiments with GST-Unc119 using immuno-
blotting (Fig. S9a) and immunohistochemistry (Fig. S9b). 
Both soluble and inclusion staining were strongly reduced 
upon preincubation with purified GST-Unc119 further con-
firming specificity of the Unc119#1 antibody (Fig. S9b). 
Importantly, this antibody also detected insoluble Unc119 
in C9orf72 patients but not in controls using filter trap 
(Fig. 6h).
Double immunofluorescence staining with both Unc119 
antibodies confirmed co-localization of poly-GA and 
Unc119 in the cortex and cerebellum of C9orf72 cases 
(Fig. 7a, b, S10a). Quantitative analysis in the frontal cor-
tex of three FTLD/ALS patients revealed that Unc119 was 
present in 9.5 ± 2.7 % of GA inclusions (mean ± stand-
ard deviation >300 poly-GA inclusions counted per 
patient). In contrast, only 0.4–3.3 % of GA inclusions were 
Unc119 positive in the cerebellum (1.6 ± 1.5 %). In the 
occipital cortex an intermediate level of co-aggregation 
was observed (5.8 ± 1.6 %). All Unc119 inclusions were 
also poly-GA positive suggesting that DPRs drive inclu-
sion formation. Importantly, despite abundant DPR and 
phospho-TDP-43 pathology in the frontal cortex, there was 
no co-localization of Unc119 and phospho-TDP-43 within 
inclusions (Fig. 6c, S10b).
Taken together, Unc119 specifically co-aggregates in 
poly-GA inclusions in C9orf72 cases. Notably, Unc119 
inclusions were preferentially detected in the frontal cor-
tex, the main region for neurodegeneration in FTLD. Thus, 
region-specific Unc119 aggregation may contribute to the 
selective vulnerability of specific neuron populations to 
C9orf72 repeat expansion in vivo.
Discussion
Our work establishes a cell culture model for C9orf72 
FTLD/ALS that reproduces core findings in patients and 
directly links C9orf72 repeat translation to neurodegen-
eration. Using quantitative analysis of the poly-GA inter-
actome, we identified a novel co-aggregating protein, 
Unc119, which has been linked to axon maintenance in C. 
elegans previously [23, 30].
DPR aggregation
Expressing DPR proteins from nearly GGGGCC-free 
synthetic genes containing ATG start codons allowed us 
to compare the aggregation properties of the five differ-
ent DPR species while largely excluding potential sec-
ondary effects through RNA toxicity. Previous work with 
GGGGCC-based expression constructs did not lead to 
inclusion formation even when a start codon was present 
[55]. The higher expression levels in our system presum-
ably accelerate disease mechanisms that would normally 
require gradual build-up of DPR proteins in the brain. In 
cell culture, the five DPR species displayed remarkably 
different properties. Only poly-GA expression resulted 
in compact cytoplasmic inclusions similar to those seen 
in C9orf72 mutation brains [33, 36, 55] suggesting that it 
may be the main driving force for aggregation (Figs. 1, 2). 
This is in line with the observation that virtually all TDP-
43-negative inclusions in C9orf72 patients contain poly-
GA, while antibodies against the other DPR species label 
only a fraction (10–50 %) of these inclusions [35, 36]. 
Interestingly, poly-GR and poly-PR formed mainly nuclear 
inclusions similar to the occasional nuclear DPR inclu-
sions previously identified in patients with poly-GA and 
p62 antibodies [1, 29, 36]. These two charged DPR species 
might be actively imported into the nucleus, because a high 
density of positively charged arginines is also common in 
classical nuclear localization signals [14]. The discrepancy 
between aggregation properties observed in patients and 
our cell culture might be due to the fact, that the synthetic 
DPR proteins used are much shorter than the several hun-
dred or even thousand repeats found in patients [5, 51].
DPR toxicity
How C9orf72 repeat expansion leads to neurodegen-
eration is poorly understood. In fly models RNA toxic-
ity from a 30-mer repeat seems to be the main cause of 
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neurodegeneration [52]. Neurons derived from C9orf72 
patients show normal viability, but increased sensitivity to 
cellular stressors [2, 15, 43]. Zu and colleagues reported 
combined RNA and protein toxicity for poly-PR and poly-
GP in non-neuronal cell culture in the absence of inclu-
sion formation [55]. Despite robust DPR expression in 
transfected HEK293 cells, we found no evidence for cell 
death due to protein toxicity in an LDH release assay with 
the five DPR species. Moreover, the GGGGCC expres-
sion constructs without ATG start codon and GGGGCC 
repeat based poly-GP construct were not toxic, suggesting 
HEK293 cells are not overtly sensitive to either C9orf72 
repeat RNA or protein toxicity under our conditions. We 
could not analyze GGGGCC repeat toxicity in neurons, 
because the repeat seems to block lentiviral packaging. In 
contrast, caspase activation and DNA fragmentation sug-
gest that p62-positive poly-GA inclusions lead to apoptosis 
in primary hippocampal and cortical neurons (Figs. 2, 3). 
Since the synthetic poly-GA gene largely lacks GGGGCC 
repeats and requires an ATG start codon to cause toxicity, 
DPR proteins themselves can cause toxicity in neurons. 
Due to our construct design these findings, however, do not 
rule out additional or synergistic effects through GGGGCC 
repeat-mediated RNA toxicity or C9orf72 haploinsuf-
ficiency in the pathogenesis of C9orf72 FTLD/ALS. Due 
to the resemblance of poly-GA aggregates in neurons and 
patients we focused our study on poly-GA toxicity in neu-
rons. However, it would also be interesting to analyze the 
effects of other DPR species alone or in combination with 
poly-GA in neuron culture.
Overexpression models have been invaluable tools to 
study neurodegenerative diseases but abnormally high lev-
els of the aggregating proteins could also complicate the 
interpretation [16]. Importantly, lentiviral transduction in 
our system led to poly-GA aggregates that were compara-
ble in size and poly-GA levels to inclusions from patients 
suggesting that the observed toxicity of poly-GA in cul-
tured cells is also relevant in vivo (Fig. S3).
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Poly-GA interactome
Revealing the interaction profile of poly-GA is an important 
step to understand the mechanisms leading to the DPR tox-
icity. Novel instruments, advances of proteomics workflows 
and new bioinformatics algorithms have greatly increased 
the accuracy and depth of analysis as well as number of 
applications for quantitative proteomics [3, 6, 37]. Using 
GA149-GFP expression, we identified several interacting 
proteins by affinity purification and quantitative proteomic 
analysis (Table 1). However, we cannot exclude that addi-
tional proteins co-aggregate with the DPR inclusions in 
C9orf72 patients. Importantly, the top hit was p62/SQSTM1, 
an ubiquitin-binding protein that is found in almost all types 
of intracellular protein aggregates in neurodegenerative dis-
eases including DPR inclusions [1, 25, 36]. This validates 
our cell culture model and the unique potential of quantita-
tive mass spectrometry to identify disease-relevant protein 
interactions. Additionally, we found several proteins asso-
ciated with the ubiquitin proteasome system, but could not 
detect altered proteasomal expression or activity in poly-
GA expressing HEK293 cells or neurons. Interestingly, a 
Gly/Ala-rich repetitive stretch of about 240 amino acids in 
EBNA1 was found to block its own proteasomal degradation 
suggesting that poly-GA may also interfere with the protea-
some system [27]. However, in contrast to our findings with 
poly-GA, the Gly/Ala-rich region in EBNA1 prevents inter-
action with the proteasome [46], which may be explained by 
the distinct sequences. EBNA1 only contains GA monomers 
and dimers and does not form cellular inclusions.
Proteasomal dysfunction has been controversially dis-
cussed as a pathomechanism in poly-Q repeat disorders 
[45]. The poly-G aggregates derived from the CGG repeat 
expansion in FXTAS are also ubiquitinated [48]. Thus, the 
ubiquitin proteasome system is clearly linked to repeat 
expansion diseases although the mechanistic contribution 
to neurodegeneration remains unclear.
Apart from the ubiquitin–proteasome system, we detected 
co-localization of poly-GA inclusions with overexpressed 
and endogenous Unc119, which was among the identi-
fied poly-GA interacting proteins (Figs. 4, 5, 7, S10). In 
the brain, many neurons with Unc119 inclusions show little 
residual cytosolic Unc119 staining indicating that poly-GA 
inclusions in C9orf72 patients lead to partial Unc119 seques-
tration (Figs. 6, 7). In cultured neurons, poly-GA expression 
strongly decreases the levels of soluble Unc119 suggesting 
a possible loss of function component in the disease in brain 
regions where it aggregates. Interestingly, we only scarcely 
detect Unc119 inclusions in the cerebellum, an area which 
shows little neurodegeneration in C9orf72 patients despite 
abundant DPR pathology [29]. Unc119 has mainly been 
studied in the C. elegans nervous system and the mammalian 
retina. Importantly, Unc119 knockout in C. elegans almost 
completely paralyzes the worms and disturbs axonal devel-
opment and maintenance [23, 30, 31]. Unc119 serves as a 
trafficking factor for myristoylated proteins, which it spe-
cifically binds through a hydrophobic pocket composed of 
β-sheets [8]. It is intriguing that the binding motif to Trans-
ducin α in the retina was mapped to the myristoylated N-ter-
minal GAGASA sequence which strongly supports our inter-
action data with poly-GA [53]. Apart from this photoreceptor 
protein the only other known cargos in the nervous system 
are Gα proteins in the C. elegans olfactory system [8]. It will 
be important to elucidate how Unc119 sequestration affects 
neuronal function in C9orf72 patients. We suspect that poly-
GA enters and clogs the hydrophobic cavity of Unc119 and 
thus inhibits transport of so far unidentified myristoylated 
Unc119 cargos in cortical neurons, which may contribute to 
neurotoxicity observed upon Unc119 knockdown or poly-
GA expression. An Unc119 nonsense mutation was found in 
a patient with cone rod dystrophy and causes retinal degen-
eration in mice [24], which is consistent with the toxicity 
we observed upon Unc119 knockdown in cortical and hip-
pocampal neurons. Importantly, Unc119 overexpression 
partially rescues poly-GA toxicity in primary neurons, while 
Unc119 knockdown does not further increase poly-GA tox-
icity. Together this indicates that Unc119 sequestration is a 
major cause of poly-GA toxicity.
In conclusion, our data strongly suggest that the unusual 
translation of the expanded repeats into poly-GA causes 
neurodegeneration. Co-sequestration of crucial neuronal 
proteins, such as Unc119, within DPR aggregates may be 
a novel pathomechanism in C9orf72 FTLD/ALS further 
strengthening the importance of DPR aggregates in disease 
context.
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Overexpression of Q-rich prion-like proteins suppresses polyQ 
cytotoxicity and alters the polyQ interactome 
An important question in neurodegeneration is by which mechanisms cells can modify the toxicity 
of aggregates. While the chaperone, proteasome and autophagy systems represent potent cellular 
mechanisms to maintain proteostasis, additional pathways might have evolved. In a toxicity screen 
in yeast, the group of Ulrich Hartl identified proteins that – when overexpressed – can rescue these 
cells from toxicity of huntingtin aggregates. We investigated whether this rescue correlates with 
changes in the aggregate composition and based on our results, hypothesized how these proteins can 
modify the toxicity of aggregates. In this collaborative effort, we chose to focus on the 
toxicity-modifying transcription factor GTS1. GTS1 itself contains a prion like polyQA domain and 
we compared the interactome of huntingtin in the presence of overexpressed GTS1 or only the 
polyQA domain. The reduced htt toxicity significantly correlated with alteration in the aggregate 
composition. While the association with other prion domain containing proteins decreased, more 
chaperones associated with the aggregates when either GTS1 or polyQA were overexpressed. In 
silico simulation and imaging data suggested that the structure of aggregates was altered by 
incorporation of polyQA sequences. In summary, these data provide novel insight into a potential 
cellular mechanism to detoxify aggregates and suggest a potential therapeutic strategy for 
neurodegerative diseases. 
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Hornburg D, Mann M, Hartl FU, Hipp MS. 
Contribution: The Group of Ulrich Hartl (MPI Biochemistry) established a screen, which allowed 
them to identify genes that suppress polyQ toxicity in yeast. I designed an affinity enrichment 
protocol to identify polyQ interacting proteins. I further analyzed the proteome composition of the 
aggregates and statistically assessed the changes in the polyQ interactome on the level of individual 
proteins and pathways in correlation with the toxicity. 
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Expansion of a poly-glutamine (polyQ) repeat in a group of
functionally unrelated proteins is the cause of several inherited
neurodegenerative disorders, including Huntington’s disease. The
polyQ length-dependent aggregation and toxicity of these disease
proteins can be reproduced in Saccharomyces cerevisiae. This sys-
tem allowed us to screen for genes that when overexpressed re-
duce the toxic effects of an N-terminal fragment of mutant
huntingtin with 103 Q. Surprisingly, among the identified suppres-
sors were three proteins with Q-rich, prion-like domains (PrDs):
glycine threonine serine repeat protein (Gts1p), nuclear polyade-
nylated RNA-binding protein 3, and minichromosome mainte-
nance protein 1. Overexpression of the PrD of Gts1p, containing
an imperfect 28 residue glutamine-alanine repeat, was sufficient
for suppression of toxicity. Association with this discontinuous
polyQ domain did not prevent 103Q aggregation, but altered
the physical properties of the aggregates, most likely early in
the assembly pathway, as reflected in their increased SDS solubil-
ity. Molecular simulations suggested that Gts1p arrests the aggre-
gation of polyQ molecules at the level of nonfibrillar species,
acting as a cap that destabilizes intermediates on path to form
large fibrils. Quantitative proteomic analysis of polyQ interactors
showed that expression of Gts1p reduced the interaction between
polyQ and other prion-like proteins, and enhanced the associa-
tion of molecular chaperones with the aggregates. These find-
ings demonstrate that short, Q-rich peptides are able to shield
the interactive surfaces of toxic forms of polyQ proteins and
direct them into nontoxic aggregates.
protein aggregation | protein misfolding | neurodegeneration | prion |
polyglutamine proteins
Expansion of a poly-glutamine (polyQ) repeat in otherwiseunrelated proteins is the cause of several inherited neuro-
logical disorders, including Huntington’s disease (HD), spino-
bulbar muscular atrophy, dentatorubral-pallidoluysian atrophy,
and spinocerebellar ataxias 1, 2, 3, 6, 7, and 17 (1). In all these
cases, increasing the length of the polyQ repeat over a critical
threshold (above 37 Q in HD) (2) results in disease manifesta-
tion, with the length of the repeat correlating inversely with age
of disease onset (3).
According to the gain-of-toxic function theory, the polyQ
expansions increase aggregation propensity and confer to the
disease proteins the ability to populate one or more toxic con-
formations, most likely including various oligomeric and higher-
order aggregate states. These aggregate species vary greatly in
number of monomeric units, detergent solubility, binding of dyes,
and identity and mobility of interacting proteins (4–6). A prominent
hypothesis suggests that the pathologic protein aggregates expose
novel, highly interactive surfaces that mediate aberrant interactions
with other proteins, resulting in their functional impairment and
sequestration (7–9). Moreover, the aggregation process is thought
to interfere with general protein quality control pathways, including
protein folding and the clearance of misfolded proteins (10–13).
The yeast S. cerevisiae has been used extensively as a model to
explore the basic mechanisms of toxicity mediated by polyQ
expansions. The polyQ length dependence of aggregation has
been reproduced in yeast upon expression of N-terminal frag-
ments of huntingtin containing the polyQ stretch (N-Htt) (14,
15). Interestingly, toxicity, as measured by growth impairment,
was found to depend critically on the properties of the sequences
flanking the polyQ region (16). Like mammalian prions, yeast
prions are able to cause detectable phenotypes without trans-
mitting any genetic material (17), and both N-Htt aggregation
and toxicity were shown to require the [RNQ+] prion (18, 19).
Although there are numerous proteins in the yeast proteome
that contain Q-rich regions (20), there is no Htt homolog in
yeast. Therefore, any toxic effects observed in this model system
on N-Htt expression can be attributed to a gain-of-toxic function.
Although polyQ aggregation is strongly associated with cell
toxicity, the exact nature and the conformational properties of
the toxic polyQ species remain elusive. To gain insight into the
basic mechanisms of polyQ toxicity, we performed an unbiased
yeast genetic screen for suppressors of the growth defect caused
by the expression of polyQ expanded N-Htt. We identified six
genes that reproducibly restored cell growth when overex-
pressed. Surprisingly, these suppressors include several proteins
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with Q-rich sequences, nuclear polyadenylated RNA-binding
protein 3 (Nab3p), minichromosome maintenance protein 1
(Mcm1p), and glycine threonine serine repeat protein (Gts1p),
which have been suggested to contain candidate prion domains
(PrDs) (21). Consistent with results from molecular modeling,
quantitative proteomic analysis revealed that these proteins act
by shielding the interactive surfaces of polyQ aggregates, thereby
reducing their aberrant interactions with endogenous proteins,
including multiple bona fide yeast prions, while promoting their
association with molecular chaperones.
Materials and Methods
Suppressor Screen. A yeast genomic DNA multicopy library cloned in YEp13
(22, 23) was transformed into YPH499 + pYES2L-103Q-GFP using a high ef-
ficiency transformation protocol (24). The cells were plated on synthetic
complete (SC) selection medium with galactose to induce 103Q-GFP ex-
pression. Of 150,000 transformants, about 200 colonies grew. Each of these
colonies was then grown on SC selection medium without 103Q-GFP in-
duction with glucose as the sole carbon source. False positives were elimi-
nated by three successive rounds of screening and positive clones were
sequenced (SI Materials and Methods).
Interactome Analysis. Yeast cells expressing 103Q-GFP and the suppressor
proteins were harvested and lysed. 103Q-GFP was isolated with anti-GFP
magnetic beads (Miltenyi). Eluates were desalted and subsequently analyzed
by LC coupled to a Q Exactive mass spectrometer (Thermo Fisher) via a nano
electrospray source. Data were analyzed using the MaxQuant software
(v 1.4.3.19) (25) and label-free algorithms (26). Raw data were searched
against the UniProtKB Yeast FASTA database (06/2012). For more details,
see SI Materials and Methods.
Results
A Yeast Screen for Suppressors of polyQ Toxicity. Previous genetic
screens in yeast identified 52 nonessential gene deletions that
enhanced the toxicity of a polyQ expanded Htt fragment (27), 28
genes that suppressed toxicity when deleted (28), and 317 genes
that suppressed toxicity when overexpressed under control of
a GAL1 promoter (29). However, overexpression of potential
suppressors under the strong GAL1 promoter may lead to var-
iations in copy number of the toxic protein (30) or result in
toxicity so that some suppressors may be missed. To overcome
these problems, we used a library of genes under the control of
their endogenous promoter on a multicopy plasmid, thus re-
sulting in an intermediate expression level (Fig. 1A). To this end,
we expressed a toxic N-Htt-GFP fusion protein with 103 Q, lack-
ing the poly-proline region and containing a N-terminal Flag-tag
(103Q-GFP) (Fig. 1B) (16), under control of a galactose inducible
promoter in yeast positive for the [RNQ+] prion. Expression of
103Q-GFP caused a strong growth defect, whereas an otherwise
identical protein containing 25 Q (25Q-GFP) caused no growth
impairment (Fig. 1C) (16, 19).
A yeast genomic DNA multicopy library (22) was transformed
into cells harboring the inducible 103Q-GFP construct (Fig. 1A).
Of 150,000 transformants, ∼200 colonies were able to grow on
induction of 103Q-GFP. After elimination of colonies that had
lost either the expression of 103Q-GFP or the [RNQ+] prion, 40
positive clones remained and were analyzed in more detail. Se-
quencing of the DNA inserts showed that most inserts were se-
lected several times and mapped to 10 different genomic regions,
suggesting that the screen was saturated. Four of the isolated
inserts encoded genes involved in the metabolism of galactose.
These genes were not further analyzed as their expression may
have interfered with the expression of 103Q-GFP.
Overview of Screen Results. We identified six different genes that
were able to suppress polyQ mediated toxicity (Fig. 1C), in-
cluding the Hsp40 chaperone SIS1, the invertase SUC2, a gene
with unknown function, SOK1, and three genes that encode
proteins with Q-rich domains: NAB3, MCM1, and GTS1.
Sis1p is an essential member of the Hsp40 chaperone family. It
functionally cooperates with Hsp70 proteins of the Ssa family
and was shown to modulate the aggregation and toxicity of Htt
polyQ proteins (14, 19, 31). We recently identified Sis1p as
a strong interactor of mutant Htt and as a critical factor in the
degradation of misfolded proteins (32). The nonessential pro-
tein Sok1p has been shown to suppress mutations in a cAMP-
dependent protein kinase, but its exact function is not known
(33). SUC2 has previously been identified as a suppressor of
polyQ-mediated toxicity (29) and encodes a nonessential in-
vertase, which hydrolyzes sucrose into glucose and fructose
(34). Its mechanism of suppression remains unclear.
The identification of Q-rich, but otherwise unrelated, proteins
as suppressors of polyQ-mediated toxicity was intriguing. Nota-
bly, a recent bioinformatics screen identified Nab3p, Mcm1p,
and Gts1p as potentially prion like (21). Nab3p is a known
interactor of expanded polyQ-containing proteins (32, 35) and
has an essential role in the termination of RNA polymerase II
transcripts (36). Mcm1p is an essential transcription factor in-
volved in pheromone response and regulation of mating type-
specific genes (37). Strong overexpression of Mcm1p causes
growth arrest (38), but when expressed under control of its en-
dogenous promoter in the multicopy plasmid pRS426, cells grew
normally and the growth defect conferred by 103Q-GFP was
suppressed (Fig. 1C). Gts1p is a nonessential transcription factor
that has been implicated in several processes including the stress
response, sporulation, and the cell cycle (39, 40). Gts1p was er-
roneously thought to contain glycine/threonine-serine repeats,
but instead contains a Q-rich region including an imperfect
glutamine-alanine repeat (QAR) in its C-terminal domain (Fig.
2A). Gts1p also contains a Zn-finger motif and an ubiquitin-
associated (UBA) domain (40). The Q-rich sequences of the
three suppressors differ from those of bona fide prion domains in
proteins such as the eukaryotic release factor Sup35p in that they
are not enriched in asparagine (N) (Fig. 2A).
Q-Rich Domains of Gts1p and Nab3p Are Sufficient to Suppress polyQ
Toxicity. The finding that three of the identified suppressors
contain uninterrupted polyQ repeats between 9 and 16 residues
in length, as well as discontinuous polyQ segments, led us to
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Fig. 1. Identification of suppressors of polyQ toxicity. (A) Workflow of
overexpression suppressor screen. A yeast genomic DNA library was trans-
formed into cells harboring the inducible 103Q-GFP construct. About 200
colonies were able to grow on induction of 103Q-GFP. False positives were
eliminated by three successive rounds of screening. Sequencing of DNA
inserts showed that inserts contained 10 different genomic regions. After
elimination of inserts that encoded genes involved in the metabolism of
galactose, six suppressors of polyQ-mediated toxicity remained. (B) Sche-
matic representation of the 25Q/103Q-GFP constructs used in this study. Dark
gray indicates the N-terminal Flag-tag, light gray indicates the N terminus of
Htt, and green represents the GFP-tag. Glutamines (Q) are shown in red;
asparagines (N) in cyan. (C) Expression of Gts1p, Nab3p, Mcm1p, Sis1p,
Sok1p, and Suc2p suppresses polyQ toxicity. The potential suppressors were
preinduced for 48 h before serial dilutions of cells were spotted on galactose
medium without doxycycline to coexpress 25Q/103Q-GFP and the sup-
pressors (Right) or on glucose plates to control for equal spotting (Left).
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investigate whether the Q-rich domains of Gts1p, Nab3p, and
Mcm1p are sufficient for suppression (Fig. 2A). Expression of
the Q-rich C-terminal regions of Gts1p or Nab3p was sufficient
to rescue cell growth to a similar extent as expression of the full-
length proteins. In contrast, the corresponding construct of
Mcm1p failed to suppress (Fig. 2B). Similarly, the Q-rich prion-
like proteins Yck1p and Taf12p (21), as well as the prion domain
of Sup35p (S35N) (Fig. 2A), also failed to suppress 103Q-GFP
toxicity, at least at the expression levels tested (Fig. 2C). Thus,
specific sequence features beyond a compositional bias toward
glutamine or the presence of a candidate prion domain must be
required for suppression of polyQ toxicity.
The Q-rich domains of Nab3p and Gts1p comprise less than
25% of the sequence of the full-length proteins and contain
neither the RNA recognition motif of Nab3p nor the Zn-finger
and UBA domain of Gts1p. Thus, it seemed likely that these
domains suppress the toxicity of 103Q-GFP by a mechanism
unrelated to the biological functions of the full-length proteins.
In the remainder of this study, we used Gts1p and its C-terminal
region (Gts1Q) as a model to investigate this mechanism.
Gts1p Expression Does Not Change the Prion Status of the Prion
Protein Rnq1p. 103Q-GFP toxicity can only be observed in yeast
cells when Rnq1p is present in the aggregated prion form [RNQ+]
(19). Curing the [RNQ+] status will suppress 103Q-GFP–mediated
toxicity, and indeed two previously identified loss-of-function
suppressors, rnq1Δ and hsp104Δ, cause the loss of [RNQ+] (28).
Heat shock protein 104 levels have been reported to be altered
by Gts1p expression (41), which might influence the Rnq1p prion
status and subsequently reduce 103Q-GFP toxicity. To address
this possibility, we investigated whether overexpression of Gts1p
alters the prion status of Rnq1p, using Rnq1-GFP as a reporter
protein (42). We found that expression of Gts1p neither cured
the [RNQ+] prion nor did it induce [RNQ+] in cells that had
previously been cured by treatment with guanidinium chloride
(GdmCl) (Fig. S1A). This conclusion is supported further by the
observation that 103Q-GFP remains localized in fluorescent foci
when Gts1p is overexpressed (Fig. 3A and Fig. S1B). In contrast,
cells cured of the [RNQ+] prion by GdmCl treatment showed
nearly no visible 103Q-GFP foci (Fig. S1B) (19).
Gts1p Expression Changes the Aggregation Status of 103Q-GFP. The
finding that 103Q-GFP is still present in visible foci on Gts1p
overexpression does not exclude the possibility that the presence
of Gts1p modifies biophysical properties of the aggregates. The
polyQ inclusions that are virtually indistinguishable by light mi-
croscopy may nevertheless differ in their physical properties:
they may be detergent (SDS) insoluble, containing ordered polyQ
fibrils, or detergent soluble, containing structurally amorphous
aggregates (15, 43). Using an established filter trap assay for the
detection of SDS insoluble aggregates larger than 0.2 μm (44),
we found that expression of Gts1p or Gts1Q strongly reduced the
amount of SDS insoluble 103Q-GFP present in cells, whereas
expression of the N-terminal Gts1p fragment was without effect
(Fig. 3B). Thus, Gts1p shifts the aggregation properties of the
protein from SDS insoluble to SDS soluble aggregate species
that still form visible inclusions (Fig. 3A), without reducing the
amount of 103Q-GFP that can be detected by gel electrophoresis
(Fig. 3C, input panel).
To demonstrate that Gts1p interacts directly with 103Q-GFP,
we added a myc-tag to the N terminus of Gts1p and Gts1Q
(Gts1-myc and Gts1Q-myc) to enable detection. Addition of this
tag did not change the Gts1p-mediated rescue of 103Q-GFP
toxicity (Fig. S2). Although Gts1-myc was diffusely distributed in
cells expressing 25Q-GFP (Fig. 3A), in 103Q-GFP expressing
cells, Gts1-myc was present in bright fluorescent foci colocalizing
with 103Q-GFP. Coimmunoprecipitation experiments confirmed
the association of Gts1-myc and Gts1Q-myc with 103Q-GFP (Fig.
3C), but showed only little association with 25Q-GFP (Fig. S3).
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insoluble 103Q-GFP. Full-length Gts1p (FL), an N-terminal fragment (N), or
a fragment containing the Q-rich C terminus (Q) were preinduced before
induction of 103Q-GFP. Cells were lysed and analyzed for SDS insoluble
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Molecular Modeling of Gts1p–polyQ Interactions. Further evidence
for direct interactions between the QA-repeat region of Gts1p
and the polyQ tract of Htt was obtained by performing atomistic
Monte Carlo simulations using the CAMPARI simulation engine
(campari.sourceforge.net) and ABSINTH implicit solvation model
and forcefield paradigm (45). This approach has recently been used
to generate accurate insights regarding the early, nonspecific steps
that lead to polyQ aggregation (46, 47) and their modulation by
sequences flanking the polyQ tract within Htt (48).
We performed simulations with a polyQ sequence of 35 Q and
the imperfect 28 residue QA-region denoted as QAR of Gts1p,
present either at a ratio of two molecules of QAR to one mol-
ecule of 35Q (a continuous polyQ repeat of 35 Q) or the reverse
ratio. The choice of a 35 residue polyQ molecule was made
because this allows for simulations that afford reliable and re-
producible statistics, and as shown in previous studies, the sim-
ulation results are unlikely to vary by increasing or decreasing the
polyQ length by five residues vis-à-vis 35Q (46, 47).
Quantifying the statistics for the occurrence of specific dis-
tances of separation between the centers of mass of pairs of
molecules provided a measure of interaction strength that can
be converted into estimates of dissociation constants. We used
cumulative distribution functions (CDFs) to quantify the prob-
ability that a pair of molecules will assume a specific inter-
molecular separation at a temperature of 315 K. According to
these CDFs, in simulations with a QAR:35Q stoichiometry of
1:2, we find that the probability of heterotypic (QAR-35Q)
interactions is equivalent to the probability of homotypic inter-
actions between 35Q molecules (Fig. 4A). This result suggests
that QAR competes just as effectively for interactions with
polyQ as do other polyQ molecules: a finding that is borne out
further in simulations with a QAR:35Q stoichiometry of 2:1.
Here, we find that QAR molecules prefer interactions with the
surfaces of polyQ molecules even in the presence of an addi-
tional QAR molecule. Representative conformations drawn
from simulations with a QAR:35Q stoichiometry of 1:2 demon-
strate the range of interaction modes that are available for QAR
to cover the surface of polyQ molecules (Fig. 4B). It is worth
noting that the ensemble is characterized by considerable struc-
tural heterogeneity implying that 35Q and QAR molecules can
associate while assuming a range of different conformations. This
finding provides a rationale for the observation that Gts1p arrests
the aggregation of polyQ molecules at the level of SDS soluble,
nonfibrillar species. Taken together, the simulations suggest that
QAR is a trans-acting cap of polyQ associations that destabilizes
intermediates en route to fibrillar species. Interactions of polyQ
with QAR presumably generate SDS soluble oligomers with less
reactive surfaces. The ability of QA repeats to compete for the
surface of polyQ globules within these simulations, in contrast to
homotypic interactions between QAR molecules, is supported by
the finding that trimers are the dominant species in simulations
with a QAR:35Q ratio of 2:1, whereas trimers make up only 50%
of the population when the QAR:35Q ratio is 1:2. Importantly,
homodimers are prominent when the QAR:35Q ratio is 1:2, whereas
heterodimers are preferred over homodimers when the QAR:35Q
ratio is 2:1 (Fig. S4). A more extensive analysis of details that emerge
from the simulations coupled with in-depth biophysical investigations
along the lines of recent efforts (49) is beyond the scope of the
current study and will be published elsewhere.
Gts1p Alters the Interaction Properties of 103Q-GFP. PolyQ proteins
are widely thought to exert toxicity by mediating aberrant inter-
actions with other proteins, resulting in their functional impairment
and sequestration (7, 8, 32, 50). Based on the finding that Gts1p
coaggregates with 103Q and consistent with the results of the
atomistic simulations, it seemed plausible that Gts1p and Gts1Q
suppress polyQ toxicity by interfering with such aberrant inter-
actions. To investigate this possibility, we applied MS-based
proteomics. We established a quantitative, label-free workflow
that allows an unbiased comparison of multiple samples (25, 26).
Using these high accuracy proteomics tools, we quantified the
interactome of 103Q-GFP in the absence and presence of Gts1Q
expression. Proteins associated with 103Q-GFP were isolated
using an anti-GFP antibody coupled to magnetic beads, followed
by LC-MS analysis. Interestingly, the group of 103Q-GFP inter-
actors that was most predominantly reduced by expression of Gts1Q
(P = 1.28 × 10−30) are known yeast prions or proteins containing
PrDs (Fig. 5 and Dataset S1) (21). Sequestration of the PrD
containing proteins Sla1p, Sla2p, and Pan1p into aggregates has
been suggested to elicit polyQ toxicity by seeding the formation
of toxic aggregates (51, 52). Thus, the reduced interaction of
these proteins with 103Q-GFP in the presence of Gts1Q can
contribute to the suppression of 103Q-GFP toxicity. It is in-
teresting to note that expression of Gts1Q also reduces the in-
teraction of 103Q-GFP with the three prion-like suppressors
identified in our screen (Nab3p, Mcm1p, and endogenous Gts1p),
thereby also reversing effects possibly due to functional depletion of
these proteins, as has been suggested for Nab3p (35).
More than half of the proteins reduced in abundance on 103Q-
GFP are nuclear proteins. Many are involved in transcription and
RNA metabolic processes, suggesting that interference with these
functions contributes to polyQ toxicity. Among the proteins that
show an increased interaction with 103Q-GFP in the presence of
Gts1Q are several chaperone proteins such as the Hsp70s Ssa3p
and Ssa4p, the Hsp90 Hsp82p, and its cochaperone Aha1p.
However, there was no change in the interaction of 103Q-GFP
with Sis1p, which is the only chaperone identified in our sup-
pressor screen. Comparable results were achieved by over-
expression of full-length Gts1p (Fig. S5 and Dataset S1). In this
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Fig. 4. Molecular modeling of Gts1p-polyQ interactions. (A) Cumulative
distribution functions quantifying the probabilities for homotypic vs. het-
erotypic intermolecular interactions. The abscissa denotes the distance
(in Angstroms) between the centers of mass of a pair of molecules. The or-
dinate F(X) is the cumulative distribution function (CDF). For a given value of
X, F(X) quantifies the probability that a specific intermolecular separation
will be less than or equal to X. The black and red curves were generated
using statistics from simulations with one molecule containing the imperfect
glutamine-alanine repeat of Gts1p (QAR) and two 35Qmolecules, respectively.
The green and blue curves were generated using statistics from simulations
with two QAR molecules and one 35Q molecule. (Inset) Zoomed in version of
the CDFs to illustrate the quantitative differences and similarities among
different curves. It also shows that the distances between the centers of mass
are equivalent when each of the F(X) curves reaches their respective plateau
value. This result is true irrespective of the stoichiometry in the simulations
and the type of interactions, heterotypic vs. homotypic, that are being an-
alyzed. (B) Representative conformations of trimers formed in simulations
with a QAR:35Q ratio of 1:2. The molecules are drawn using backbone
traces. The 35Q molecules are shown in orange and yellow, respectively,
whereas the QAR molecule is colored using green for the alanine (A)/valine
(V) residues and purple for the Q residues. The conformations represent the
centers of distinct conformational clusters. Below each representative con-
formation we show the percent probability of sampling the conformational
type within ensembles generated at 315 K. Details of the move sets utilized
for the simulations analyzed in A and B can be found in Table S1.
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case, the function of Gts1p as transcription factor may alter the
composition of the proteome in a manner unrelated to the
mechanism described here. The use of Gts1p instead of Gts1Q,
for which no tryptic peptides can be detected, allows us to cal-
culate the relative abundances of 103Q-GFP and Gts1p in the
interactome. As expected, Gts1p and 103Q-GFP are among the
most abundant proteins quantified. The similarity of the nor-
malized MaxLFQ values for Gts1p and 103Q-GFP is consistent
with the formation of a 1:1 stoichiometric complex (Fig. S5C).
The displacement of functionally critical nuclear components
from the polyQ aggregates by Gts1p in combination with the
more effective shielding of the aggregates by molecular chaper-
ones can explain how Gts1p suppresses polyQ toxicity. It is also
possible that the reduced interaction of the polyQ aggregates
with known prions and PrD containing proteins contributes to
the suppression of toxicity.
Discussion
Neutralizing the toxic effects of protein aggregates is a rational
strategy in the development of treatments for various neurode-
generative disorders, including Huntington’s, Parkinson’s, and
Alzheimer’s diseases. In this study, we performed a yeast screen
for suppressors of the toxicity of polyQ protein aggregation
without making assumptions about the nature of the toxic ag-
gregate species. Among the six suppressors identified were
one Hsp40 chaperone, Sis1p, and three proteins that contain
C-terminal domains with interrupted polyQ repeats and a com-
positional bias toward glutamine (Fig. 2A). Interestingly, the
C-terminal regions of these proteins were previously predicted to
contain PrDs (21). For two of the proteins, Gts1p and Nab3p, we
demonstrated that expression of the Q-rich C terminus alone is
sufficient to prevent polyQ mediated toxicity (Fig. 2B). Thus,
these proteins use some shared property of their Q-rich domains
to modulate polyQ toxicity, apparently by interacting directly
with the polyQ sequence of Htt. Association with the suppressor
did not prevent 103Q-GFP aggregation but altered the physical
properties of the aggregates. As a result, the association of
molecular chaperones of the Hsp70 and Hsp90 systems with the
polyQ aggregates was enhanced, and their ability to sequester
nuclear proteins was strongly reduced. Protein sequestration into
aggregates may lead to an impairment of multiple key cellular
pathways and is considered an important mechanism of aggre-
gate toxicity (7, 9, 10, 32, 50, 53–58).
The observed ability of Gts1p and Nab3p to suppress polyQ
toxicity was not shared by all proteins containing a PrD (Fig. 2C)
(30), suggesting that it is based on specific sequence properties of
the Q-rich domain and its context with flanking sequences. Our
observation that the three PrDs of the suppressors identified in
our screen are not enriched for N is in agreement with a recent
study that demonstrates that the relative Q and N content of
overexpressed PrDs is critical for their ability to suppress polyQ-
mediated toxicity (30). Our molecular simulations indicated that
the QA stretch might interact with early polyQ intermediates,
thereby modulating their surface properties and preventing the
formation of large fibrillar aggregates.
Expression of Gts1p markedly reduced the association of yeast
prion proteins with the polyQ aggregates. The prion status has
been shown to be required for the efficient aggregation of polyQ
expansion proteins in yeast, and it has been suggested that the
prion aggregates function by seeding toxic polyQ aggregation
(18, 19). It seems plausible that Gts1p competes with the yeast
prions for interaction with polyQ sequences, thereby shifting the
aggregation pathway toward formation of more benign aggre-
gates. Two recent screens suggest that expression of a subset of
PrD containing proteins additionally modulates the spatial or-
ganization of 103Q-GFP foci (30, 35). At the same time, Gts1p
enhances the association of polyQ aggregates with chaperones,
which may then cooperate with Gts1p in shielding potentially
dangerous surfaces of the polyQ aggregates. Indeed, Gts1Q also
reduced the interaction of 103Q-GFP with PrD-containing pro-
teins. A functional depletion of several of these proteins by se-
questration into the aggregates has been invoked as a cause of
polyQ toxicity (35, 51, 52).
The striking effect of Gts1p in reducing polyQ toxicity may
suggest a biological role for proteins with similar QA-repeat
sequence motifs in mitigating potentially toxic polyQ inter-
actions, comparable to what has been described for dominant
prion mutants (59). Although there is no direct mammalian
homolog of Gts1p, the human transcription elongation regulator
TCERG1/CA150 also contains a long QA-repeat. Interestingly,
TCERG1/CA150 was reported to bind to Htt (60), and over-
expression of this transcription factor was shown to protect
striatal cells from mutant Htt toxicity in a QA-repeat–dependent
manner (61). Expression of peptides with a specific Q-rich re-
gion, like the QA-repeat of Gts1p or TCERG1/CA150, might
present a strategy to interfere with Htt toxicity. However, regions
with QA-repeats may themselves tend to aggregate, as reflected
by the aggregation propensity of Gts1p (21, 62) and Cyc8p, an-
other yeast prion with a QA-repeat (63). Indeed, expansion of
the QA-repeat of TCERG1/CA150 can lead to an earlier onset
of HD (60), presumably by placing a burden on the cellular
proteostasis system (10). Nevertheless, controlled expression of
peptides containing specific Q-rich domains may be a way to
influence Htt toxicity. Future experiments will have to show
whether specific interactions between short peptides containing
regions similar to the ones discovered in this study can prevent
the formation of toxic aggregates and whether this approach can
be developed to benefit patients.
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Fig. 5. Gts1Q changes the 103Q-GFP interactome. (A) Gts1Q induced al-
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converse shifts for proteins with a predicted PrD and those involved in
protein folding. Interactors involved in protein folding are labeled red,
interactors with a predicted prion domain (PrD) are shown in green, and all
other identified proteins are shown in gray.
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-Secretase processing of APP inhibits hippocampal 
neuronal activity 
Alzheimer’s disease is the most common neurodegenerative disorder. For this disease, the 
accumulation of extracellular amyloid plaques and intracellular tangles is characteristic. The amyloid 
plaques are predominantly composed of amyloid-peptides (Aβ), which derive from proteolytic 
cleavage of the amyloid precursor protein termed APP. For many years, two proteolytic pathways 
have been held responsible to either promote (β-secretase activity) or suppress (α-secretase activity) 
generation of toxic Aβ in a competitive manner. Using biochemical and mass spectrometric tools, 
we identified a third dominant proteolytic pathway for APP, which generates previously unknown 
neurotoxic fragments, termed Aη. In vivo, membrane bound matrix-metalloproteinases, referred to 
as η-secretases, cleave APP, releasing long and short Aη fragments after following α-secretase and 
β- secretase cleavage. These peptides are enriched in dystrophic neurites in an Alzheimer’s disease 
mouse model and human patient brains. Strikingly, when recombinant or synthetic Aη-α was applied 
on hippocampal slices, long-term potentiation is lowered ex vivo. In addition, in vivo Ca2+ imaging 
revealed that hippocampal neuronal activity is attenuated by Aη-α. To unravel the exact fragment 
sequence, we adapted the proteomics workflow and employed the latest generation of hybrid 
quadrupole Orbitrap instrumentation. We combined various proteases of different specificities with 
partial digestion. This approach allowed us to boost the evidence for the Aη fragments several fold 
compared to conventional sample preparation and to map the novel cleavage site ‘Aη’. These data 
highlight a third, so for unknown pathway in Alzheimer’s disease with high pathological and 
potential therapeutic relevance. 
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(Ludwig-Maximilian-University Munich). To characterize novel cleavage products of 
α/β/η-secretases I established protocols for partial proteolysis of these proteins using time courses 
and employed proteases of different specificities to map proteolytic events in APP processing. I 
prepared and measured the samples and analyzed the data. Furthermore, I wrote R scripts to calculate 
and visualize overlapping evidences from peptides generated in the experiments. In line with 
biochemical evidences, we were able to confirm and map novel APP processing mechanisms. 
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g-Secretase processing of APP inhibits neuronal
activity in the hippocampus
Michael Willem1, Sabina Tahirovic2, Marc Aurel Busche3,4,5, Saak V. Ovsepian2, Magda Chafai6, Scherazad Kootar6,
Daniel Hornburg7, Lewis D. B. Evans8, Steven Moore8, Anna Daria1, Heike Hampel1, Veronika Müller1, Camilla Giudici1,
Brigitte Nuscher1, Andrea Wenninger-Weinzierl2, Elisabeth Kremmer2,5,9, Michael T. Heneka10,11, Dietmar R. Thal12,
Vilmantas Giedraitis13, Lars Lannfelt13, Ulrike Müller14, Frederick J. Livesey8, Felix Meissner7, Jochen Herms2,
Arthur Konnerth4,5, Hélène Marie6 & Christian Haass1,2,5
Alzheimer disease (AD) is characterized by the accumulation of
amyloid plaques, which are predominantly composed of amyloid-b
peptide1. Two principal physiological pathways either prevent or
promote amyloid-b generation from its precursor, b-amyloid pre-
cursor protein (APP), in a competitive manner1. Although APP
processing has been studied in great detail, unknown proteolytic
events seem to hinder stoichiometric analyses of APP metabolism
in vivo2. Here we describe a new physiological APP processing
pathway, which generates proteolytic fragments capable of inhib-
iting neuronal activity within the hippocampus.We identify higher
molecular mass carboxy-terminal fragments (CTFs) of APP,
termed CTF-g, in addition to the long-known CTF-a and CTF-b
fragments generated by the a- and b-secretases ADAM10 (a disin-
tegrin and metalloproteinase 10) and BACE1 (b-site APP cleaving
enzyme 1), respectively. CTF-g generation is mediated in part by
membrane-bound matrix metalloproteinases such as MT5-MMP,
referred to as g-secretase activity. g-Secretase cleavage occurs
primarily at amino acids 504–505 of APP695, releasing a truncated
ectodomain. After shedding of this ectodomain, CTF-g is further
processed by ADAM10 and BACE1 to release long and short Ag
peptides (termed Ag-a and Ag-b). CTFs produced by g-secretase
are enriched in dystrophic neurites in an AD mouse model and in
human AD brains. Genetic and pharmacological inhibition of
BACE1 activity results in robust accumulation of CTF-g and
Ag-a. Inmice treatedwith a potent BACE1 inhibitor, hippocampal
long-term potentiation was reduced. Notably, when recombinant
or synthetic Ag-a was applied on hippocampal slices ex vivo, long-
term potentiation was lowered. Furthermore, in vivo single-cell
two-photon calcium imaging showed that hippocampal neuronal
activity was attenuated by Ag-a. These findings not only dem-
onstrate a major functionally relevant APP processing pathway,
but may also indicate potential translational relevance for thera-
peutic strategies targeting APP processing.
To identify new proteolytic pathways of APP, we searched for CTFs
other than those giving rise to P3 fragment (CTF-a) or amyloid-b
(CTF-b)3–5. A new CTF with an approximate molecular mass of
30 kilodaltons (kDa) was revealed, which was recognized by an antibody
to the C terminus of APP (Y188) and was absent in the brains of APP-
knockout mice6 (Fig. 1a and Supplementary Table 1). The molecular
mass of the novel CTF suggests an additional physiological cleavage of
APP amino-terminal to the known cleavage sites of b- and a-secre-
tases, which we named accordinglyg-cleavage of APP (Extended Data
Fig. 1). In the soluble fraction, we detected the N-terminal cleavage
product (sAPP-g; Extended Data Fig. 2), with a molecular mass of
approximately 80 kDa that distinguishes it from alternative
N-terminal APP fragments described previously7–9. In addition, we
observed lowermolecularmass soluble peptides (Ag), which presum-
ably derived from processing of CTF-g by BACE1 (Ag-b) or
ADAM10 (Ag-a), or alternatively from sAPP-a/b cleavage
(Fig. 1b). Ag was identified in the soluble fraction of mouse brains
as several closely spaced peptides by antibody M3.2 (Fig. 1b), dem-
onstrating that some of these fragments contain the N-terminal part
of the amyloid-b domain and probably end at the a-secretase cleavage
site. Ag fragments were further validated by antibody 9478D directed
against an epitope N-terminal to the amyloid-b domain (Fig. 1b).
Consistent with g-secretase cleavage of APP in wild-type mice, we
observed increased CTF-g and Ag production in brain homogenates
of APPPS1-21 transgenic mice10 (Fig. 1c, d). Furthermore, antibody
192swe selectively identified the Ag-b species ending at the BACE1
cleavage site (Fig. 1d). Consistent with increased BACE1 cleavage of
Swedish mutant APP, only minor amounts of Ag-a were detected in
this mouse model with antibody 2D8 (Fig. 1d). Physiologicalg-secre-
tase processing was further confirmed in cerebrospinal fluid (CSF)
from humans with and without the Swedish mutation (APPswe)
(Fig. 1e). Fivefold higher Ag than amyloid-b levels were observed
in human CSF (5.336 1.39 times (mean6 s.d.) higher Ag than amy-
loid-b estimated by 2D8 blot signals; n5 7, P. 0.0001, Student’s
t-test). Using antibody 192swe, Ag-b was selectively detected in the
CSF of patients with the Swedish mutation, whereas antibodies 2E9
and 2D8 detected Ag-a in all analysed samples (Fig. 1e). Moreover,
while these peptides are generated byg-secretase cleavage N-terminal
to the amyloid-b domain, they do not reach the c-secretase site (see
mass spectrometric analysis in Fig. 1f), demonstrating that they are
different to the previously described N-terminally extended amyloid-
b variants11,12. Membrane-bound matrix metalloproteinases such as
MT1-MMP and MT5-MMP (also known as MMP14 and MMP24,
respectively) were shown to cleave APP in vitro at a site consistent
with the molecular mass of g-secretase processing products13,14. We
therefore produced a neo-epitope-specific antibody (10A8; Extended
Data Fig. 2) to identify the g-secretase cleavage site. Antibody 10A8
detected a protein corresponding to sAPP-g with an approximate
molecular mass of 80 kDa in mouse brain lysates, which was absent
in the APP-knockout mouse brain (Extended Data Fig. 2). Thus,
g-secretase cleavage of APPmay occur in vivo at least in part at amino
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acids 504–505 of APP695. To determine the N- and C-terminal cleav-
age sites of Ag peptides, we performed immunoprecipitation with
antibodies 9476M, 9478D, 2D8 and 2E9 (Extended Data Fig. 3a, b).
Isolated Ag peptides were digested with three different proteases to
produce several overlapping peptides, and analysed by mass spectro-
metry. We identified several peptides covering the entire sequence
between the cleavage site N504–M505 of APP695 starting with the
sequence MISEPRISY after the g-secretase cleavage site (Fig. 1f).
Mass spectrometry also supports the C-terminal cleavages at the b-
and a-secretase sites. After immunoprecipitation with 2D8, frag-
ments of the amyloid-b domain were also observed in smaller
amounts alongside the novel Ag peptides (Fig. 1f and Extended
Data Fig. 3c). As the g-secretase cleavage site at amino acid 505 of
APP is consistent with the previously described in vitro cleavage sites
of APP695 by MT1-MMP and MT5-MMP (refs 13, 14), we investi-
gated brains from MT5-MMP- and MT1-MMP-knockout mice15,16
(Extended Data Fig. 4). Whereas MT1-MMP knockout had no
marked effect on Ag-a levels (Extended Data Fig. 4b), the generation
of Ag-a was reduced in brains from MT5-MMP-knockout mice
(Extended Data Fig. 4c). Furthermore, after MT5-MMP overexpres-
sion in murine N2a cells, a selective increase in Ag-a peptide of
approximately 16 kDa was observed (data not shown). Thus, MT5-
MMP displays g-secretase activity in intact mouse brains, although
the contribution of other g-secretases must be considered.
While investigating protease inhibitors capable of blocking
g-secretase, we observed that pharmacological BACE1 inhibition led
to a pronounced accumulation of the long Ag-a species in Chinese
hamster ovary (CHO) 7PA2 cells (Fig. 2a). This indicates that after
blockade of b-secretase activity, processing by a-secretase leads to
enhanced production of the long Ag-a species at the expense of the
shorter BACE1-generated Ag-b. Similarly, BACE1 inhibition also
led to an accumulation of endogenous CTF-g and enhanced produc-
tion of endogenous Ag-a in primary mouse hippocampal neurons
(Fig. 2b, c), as well as human neurons differentiated from embryonic
pluripotent stem cells (H9 cells17; Fig. 2d–g). Furthermore, in
human neurons we not only detected a 65% increase (Fig. 2g) in the
slightly longer Ag-a species after BACE inhibition, but also a con-
comitant decrease in Ag-b peptides (Fig. 2e, top). Importantly,
g-secretase processing significantly exceeded amyloidogenic proces-
sing (9.56 1.87 times Ag compared to amyloid-b estimated for
human neurons; n5 8, P. 0.001, Student’s t-test). Pharmacological
intervention with a BACE1 inhibitor in vivo caused a clear and time-
dependent increase in CTF-g and Ag-a levels in APPV717I transgenic
mice18 (Fig. 2h), which was fully reversible within 24 h after admin-
istration. In agreement, increased CTF-g and Ag-a levels were also
observed in a BACE1-knockout mouse19 in vivo (Fig. 2i).
To identify a potential contribution ofg-secretase processing to AD
pathology, immunohistochemical analyses were performed with
brains derived from six-month-old APPPS1-21 (ref. 20) mice
(Extended Data Fig. 5a). This revealed co-labelling of antibody Y188
with antibody 2E9 in dystrophic neurites. No signal for Ag peptides
was obtained in plaque cores in which aggregated amyloid-b was
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Figure 1 | A novel APP proteolytic processing pathway. a, A 30-kDa APP
CTF-g is detected in the brains of adult and postnatal mice (P10, postnatal day
10). APP-FL, full-length APP; KO, knockout; WT, wild type. b, Ag was
detected in the soluble (sol.) fraction of adult and P10 mice by antibody M3.2
and 9478D (antibody 9478D may not be sensitive enough to detect the lower
Ag levels in adult brain). c, Higher levels of CTF-g are observed in APPPS1-21
mouse brains as compared to wild-type in the membrane (mem.) fraction.
Short and long exposures indicated. Background bands are indicated by
asterisks. d, Soluble extracts of APPPS1-21mouse brains containedAg species,
as detected by 2E9 antibody. Ag-bswe was selectively detected by antibody
192swe. e, Ag and amyloid-b (Ab) were readily detectable in human CSF by
antibody 2D8. Antibody 2E9 allowed the detection of Ag in all samples,
whereas 192swe specifically detected Ag-bswe. f, Mass spectrometric analysis of
Ag. Peptide intensities were summed per amino acid residue and plotted in
relation to each other.
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detected by 6E10 staining (Extended Data Fig. 5a). Similar data were
obtained in human AD brains (Extended Data Fig. 6). To verify accu-
mulation of CTF-g in dystrophic neurites, we used laser capture
microdissection (LCM). Western blot analysis revealed not only
CTF-b and CTF-a, but also CTF-g within the halo, but not within
the plaque core area or regions devoid of plaques (Extended Data
Fig. 5b). As expected, amyloid-b was observed within the plaque core
as well as in the surrounding halo (Extended Data Fig. 5b).
Since the cleavage products of g-secretase APP processing accu-
mulate after BACE1 inhibition and are enriched in dystrophic neur-
ites, we examinedwhether soluble Ag peptides interfere with neuronal
function, similar to soluble amyloid-b oligomers1. Long-term poten-
tiation (LTP) is considered as a synaptic correlate of memory, and is
widely used as a model for investigating the neurotoxic effects of
amyloid-b oligomers on synaptic function21–23. A single oral dose of
the BACE1 inhibitor SCH1682496 increased the CTF-g levels, and
almost doubled the Ag-a level in soluble brain extracts prepared from
animals 3 h after treatment (Extended Data Fig. 7). This was accom-
panied by a significant reduction of hippocampal LTP (Fig. 3a, b).
These findings may suggest an involvement of Ag-a in LTP deficit
under acute blockade of b-secretase activity. To validate the potential
effects of Ag peptides on synaptic transmission and plasticity directly,
we expressed Ag-b and Ag-a in CHO cells (Fig. 3c). Concentrated
conditioned media was further enriched for Ag by size-exclusion
chromatography (SEC) and applied to hippocampal slices before
LTP induction in CA1 pyramidal neurons. Neither Ag-b nor Ag-a
influenced the baseline synaptic transmission (Extended Data Fig. 8).
Comparison of LTP60min after its induction in the presence ofAg-b or
Ag-awith control conditions (Fig. 3d–g) revealed thatAg-a lowered the
LTP to a degree comparable to synthetic amyloid-b dimers23 (Extended
Data Fig. 9a, b), while truncated Ag-b had no effect (Fig. 3e, g). In
support of this observation, synthetic Ag-a reduced LTP to a similar
extent at a concentration of 100nM (Extended Data Fig. 9c, d). To
examine the direct effects of Ag peptides on neuronal activity in vivo,
we used two-photon calcium imaging at single-cell resolution24,25.
Figure 4a–d illustrates results from experiments in which the activity
of neurons in the CA1 pyramidal cell layer was monitored before and
after superfusion of the exposed hippocampus with Ag peptides or the
respective control peptides. Ag-a strongly suppressed the activity of
hippocampal neurons in vivo, an effect not observed with Ag-b or the
control peptide (Fig. 4a–d and Extended Data Fig. 10). By using local
application of synthetic Ag-a to hippocampal neurons, we demonstrate
that the inhibitory effect of Ag-a on neurons was readily reversible after
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washout (Fig. 4e). A summary of the results from all experiments is
shown in Fig. 4f, g.
We have identified a new APP processing pathway that exceeds
amyloidogenic processing. Similar to amyloid-b production26, the
alternative proteolytic processing pathway occurs under physiological
conditions but may be altered during AD pathogenesis. Accumulation
ofg-secretase27 andCTF-gwithin dystrophic neurites in close vicinity to
neuritic plaquesmay also support its potential contribution toADpatho-
logy. However, all APP and presenilin-associated familial ADmutations
affect amyloid-b production and aggregation (reviewed in ref. 26),
whereas the Icelandic mutation APPA673T prevents AD and dementia
by moderately reducing amyloid-b production28. Indeed, the Swedish
mutation decreased Ag-a by strongly enhancing BACE1-mediated
APP processing. However, g-secretase accumulation27 and its activity
near amyloid plaques may suggest that g-secretase stimulation by amy-
loid-b could be a downstream effector within the amyloid cascade.
Although Ag may be involved in the modulation of neuronal activity
and synaptic plasticity, the differential bioactivity of recombinant Ag-a
and Ag-b is currently unclear. One may speculate that the longer Ag-a
peptide is more stable owing to unknown post-translational modifica-
tions. This would be consistent with our observation that, in contrast to
cell-produced Ag-b, 100nM of synthetic Ag-b inhibits LTP (data not
shown). Finally, it is important to note that low-n amyloid-b oligomer
preparations from 7PA2 supernatants contain considerable amounts of
Ag (data not shown). Thus, the previously observed inhibition of LTP
with such fractions may also be attributed to the presence of Ag. Our
findingsmay also be considered in the context of continuing clinical trials
with BACE1 inhibitors. Together with the identification of numerous
brain-specific BACE1 substrates29,30, our data indicate that therapeutic
inhibition of BACE1 activity requires careful titration to prevent
unwanted adverse effects at several levels.
Online Content Methods, along with any additional Extended Data display items
andSourceData, are available in theonline versionof thepaper; referencesunique
to these sections appear only in the online paper.
Received 27 March; accepted 25 June 2015.
Published online 31 August 2015.
1. Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons
from the Alzheimer’s amyloid b-peptide. Nature Rev. Mol. Cell Biol. 8, 101–112
(2007).
2. Dobrowolska, J. A. et al.CNSamyloid-b, soluble APP-a and -b kinetics duringBACE
inhibition. J. Neurosci. 34, 8336–8346 (2014).
3. Haass, C., Koo, E. H., Mellon, A., Hung, A. Y. & Selkoe, D. J. Targeting of cell-surface
b-amyloid precursor protein to lysosomes: alternative processing into amyloid-
bearing fragments. Nature 357, 500–503 (1992).
4. Estus, S. et al. Potentially amyloidogenic, carboxyl-terminal derivatives of the
amyloid protein precursor. Science 255, 726–728 (1992).
5. Haass, C. et al. b-Amyloid peptide and a 3-kDa fragment are derived by distinct
cellular mechanisms. J. Biol. Chem. 268, 3021–3024 (1993).
6. Müller, U. et al. Behavioral and anatomical deficits in mice homozygous for a
modified b-amyloid precursor protein gene. Cell 79, 755–765 (1994).
7. Nikolaev, A., McLaughlin, T., O’Leary, D. D. & Tessier-Lavigne, M. APP binds DR6 to
trigger axon pruning and neuron death via distinct caspases. Nature 457,
981–989 (2009).
8. Jefferson,T.etal.MetalloproteasemeprinbgeneratesnontoxicN-terminalamyloid
precursor protein fragments in vivo. J. Biol. Chem. 286, 27741–27750 (2011).
9. Vella, L. J. & Cappai, R. Identification of a novel amyloid precursor protein
processing pathway that generates secreted N-terminal fragments. FASEB J. 26,
2930–2940 (2012).
10. Radde, R. et al. Ab42-driven cerebral amyloidosis in transgenic mice reveals early
and robust pathology. EMBO Rep. 7, 940–946 (2006).
a 
b 
c 
d 
e f g
Control CHO
CHO Aη-β
CHO Aη-α
Synthetic Aη-α
Synthetic Aη-α
(local)
Cell 1
Cell 2
Cell 3
Cell 4
Cell 5
Cell 1
Cell 2
Cell 3
Cell 4
Cell 5
Cell 1
Cell 2
Cell 3
Cell 4
Cell 5
Cell 1
Cell 2
Cell 3
Cell 4
Cell 1
Cell 2
Cell 3
Cell 4
Cell 5
Control
Control
10 s
10 s
10 s
10 s
2 s
10
0%
 Δ
F/
F
50
%
 Δ
F/
F
10
0%
 Δ
F/
F
10
0%
 Δ
F/
F
10
0%
 Δ
F/
F
Control
Control C
on
tr
ol
p
ep
tid
e
P
er
ce
nt
ag
e 
of
 s
ile
nt
 c
el
ls
Wash-in
Control Wash-out
Control
Peptides
C
H
O
 A
η-
β
C
H
O
C
H
O
 A
η-
α
S
yn
th
et
ic
A
η-
α 
(b
at
h)
S
yn
th
et
ic
A
η-
α 
(lo
ca
l)
Control
peptide
CHO Aη-β
CHO
Synthetic
Aη-α (local)
Synthetic
Aη-α (bath)
CHO Aη-α
18
16
14
12
10
8
6
4
2
0
M
ea
n 
fr
eq
ue
nc
y 
(tr
an
si
en
ts
 m
in
–1
) 17
16
15
14
12
10
11
13
9
8
7
6
Figure 4 | Ag-a reducesneuronal activity in vivo.
a–d, Left, in vivo images of CA1 hippocampal
neurons labelled with the fluorescent calcium
indicator fluo-8AM. Middle and right, calcium
transients of five representative neurons,marked in
the corresponding left panels, before and during
bath-application of Ag or CHO conditioned
media. e, Calcium transients in hippocampal
neurons before, during and after local application
of synthetic Ag-a. f, g, Summary results of the
changes in the average rates of calcium transients (f),
and in the fractions of silent neurons (g); for statistics
see Supplementary Tables 2 and 3. Error bars
represent s.e.m.
RESEARCH LETTER
4 | N A T U R E | V O L 0 0 0 | 0 0 M O N T H 2 0 1 5
G2015 Macmillan Publishers Limited. All rights reserved
11. Portelius, E. et al.Mass spectrometric characterization of amyloid-b species in the
7PA2 cell model of Alzheimer’s disease. J. Alzheimers Dis. 33, 85–93 (2013).
12. Welzel, A. T. et al. Secreted amyloid b-proteins in a cell culture model include
N-terminally extended peptides that impair synaptic plasticity. Biochemistry 53,
3908–3921 (2014).
13. Higashi, S.&Miyazaki, K.Novel processingofb-amyloidprecursor protein catalyzed
bymembrane type 1 matrix metalloproteinase releases a fragment lacking the
inhibitor domain against gelatinase A. Biochemistry 42, 6514–6526 (2003).
14. Ahmad, M. et al. Cleavage of amyloid-b precursor protein (APP) by membrane-
type matrix metalloproteinases. J. Biochem. 139, 517–526 (2006).
15. Folgueras, A. R. et al. Metalloproteinase MT5-MMP is an essential modulator of
neuro-immune interactions in thermal pain stimulation. Proc. Natl Acad. Sci. USA
106, 16451–16456 (2009).
16. Zhou, Z. et al. Impaired endochondral ossification and angiogenesis in mice
deficient in membrane-type matrix metalloproteinase I. Proc. Natl Acad. Sci. USA
97, 4052–4057 (2000).
17. Shi, Y., Kirwan, P.& Livesey, F. J.Directeddifferentiationofhumanpluripotent stem
cells to cerebral cortex neurons and neural networks. Nature Protocols 7,
1836–1846 (2012).
18. Moechars, D. et al. Early phenotypic changes in transgenic mice that overexpress
different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274,
6483–6492 (1999).
19. Cai, H. et al. BACE1 is the major b-secretase for generation of Ab peptides by
neurons. Nature Neurosci. 4, 233–234 (2001).
20. Radde, R. et al. Ab42-driven cerebral amyloidosis in transgenic mice reveals early
and robust pathology. EMBO Rep. 7, 940–946 (2006).
21. Walsh,D.M.et al.Naturally secretedoligomersof amyloidbproteinpotently inhibit
hippocampal long-term potentiation in vivo. Nature 416, 535–539 (2002).
22. Shankar, G. M. et al.Natural oligomers of the Alzheimer amyloid-b protein induce
reversible synapse loss by modulating an NMDA-type glutamate receptor-
dependent signaling pathway. J. Neurosci. 27, 2866–2875 (2007).
23. Shankar, G. M. et al. Amyloid-b protein dimers isolated directly from Alzheimer’s
brains impair synaptic plasticity and memory. Nature Med. 14, 837–842 (2008).
24. Busche, M. A. et al. Clusters of hyperactive neurons near amyloid plaques in a
mouse model of Alzheimer’s disease. Science 321, 1686–1689 (2008).
25. Busche, M. A. et al. Critical role of soluble amyloid-b for early hippocampal
hyperactivity in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA
109, 8740–8745 (2012).
26. Haass, C. Take five–BACE and the c-secretase quartet conduct Alzheimer’s
amyloid b-peptide generation. EMBO J. 23, 483–488 (2004).
27. Sekine-Aizawa, Y. et al. Matrix metalloproteinase (MMP) system in brain:
identification and characterization of brain-specific MMP highly expressed in
cerebellum. Eur. J. Neurosci. 13, 935–948 (2001).
28. Jonsson, T. et al. Amutation in APP protects against Alzheimer’s disease and age-
related cognitive decline. Nature 488, 96–99 (2012).
29. Kuhn, P. H. et al. Secretome protein enrichment identifies physiological BACE1
protease substrates in neurons. EMBO J. 31, 3157–3168 (2012).
30. Zhou, L. et al. The neural cell adhesion molecules L1 and CHL1 are cleaved by
BACE1 protease in vivo. J. Biol. Chem. 287, 25927–25940 (2012).
Supplementary Information is available in the online version of the paper.
Acknowledgements The authors thank S. Lammich, N. Exner andH. Steiner for critical
comments. We thank A. Sülzen, N. Astola, S. Diederich, E. Grießinger and J. Gobbert for
technical help. The APPPS1-21 colony was established from a breeding pair provided
by M. Jucker.MT1-MMP2/2 mouse brains were obtained from Z. Zhou.MT5-MMP2/2
mouse brains were obtained from I. Farinas. We thank H. Jacobsen for the BACE1
inhibitor RO5508887. This work was supported by the European Research Council
under the European Union’s Seventh Framework Program (FP7/2007–2013)/ERC
grant agreement no. 321366-Amyloid (advanced grant to C.H.). Thework of D.R.T. was
supported by AFI (grant 13803). The research leading to these results has received
funding (F.M. and D.H.) from the European Research Council under the European
Union’s Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no.
318987 [TOPAG]. We thank J. Cox and M. Mann for critical discussions and the mass
spectrometry infrastructure. We also acknowledge support by grants from Deutsche
Forschungsgemeinschaft (MU 1457/9-1, 9-2 to U.M.) and the ERA-Net Neuron
(01EW1305A to U.M.). Further support came from the ATIP/AVENIR program (Centre
national de la recherche scientifique, CNRS) to H.M.; the French Fondation pour la
Coopération Scientifique – Plan Alzheimer (Senior Innovative Grant 2010) to M.C. and
H.M., and the French Government (National Research Agency, ANR) through the
‘‘Investments for the Future’’ LABEX SIGNALIFE: program reference ANR-11-LABX-
0028-01 to S.K. M.A.B. was supported by the Langmatz Stiftung. F.J.L. is a Wellcome
Trust Investigator. In vivoBACE1 inhibition experimentswithAPP transgenicmicewere
performed together with reMYND (Bio-Incubator, 3001 Leuven-Heverlee, Belgium).
Author Contributions M.W. and C.H. designed the study and interpreted the results.
M.W. generated all biochemical data together with H.H., V.M., B.N. and C.G. S.T.,
supported by A.W.-W., provided primary neuronal cultures, performed and analysed
immunohistological stainings, and together with A.D. performed LCM. D.R.T. provided
and analysed human brain sections. M.T.H. provided CSF samples. U.M. provided
APP-knockoutmice. E.K. producednewmonoclonal antibodies. D.H. andF.M. designed
and conducted mass spectrometry and data analysis. L.D.B.E., S.M. and F.J.L. carried
out BACE1 inhibitionof humanneurons. H.M. togetherwithM.C. and S.K. performedall
electrophysiological recordings (LTP) in vitro and analysis in relation to application of
peptides. S.V.O. and J.H. performed all electrophysiological recordings (LTP) in vitro in
relation to the BACE1 inhibitor tests. M.A.B and A.K. performed all Ca21-imaging
experiments in vivo and analysis. M.W. and C.H. wrote the manuscript with input from
the other authors. Correspondence and requests for materials should be addressed to
M.W. and C.H.
Author Information Reprints and permissions information is available at
www.nature.com/reprints. The authors declare competing financial interests: details
are available in the online version of the paper. Readers are welcome to comment on
the online version of the paper. Correspondence and requests for materials should be
addressed to M.W. (michael.willem@mail03.med.uni-muenchen.de) or C.H.
(christian.haass@mail03.med.uni-muenchen.de).
LETTER RESEARCH
0 0 M O N T H 2 0 1 5 | V O L 0 0 0 | N A T U R E | 5
G2015 Macmillan Publishers Limited. All rights reserved
METHODS
Cell culture. Mycoplasm-free CHO and 7PA2 (ref. 31) cells (gift from E. Koo)
were grown in DMEM/F12 (Thermo Scientific) supplemented with 10% FCS
(Thermo Scientific) plus penicillin/streptomycin and non-essential amino acids
(PAA) in a humid incubator with 5%CO2 at a temperature of 37 uC. For inhibitor
treatment, cell culture medium was replaced with fresh, pre-warmed serum free
medium (OPTIMEM; Thermo Scientific) supplementedwith inhibitors orDMSO
as vehicle control. Treatment was initiated when cells reached 90–100% con-
fluency and conditioned media were collected after 20–24 h. Supernatants were
cleared by centrifugation (10min, 5,500g at 4 uC). To obtain cell lysates, cell
monolayers were washed once with ice-cold PBS and detached in 1 ml PBS using
a cell scraper. The cell suspension was pelleted by centrifugation (5min, 1,000g at
4 uC) and lysedwith RIPAbuffer (20mMsodium citrate, pH6.4, 1mMEDTA, 1%
Triton X-100 in ddH2O) supplemented with Protease Inhibitor Cocktail (Sigma-
Aldrich). The protein concentration of lysates was determined using the Uptima
BC Assay Protein Quantitation kit (Interchim).
Primary cell culture.Hippocampal neurons were isolated from embryonic day 18
CD rats (Charles River) as described previously32. Dissociated neurons were plated
at 17,700 cells cm22 onto 6-cm dishes coated with poly-L-lysine (1mgml21;
Sigma) and cultured in Neurobasal medium supplemented with 2% B27 and
0.5mML-glutamine (all from Invitrogen).Hippocampal culturesweremaintained
in a humidified 5%CO2 incubator at 37 uC. For inhibitor treatment,DIV16 culture
medium was replaced with fresh, pre-equilibrated N2 medium (supplemented
with 20% of 4 days conditioned N2 medium from pure primary cultured astro-
cytes) to which inhibitors or DMSO as vehicle control were added.
Generation and BACE1 inhibition of cerebral cortex neurons induced from
human embryonic stem cells. Cell lines in this study were H9 ES (WiCell
Research Institute)33. Pluripotent cells were cultured on mouse embryonic
fibroblasts (GlobalStem) in DMEM/F12 containing 20% (v/v) KSR, 100mm
non-essential amino acids, 100mM 2-mercaptoethanol, 50Uml21 penicillin and
50mgml21 streptomycin (Life Technologies) and 10ngml21 FGF2. Directed
differentiation of human embryonic stem cells to cerebral cortex neurons was
carried out as described17,34. Human neurons (75 days after induction) were
treated with 1mM b-secretase inhibitor LY2886721 (Selleck) dissolved in
DMSO (20mM stock). Vehicle-only control assays were performed using
DMSO. The compound was applied twice at 48-h intervals. Extracellular media
was collected before drug addition and at subsequent 48-h intervals. Neurons were
collected after 4 days of treatment using 0.5mM EDTA in PBS.
Transgenic mice, animal care and animal handling. Bace12/2 and APPPS1-21
mice were described before10,19 and were bred for this study in a Bl6C57/J back-
ground. All treatments were approved by the local committee for animal use and
were performed in accordance to state and federal regulations (license number
KVR-I/221-TA116/09). Mice had access to pre-filtered sterile water and standard
mouse chow (Ssniff Ms-H, Ssniff Spezialdiäten GmbH, Soest, Germany) ad libi-
tum and were housed under a reversed day–night rhythm in IVC System Type II
L-cages (528 cm2) equippedwith solid floors and a layer of bedding, in accordance
to local legislation on animal welfare.
BACE1 inhibitor treatment. Randomized APPV717I (ref. 18) mice were treated
with vehicle or with the inhibitor RO5508887 provided by Hoffmann-La Roche35.
The groups of treatedmicewere blinded to the examiner anduncoded at the end of
the experiments. Three-month-old heterozygous female transgenicmice inmixed
FVB/N3C57Bl/6J background expressing human APPV717I (ref. 18) were used
for BACE1 inhibition studies. Gavage mediated administration of BACE1 inhib-
itor (90mgkg21, 14.06ml kg21) or vehicle (14.06ml kg21) was performed once35.
The BACE1 inhibitor was diluted in 5% ethanol (Merck) and 10% solutol (Sigma-
Aldrich) in sterile water (Baxter). Animals were sacrificed after 5, 8 and 24 h.Mice
were anaesthetized with 3.5 ml per gram body weight of a mixture of ketamine
(115mgml21 ketamine hydrochloride, Eurovet), xylazin 2% (23.32mgml21 xyla-
zine hydrochloride, VMD Arendonk), atropine (0.50mgml21 atropine sulphate,
Sterop) and saline (8:5:2:5, v/v/v/v). For brain preparation, mice were flushed
trans-cardially with ice-cold saline (3.5mlmin21, 3min). The brain was removed
from the cranium and dissected into left and right hemiforebrain, brainstem,
cerebellum and olfactory bulb. The brain structures were promptly immersed in
liquid nitrogen and stored at 280 uC. Different tissues (kidneys, spleen, liver,
stomach, gut, lungs and heart) were examined and checked for gross abnormal-
ities. No obvious abnormalities were observed in any of the treatment groups.
Preparation of protein extracts from brain. Brains were removed from the
cranium and dissected into left and right hemispheres. Brain tissue was snap-
frozen in liquid nitrogen and stored at 280 uC. Soluble proteins were extracted
with DEA buffer (50mMNaCl, 0,2% diethylamine, pH 10, plus protease
inhibitor (P8340, Sigma-Aldrich))36, membrane proteins were extracted with
RIPA buffer (20mM Tris-HCl, pH 7.5, 150mMNaCl, 1mM EDTA, 1mM
EGTA,1% NP-40,1% sodium deoxycholate, 2.5mM sodium pyrophosphate
plus protease inhibitor) or applying a membrane preparation protocol as
described before37.
Protein analysis. Proteins were separated under denaturing conditions using
discontinuous SDS–PAGE. Equal amounts of proteins denatured in Laemmli
buffer were loaded onto the gel and 10ml of the SeeBlue Plus2 Prestained
Standard (Invitrogen) served as molecular mass marker. Electrophoresis was per-
formed in Tris-glycine buffer (25mM Tris, 190mM glycine in ddH2O) using the
Mini-PROTEAN system (BIORAD) on activated PVDF membranes. Low
molecular mass proteins (,16 kDa) were separated using precast gradient
Tricine Protein Gels (10–20%, 1mm, Novex) in Tris-tricine buffer using the
XCell SureLock Mini-Cell system (Novex). After separation by SDS–PAGE, pro-
teins were transferred onto membranes using the tank/wet Mini Trans-Blot cell
system (BIORAD). CTFs, Ag and amyloid-b were detected after transfer on
Nitrocellulose membranes (Protran BA85; GE Healthcare), while other proteins
were blotted on PVDF (Immobilon-P, Merck Millipore). As size markers for Ag
synthetic peptides Ag-b (92 amino acids; 1-MISEPRISYGNDALMPSLTETKT
TVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTT
RPGSGLTNIKTEEISEVKM-92) and the slightly longer Ag-a (108 amino acids;
1-MISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSV
PANTENEVEPVDARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSG
YEVHHQK-108)were obtained fromPeptide Speciality Laboratories. After com-
pletion of the transfer and before blocking, proteins transferred to nitrocellulose
membranes were additionally denatured by boiling the membrane in PBS
(140mMNaCl, 10mM Na2HPO4, 1.75mM KH2PO4, 2.7mMKCl in ddH2O,
pH 7.4) for 5min. After cooling to room temperature, nitrocellulose membranes
as well as the PVDF membranes were blocked in I-Block solution (0.2% Tropix
I-Block (Applied Biosystems), 0.1%Tween20 in PBS) for 1 h at room temperature
or overnight at 4 uC (with agitation). Transferred proteins were detected using
immunodetection and enhanced chemiluminescence (ECL). First, blockedmem-
branes were incubated with primary antibodies diluted in I-Block solution over-
night at 4 uC (with agitation). After removal of the antibody, membranes were
washed three times in TBS-T buffer (10 min each, at room temperature, with
agitation; 140mMNaCl, 2.68mM KCl, 24.76mM Tris, 0.3% Triton X-100 in
ddH2O, pH 7.6) and subsequently incubated with a horseradish-peroxidase-
coupled secondary antibody (obtained from Promega or Santa Cruz). Secon-
dary antibodies were diluted in I-Block solution and membranes were incubated
for 1 h at room temperature (with agitation) followed by three washes in TBS-T.
For ECL detection, membranes were incubated with horseradish peroxidase sub-
strate (ECL, GE Healthcare or ECL Plus, Thermo Scientific) for 1min at room
temperature and signals were captured with X-ray films (Super RX Medical
X-Ray, Fujifilm), which were subsequently developed using an automated film
developer (CAWOMAT 2000 IR, CAWO). Quantitation of protein was con-
ducted using ImageJ software. Ratios were obtained from signals on the same
film for Ag over amyloid-b. Quantitative data were analysed statistically by using
a two-tailed Student’s t-test.
Molecular cloning and transfection. For the expression of Ag-a and Ag-b in
CHO cells, the complementary DNAs of the respective fragments were amplified
by PCR and subcloned into the pSecTag2A (Invitrogen) vector that features an
N-terminal secretion signal. CHO cells were cultured in DMEM with 10% FCS
and non-essential amino acids. Transfections were carried out using Lipofecta-
mine 2000 (Invitrogen) according to the manufacturer’s instructions.
Mass spectrometry analysis of samples. Beads with immunoprecipitated pep-
tideswere resuspended in ddH2O and reducedwith 10mMdithiothreitol followed
by alkylation with 55mM 2-chloroacetamide. Samples were divided into three
parts and digested with either 1mg of trypsin (1.2M urea, 0.4M thiourea and
50mM ammonium bicarbonate), LysC (5M urea, 1.7M thiourea and 50mM
ammonium bicarbonate) or chymotrypsin (0.3M urea, 0.1M thiourea and
50mM ammonium bicarbonate). To increase the sequence coverage further, par-
tially cleaved peptideswere generated by digesting for 5, 10, 20, 40, 60, 120, 180 and
720 min. Samples from all time points of a respective protease were pooled and
desalted on stage tips38.
For liquid chromatography–tandemmass spectrometry (LC–MS/MS), peptides
were separated on a Thermo Scientific EASY-nLC 1000 HPLC system (Thermo
Fisher Scientific) and in-house packed columns (75mm inner diameter, 20 cm
length, 1.9mmC18 particles (Dr.MaischGmbH). The peptidemixturewas loaded
in buffer A (0.5% formic acid) and separated with a gradient from 10% to 60%
buffer B (80% acetonitrile, 0.5% formic acid) within 40min at 250nlmin21 at a
column temperature of 50 uC. A Quadrupole Orbitrap mass spectrometer39 (Q
Exactive, Thermo Fisher Scientific) was coupled to the HPLC system via a nano
electrospray source.We used data-dependent acquisitionwith a survey scan range
of 300 to 1,650 m/z, at a resolution of 60,000 m/z and selected up to five most
abundant features with a charge state $2 for HCD fragmentation40 at a normal-
ized collision energy of 27 and a resolution of 15,000 atm/z 200. To limit repeated
RESEARCH LETTER
G2015 Macmillan Publishers Limited. All rights reserved
sequencing, dynamic exclusion of sequenced peptides was set to 20 s. Thresholds
for ion injection time and ion target values were set to 20ms and 33 106 for the
survey scans, and 120ms and 13 105 for the MS/MS scans. Data were acquired
using the Xcalibur software (Thermo Scientific).
Data analysis. To process mass spectrometry raw files, we used the MaxQuant
software (v1.5.2.16)41. We used the Andromeda search engine42, which is inte-
grated into MaxQuant, to search MS/MS spectra against the APP695 and 247
common contaminating proteins42. We set enzyme specificity to unspecific to
detect novel cleavage sites and set a peptide search length from 7 to 40 amino
acids. A false discovery rate cutoff of 1% was applied at the peptide level. For data
visualization we used R43. Identified peptides were mapped to APP695. To display
quantitative evidence for overlapping peptides, intensities of identified peptides
were summed and plotted per amino acid residue. The data of the individual
immunoprecipitation and mass spectrometry analyses are depicted in Extended
Data Fig. 3.
Human CSF samples. Human CSF samples collected at the Department of
Neurology Outpatient unit for neurodegenerative disease (KBFZ) of the
University of Bonn were obtained by lumbar puncture at position L3, centrifuged
and divided in small aliquots. For further analysis, samples were stored at280 uC.
Turbid or blood-contaminated samples were excluded from analysis. Use of these
samples for research purposes has been consented by all patients according to the
ethical committee requirements of the University of Bonn Ethical committee and
approval number 279/10. For the analysis of APPswe carriers with antibodies
192swe (ref. 44) lumbar CSF was obtained from family members. Tubes with
CSF were stored at 270 uC until analysis. The clinical diagnosis of probable AD
was based onNINCDS-ADRDA criteria45. The diagnosis of ADwas confirmed by
neuropathological examination of the brain of one deceased mutation-carrier46,47.
This study was approved by research ethics committee at the Uppsala University
Hospital (Dnr 048-2005).
Neuropathology and immunohistochemistry.Use of brain samples for research
purposes has been consented by all patients according to the ethical committee
requirements of the University of Ulm Ethical committee and approval number
54/08. Braak-NFT stages48, and CERAD49 scores for neuritic plaques were used to
determine the degree of AD pathology according to the NIA-AA guidelines50.
Consecutive paraffin sections from the human medial lobe were stained with
22C11, 9476M and 9478D. Primary antibodies were detected with biotinylated
anti-mouse and anti-rabbit IgG secondary antibodies and visualized with avidin-
biotin-complex (ABC-Kit, Vector Laboratories) and diaminobenzidine-HCl
(DAB). The sections were counterstained with haematoxylin. Positive and nega-
tive controls were performed. 9476M and 9478D stainings were assessed in 10
control and 10 AD patient cases.
For double immunofluorescence analysis of APPPS1-21 brain sections,
6-month-old mice were killed by CO2 inhalation according to animal handling
laws. Brains were dissected and fixed with 4% paraformaldehyde in 0.1M PBS,
pH 7.4 for 48 h. For immunohistochemistry, 25-mm-thick sagittal mouse brain
cryosections were treated with 10mM sodium citrate, pH 6 at 95 uC for 20min,
washed with 0.5% Triton X-100 in PBS, blocked with 5% goat serum (Invitrogen)
and 0.5% Triton X-100 in PBS for 1 h and subsequently incubated overnight with
primary antibodies diluted in blocking solution. Primary antibodies were used as
listed in Supplementary Table 1. DAPI was used to counterstain nuclei. Signals
were visualized using fluorescently labelled secondary antibodies. Confocal images
were acquired using a Plan-Apochromat 253/0.8 oil differential interference con-
trast objective on a LSM 710 confocal microscope (Zeiss) in sequential scanning
mode using ZEN 2011 software package (black edition, Zeiss).
LCM of plaque enriched brain material. For laser capture microdissection of
plaque cores andhalos, 10-, 11-, 14-, 16- and24-month-old transgenicAPPPS1-21
mice were used according to a previously published protocol51 with slight mod-
ifications. Mice brains were dissected and immediately frozen on crushed dry ice.
Ten-micrometre-thick sagittal sections were cut using aMicromHM560 cryostat
(Thermo Scientific), mounted on frame slides containing a 1.4mm polyethylene
terephthalatemembrane (LeicaMicrosystems) and subsequently stained or stored
at280 uC for later usage. Staining was performed as follows: brain sections were
thawed briefly at room temperature, fixedwith 75%ethanol for 1min, stainedwith
0.05% Thioflavin-S for 5min, washed with 75% ethanol and dried at room tem-
perature. LCMwas performedon the same day using a laser dissectionmicroscope
(Leica, LMD7000)with the following settings: excitationwavelength 495nm, laser
power 30, aperture 5, speed 6 and pulse frequency 119. From each animal, at least
800 plaque cores and halos, dissected from 12 brain sections were cut using a 633
magnification objective, collected in 0.5ml caps (Leica Microsystem) and subse-
quently pooled for protein analysis. Areas containing no plaques were cut using a
103magnification objective and were used as controls. Protein lysates were done
essentially as described above using RIPA with 0.1% SDS.
Slice preparation and electrophysiological recordings applyingAg peptides in
vitro. Transverse hippocampal slices (350mm) were prepared from P20–30 Swiss
mice following standard procedures52. Slices were cut in ice-cold oxygenated
(95% O2, 5% CO2) solution containing 206mM sucrose, 2.8mMKCl, 1.25mM
NaH2PO4, 2mMMgSO4, 1mM MgCl2, 1mMCaCl2, 26mMNaHCO3, 0.4mM
sodium ascorbate and 10mM glucose, pH 7.4. For recovery (1 h), slices were
incubated at 27 uC in oxygenated standard ACSF containing: 124mMNaCl,
2.8mMKCl, 1.25mMNaH2PO4, 2mMMgSO4, 3.6mMCaCl2, 26mM NaHCO3,
0.4mM sodium ascorbate, 10mM glucose (pH 7.4)53. Slices were inspected in a
chamber on an upright microscope (Slicescope, Scientifica Ltd) with infrared
differential interference contrast illumination, and were perfused with the oxyge-
nated ACSF at 276 1 uC. fEPSPs were recorded in the stratum radiatum of the
CA1 region using a glass electrode (filled with 1MNaCl, 10mMHEPES, pH 7.4)
and the stimuli (30% ofmaximal fEPSP) were delivered to the Schaeffer Collateral
pathway by a monopolar glass electrode (filled with ACSF). Electrodes were
specifically placed just below the surface of the slice to maximize the exposure
to circulating peptides. A minimum of 15–20min stable baseline was first
obtained in standard ACSF followed by another 15–20min of bath application
of ACSF containing SEC fractions (CHO, Ag-a or Ag-b; 1/15 dilution, inter-
leaved recordings) using re-circulation with a peristaltic pump at 2.5–3mlmin21
while being continuously aerated with 95% oxygen. No alterations in fEPSP
baseline responses were observed after incubation with the SEC fractions
(Extended Data Fig. 8). In the continuous presence of ACSF/SEC solution, LTP
was induced using a high-frequency stimulation protocol with two pulses of
100 Hz for 1 s with a 20 s interval between pulses, and recorded for 1 h. Control
recordings (no application of SEC fractions) were obtained in an interleaved
fashion in which ACSF was re-circulated using an identical procedure. For
LTP analysis, the first third of the fEPSP slopewas calculated in baseline condition
(15–20 min before induction of LTP) and compared to that after LTP induction
(60 min after tetanization of Schaffer collaterals). The average baseline value was
normalized to 100% and all values of the experiment were normalized to this
baseline average (1-min bins). Experimental data were pooled per condition and
presented as mean6 s.e.m. Data analysis was performed with the Clampfit soft-
ware (Molecular Devices). The test samples were blinded to the investigator and
uncoded at the end of the experiments. Statistical analysis was performed using
GraphPad (Prism 6) with the last 15min of the recordings compared tomeasure-
ments of 15–20min of baseline, using a two-tailed Student’s t-test for statistical
analysis on two samples or one-way ANOVA and post hoc Bonferroni test for
statistical analysis on three and more samples, with P, 0.05 taken as statistically
significant. No power analysis was done to estimate sample size, and there was no
randomization.
Electrophysiological recordings of the effects of BACE1 inhibitor in vitro.
BACE1 inhibitor (100mgkg21, single gavage) or vehicle-treated mice (12 weeks
old) were deeply anaesthetized with isoflurane (1% in O2) and decapitated with
brains rapidly extracted and placed for 5–6 min in ice-cold bubbled (95% O2, 5%
CO2) slicing solution (inmM): 75 sucrose, 85NaCl, 2.5 KCl, 1.25NaH2PO4,
25NaHCO3, 0.5 CaCl2, 4MgCl2, 25 glucose, pH 7.4. Coronal slices (400mm)
containing the hippocampus were cut (VT1200S; Leica) and transferred into a
warming chamber (35 uC) filled with bubbled solution of the same composition,
except sucrose was omitted and NaCl increased to 125mM (30min). This was
followed by the transfer of slices into recordingACSF (inmM): 125NaCl, 2.5 KCl,
1.25NaH2PO4, 25 NaHCO3, 2 CaCl2, 2 MgCl2, 25 glucose. Recordings of fEPSP
were made from the hippocampal CA1 area. A glass bipolar stimulating electrode
was placed in the stratum radiatum of CA2–CA3 subfields to stimulate Schaffer
collaterals with 0.2ms current pulses at 0.033 Hz (A-360, WPI), with evoked
responses recorded in the stratum radiatum of CA1 area. Incrementing current
pulses (0.2mA) were used for obtaining stimulus-response relationship graphs.
Stable baseline and LTP recordings were made using one-half of the maximal
stimulus intensities; LTP was induced by high-frequency stimulation of Schaffer
collaterals with 10 trains of 10 pulses at 100 Hz applied, with 2-s inter-train
intervals. Signals were filtered at 5 kHz, digitally sampled at 10 kHz and stored
for offline analysis. The relative slope and peak amplitude of evoked fEPSPs were
measured using FitMaster (HEKA Electronics). The groups of treated mice were
blinded to the investigator and uncoded at the end of the experiments. A one-way
ANOVA and post hoc Bonferroni test have been used for statistical analysis, with
P , 0.05 taken as statistically significant.
In vivo two-photon Ca21 imaging. All experimental procedures were in com-
pliance with institutional animalwelfare guidelines andwere approved by the state
government of Bavaria, Germany. The animal preparation procedure was similar
to that described previously25. In brief, C57Bl/6 mice (male or female, ,P40)
were anaesthetized with isoflurane (1–1.5%) and placed onto a warming plate
(37–38 uC). The skin was removed and a custom-made recording chamber
was glued to the exposed skull. A craniotomy (,1mm) was made over the
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hippocampus (2.5mm posterior to bregma, 2.2mm lateral to the midline) and a
small portion of the overlying cortical tissue was carefully removed by aspiration.
The animal was placed under a microscope on a warm heating plate (37–38 uC)
and kept anaesthetized with low-levels of isoflurane (,0.8%). Respiratory and
pulse rates were continuously monitored. The recording chamber was perfused
with warm normal Ringer’s solution containing 125mM NaCl, 4.5mM KCl,
26mMNaHCO3, 1.25mM NaH2PO4, 2mM CaCl2, 1mM MgCl2 and 20mM
glucose (pH 7.4 when bubbled with 95% O2 and 5% CO2). The exposed CA1
region of the hippocampus was then stained with fluo-8AM (AAT Bioquest;
0.6mM) using the multi-cell bolus loading technique54.
In vivo imaging was performed with a custom-built two-photon microscope
equipped with a Ti:sapphire laser system (Coherent; laser wavelength 925nm), a
resonant scanner and a Pockel’s cell for laser intensity modulation. Full-frame
images were acquired at 30 Hz using a water-immersion objective (Nikon; 403,
0.8 numerical aperture). Data acquisition was controlled using custom-written
software based on LabVIEW (National Instruments). Image analysis was per-
formed off-line by using custom routines in LabVIEW and Igor Pro
(Wavemetrics). Cellular regions of interest were drawn around individual somata,
and then relative fluorescence change (DF/F) versus time traces were generated for
each region of interest. Ca21 transients were identified as changes in DF/F that
were three times larger than the s.d. of the noise band.
To assess the effects of Ag peptides on neuronal activity in vivo, the peptides or
the respective controls (SEC fractions obtained from untransfected CHO cells or a
synthetic peptide (46 amino acids; 1-ADSVPANTENEVEPVDARPAADRGL
TTRPGSGLTNIKTEEISEVKM-46) of a middle part of Ag were added to the
normal Ringer’s solution used for perfusion of the recording chamber (bath-
application technique; 45–60min each wash-in). In a subset of experiments, syn-
thetic Ag-a (92 amino acids; 1-MISEPRISYGNDALMPSLTETKTTVELLPV
NGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLT
NIKTEEISEVKM-92) was applied locally by gentle pressure injection through a
glass pipette that was placed close to the neurons of interest (local application
technique; 40 s each pressure injection).
The samples were blinded to the investigator and uncoded at the end of the
experiments. Statistical analysis was performed using SPSS. The statistical meth-
ods used were the Student’s t-test and the Fisher’s exact test. P , 0.05 was con-
sidered statistically significant.
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The impact II, a very high resolution quadrupole time-of-flight 
instrument for deep shotgun proteomics 
Hybrid quadrupole time-of-flight (QTOF) mass spectrometers are one of the two major principles in 
mass spectrometry. Over the last decades, QTOF mass spectrometers have greatly evolved in terms 
of achievable resolution, mass accuracy and dynamic range. The Bruker impact platform of QTOF 
instruments takes advantage of these developments and here we develop, optimized and evaluate the 
impact II for shotgun proteomics applications. This instrument features highly efficient ion optics 
and improvements on the reflectron and ion detector, providing almost twice the resolution compared 
to its predecessor. These improvements, combined with the principle advantages of TOF technology 
including high sequencing speed and dynamic range, the 𝑚 𝑧⁄  independent resolution and
comparably low price, make QTOF very appealing for shotgun proteomics. We integrated the impact 
II into the state of the art proteomics workflow. We then benchmarked this proteomic pipeline for 
the analysis of complex biological samples. With the QTOF we identified over 4,800 proteins in Hela 
within 90 min measuring time. Using high pH fractionation, we could quantify over 11,000 proteins 
in murine cerebellum, which is the deepest proteome acquired with a QTOF instrument to date. 
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The Impact II, a Very High-Resolution
Quadrupole Time-of-Flight Instrument (QTOF)
for Deep Shotgun Proteomics*□S
Scarlet Beck‡, Annette Michalski§, Oliver Raether§, Markus Lubeck§,
Stephanie Kaspar§, Niels Goedecke§, Carsten Baessmann§, Daniel Hornburg‡,
Florian Meier‡, Igor Paron‡, Nils A. Kulak‡, Juergen Cox¶, and Matthias Mann‡
Hybrid quadrupole time-of-flight (QTOF) mass spectrom-
etry is one of the two major principles used in proteomics.
Although based on simple fundamentals, it has over the
last decades greatly evolved in terms of achievable reso-
lution, mass accuracy, and dynamic range. The Bruker
impact platform of QTOF instruments takes advantage of
these developments and here we develop and evaluate
the impact II for shotgun proteomics applications. Adap-
tion of our heated liquid chromatography system
achieved very narrow peptide elution peaks. The impact II
is equipped with a new collision cell with both axial and
radial ion ejection, more than doubling ion extraction at
high tandem MS frequencies. The new reflectron and de-
tector improve resolving power compared with the previ-
ous model up to 80%, i.e. to 40,000 at m/z 1222. We
analyzed the ion current from the inlet capillary and found
very high transmission (>80%) up to the collision cell.
Simulation and measurement indicated 60% transfer into
the flight tube. We adapted MaxQuant for QTOF data,
improving absolute average mass deviations to better
than 1.45 ppm. More than 4800 proteins can be identified
in a single run of HeLa digest in a 90 min gradient. The
workflow achieved high technical reproducibility (R2 >
0.99) and accurate fold change determination in spike-in
experiments in complex mixtures. Using label-free quan-
tification we rapidly quantified haploid against diploid
yeast and characterized overall proteome differences in
mouse cell lines originating from different tissues. Finally,
after high pH reversed-phase fractionation we identified
9515 proteins in a triplicate measurement of HeLa peptide
mixture and 11,257 proteins in single measurements of
cerebellum—the highest proteome coverage reported
with a QTOF instrument so far. Molecular & Cellular
Proteomics 14: 10.1074/mcp.M114.047407, 2014–2029,
2015.
Building on the fundamental advance of the soft ionization
techniques electrospray ionization and matrix-assisted laser
desorption/ionization (1, 2), MS-based proteomics has ad-
vanced tremendously over the last two decades (3–6). Bot-
tom-up, shotgun proteomics is usually performed in a liquid
chromatography-tandem MS (LC-MS/MS)1 format, where
nanoscale liquid chromatography is coupled through electro-
spray ionization to an instrument capable of measuring a
mass spectrum and fragmenting the recognized precursor
peaks on the chromatographic time scale. Fundamental chal-
lenges of shotgun proteomics include the very large numbers
of peptides that elute over relatively short periods and peptide
abundances that vary by many orders of magnitude. Devel-
opments in mass spectrometers toward higher sensitivity,
sequencing speed, and resolution were needed and helped to
address these critical challenges (7, 8). Especially the intro-
duction of the Orbitrap mass analyzers has advanced the
state of the art of the field because of their very high resolution
and mass accuracy (9, 10). A popular configuration couples a
quadrupole mass filter for precursor selection to the Orbitrap
analyzer in a compact benchtop format (11–13).
In addition to the improvements in MS instrumentation,
there have been key advances in the entire proteomics work-
flow, from sample preparation through improved LC systems
and in computational proteomics (14–16). Together, such
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advances are making shotgun proteomics increasingly com-
prehensive and deep analyses can now be performed in a
reasonable time (13, 17–19). Nevertheless, complete analysis
of all expressed proteins in a complex system remains ex-
tremely challenging and complete measurement of all the
peptides produced in shotgun proteomics may not even be
possible in principle (20, 21). Therefore, an urgent need for
continued improvements in proteomics technology remains.
Besides the Orbitrap analyzer and other ion trap technolo-
gies, the main alternative MS technology is time-of-flight, a
technology that has been used for many decades in diverse
fields. The configuration employed in proteomics laboratories
combines a quadrupole mass filter via a collision cell and
orthogonal acceleration unit to a reflectron and a multichannel
plate (MCP) detector (22). TOF scans are generated in much
less than a millisecond (ms), and a number of these “pulses”
are added to obtain an MS or MS/MS spectrum with the
desired signal to noise ratio. Our own laboratory has used
such a quadrupole time-of-flight (QTOF) instrument as the
main workhorse in proteomics for many years, but then
switched to high-resolution trapping instruments because of
their superior resolution and mass accuracy. However, TOF
technology has fundamental attractions, such as the ex-
tremely high scan speed and the absence of space charge,
which limits the number of usable ions in all trapping instru-
ments. In principle, the high spectra rate makes TOF instru-
ments capable of making use of the majority of ions, thus
promising optimal sensitivity, dynamic range and hence quan-
tification. It also means that TOF can naturally be interfaced
with ion mobility devices, which typically separate ions on the
ms time scale. Data independent analysis strategies such as
MSE, in which all precursors are fragmented simultaneously
(23, 24) or SWATH, in which the precursor ion window is
rapidly cycled through the entire mass range (25), also make
use of the high scanning speed offered by QTOF instruments.
It appears that QTOFs are set to make a comeback in pro-
teomics with recent examples showing impressive depth of
coverage of complex proteomes. For instance, using a variant
of the MSE method, identification of 5468 proteins was re-
ported in HeLa cells in single shots and small sample amounts
(26). In another report, employing ion mobility for better trans-
mission of fragment ions to the detector led to the identifica-
tion of up to 7548 proteins in human ovary tissue (27).
In this paper, we describe the impact II™, a benchtop QTOF
instrument from Bruker Daltonics, and its use in shotgun
proteomics. This QTOF instrument is a member of an instru-
ment family first introduced in 2008, which consists of the
compact, the impact, and the maXis. The original impact was
introduced in 2011 and was followed by the impact HD, which
was equipped with a better digitizer, expanding the dynamic
range of the detector. With the impact II, which became
commercially available in 2014, we aimed to achieve a reso-
lution and sequencing speed adequate for demanding shot-
gun proteomics experiments. To achieve this we developed
an improved collision cell, orthogonal accelerator scheme,
reflectron, and detector. Here we measure ion transmission
characteristics of this instrument and the actually realized
resolution and mass accuracy in typical proteomics experi-
ments. Furthermore, we investigated the attainable proteome
coverage in single shot analysis and we ask if QTOF perfor-
mance is now sufficient for very deep characterization of
complex cell line and tissue proteomes.
EXPERIMENTAL PROCEDURES
Preparation of HeLa Lysates—HeLa cells (ATCC, S3 subclone)
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) con-
taining 10% fetal bovine serum, 20 mM glutamine and 1% penicillin-
streptomycin (all from PAA Laboratories, Freiburg, Germany). Cells
were collected by centrifugation at 200  g for 10 min, washed once
with cold phosphate buffered saline (PBS) and centrifuged again.
Supernatant was carefully discarded and the cell pellet shock frozen
in liquid nitrogen and stored at 80 °C until further use. A pellet
containing 5  107 cells was resuspended in 1.5 ml of ice cold Milli-Q
water, then an equal volume of trifluoroethanol (Sigma-Aldrich,
Taufkirchen, Germany) was added. The cell suspension was kept on
ice for 10 min, vortexed for 1 min and sonicated for 2 min at 20% duty
cycle and output control 3 (Branson Ultrasonics sonifier, Danbury, CT;
model 250). After the addition of 200 l Tris (pH 8.5, final concentra-
tion: 100 mM), 400 l TCEP (final concentration: 10 mM) and 400 l
2-chloroacetamide (CAA) (final concentration: 40 mM) the lysate was
incubated for 10 min at 95 °C. Then the sample was diluted to 15 ml
with 50 mM ammonium bicarbonate. The mixture was digested by
adding LysC (Wako Chemicals GmbH, Neuss, Germany; ratio 1 g
LysC:100 g sample protein) for 2 h at 37 °C, followed by adding
trypsin (ratio 1 g trypsin:75 g sample protein, Promega GmbH,
Mannheim, Germany) at 37 °C overnight. After a further digestion with
trypsin (ratio 1:125) for 5 h at 37 °C, the digested peptides with an
estimated concentration of 1 g/l were diluted 1:4 with water and
acidified by adding formic acid (FA) (final concentration: 0.2%) and
purified on Sep-Pak tC18 cartridges (Waters, Milford, MA) according
to manufacturer’s instructions. Peptide concentration was deter-
mined using a NanoDrop spectrophotometer (Thermo Scientific,
Wilmington, DE).
Preparation of Yeast Lysates—Saccharomyces cerevisiae strains
BY4742 and BY4743 (EUROSCARF) were grown at 30 °C in yeast
extract peptone dextrose (YPD) media (10 g/l BactoYeast extract,
20 g/l BactoTM peptone (BD), 2% w/v glucose). Cells were grown to
log phase (OD600 of 0.6), harvested by centrifugation at 1600  g for
10 min at 4 °C, washed with cold Milli-Q water and then collected
again by centrifugation at 10,000  g for 5 min at 4 °C. Cells were
lysed in 1% sodium deoxycholate, 10 mM TCEP, 40 mM CAA in 100
mM Tris pH 8.5, boiled for 10 min at 95 °C and sonicated for 3 min at
30% duty cycle and output control 3 (Branson Ultrasonics sonifier;
model 250). Protein concentrations were determined by tryptophan
fluorescence emission assay. Cell lysates were diluted 1:2 with Milli-Q
water and digested by adding LysC (Wako Chemicals GmbH, ratio 1
g LysC:50 g sample protein) for 4 h at 37 °C, followed by adding
again LysC (ratio 1:50) overnight at 37 °C. An equal volume of ethyl
acetate acidified with 1% TFA was added to the solution, samples
were vortexed for 2 min and digested peptides were purified with
SDB-RPS StageTips as described in Kulak et al. (19). Peptide con-
centrations were determined using a NanoDrop spectrophotometer.
Preparation of MEFs, Hepa, and NSC Cell Line Lysates—Spinal
cord neuron-neuroblastoma (NSC-34) (CED-CLU140, Biozol, Eching,
Germany), mouse embryonic fibroblasts (MEFs) (American Type Cul-
ture Collection, Manassas, VA), and mouse hepatoma (liver cancer,
Hepa 1–6) (CRL-1830, American Type Culture Collection) cell lines
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were cultured and proteins prepared as previously described (28).
Briefly, the cells were lysed in lysis buffer (4% SDS, 10 mM Hepes, pH
8.0) during sonication for 15 min (level 5, Bioruptor; Diagenode,
Seraing (Ougrée) - Belgium). Cell lysis was followed by reduction of
disulfide bonds with 10 mM DTT for 30 min and subsequent alkylation
with 55 mM IAA for 45 min. To remove the detergent, cold acetone
(20 °C) was added to 100 g of proteins to a final concentration of
80% v/v, and proteins were precipitated for at least 2 h at 20 °C.
The suspension was centrifuged for 15 min (4 °C, 16,000  g) and the
precipitate was washed with 80% acetone (20 °C) prior to re-sus-
pension in 50 l of 6 M urea/2 M thiourea, 10 mM Hepes, pH 8.0. An
initial digestion step (3 h) was carried out after the addition of 1 g of
LysC, followed by dilution with four volumes of 50 mM ammonium
bicarbonate and the final digestion with 1 g of trypsin overnight at
room temperature. The resulting peptide mixtures were desalted on
SDB-RPS StageTips (29) and subjected to single shot LC-MS/MS
analysis.
Preparation of Cerebellum Lysates—Cerebellum from a single
mouse (strain: C57Bl6) was homogenized in 4% SDS in 100 mM Tris
pH 7.6 using a FastPrep 24 homogenizer (MP Biomedicals, Es-
chwege, Germany), incubated for 10 min at 95 °C and sonicated for 3
min at 30% duty cycle and output control 3 (Branson Ultrasonics
sonifier; model 250). To remove the detergent, acetone (20 °C) was
added to a final concentration of 80% v/v and proteins were precip-
itated overnight at 20 °C. Supernatants were carefully discarded
after centrifugation at 1600  g for 20 min at 4 °C, and the pellets
were washed with 80% acetone (20 °C). The protein pellets were
dissolved in 8 M Urea in 10 mM Hepes and protein concentrations
were determined by the tryptophan fluorescence emission at 350 nm
using an excitation wavelength of 295 nm. Proteins were reduced with
10 mM DTT for 30 min and alkylated with 55 mM iodoacetamide for 20
min. After addition of thiourea to a final concentration of 0.1 M,
samples were digested by adding LysC (Wako Chemicals, ratio 1 g
LysC:100 g sample protein) for 3 h at RT, diluted with four volumes
of 50 mM ammonium bicarbonate, and further digested with trypsin
(ratio 1 g trypsin:100 g sample protein, Promega) at RT overnight.
After a further digestion with LysC and trypsin (ratio 1:100) for 8 h at
RT, digested peptides were acidified by adding TFA (final concentra-
tion: 0.5%) and purified on Sep-Pak tC18 cartridges (Waters) accord-
ing to manufacturer’s instructions. Peptide concentrations were de-
termined using a NanoDrop spectrophotometer.
Sample Preparation for Quantification—Universal Proteomics
Standard (UPS-1, Sigma-Aldrich) and Proteomics Dynamic Range
Standard (UPS-2, Sigma-Aldrich), both containing 48 human pro-
teins, either at equimolar concentrations (UPS-1) or formulated into a
dynamic range of concentrations, covering five orders of magnitude
(UPS-2), were prepared according to ref (30). Predigested yeast sam-
ple (Promega) was re-suspended in 0.1% trifluoroacetic acid to a final
concentration of 500 ng/l. Digested UPS-2 sample was spiked in
two different amounts of 250 fmol to 2.5 amol peptide amount for
sample 1 and 500 fmol to 5 amol for sample 2 into 500 ng yeast
background, thereby creating two samples with a theoretical ratio 1:1
for the yeast proteome and 1:2 for the UPS peptides. In another
sample, digested UPS-1 sample (25 fmol for all components) was
spiked into 500 ng yeast.
High-pH Reverse-Phase Fractionation—We performed high-pH re-
versed-phase peptide prefractionation with fraction concatenation on
175 g HeLa or cerebellum peptides on a 2.1  300 mm Acquity
UPLC Peptide BEH column packed with 130 Å pore, 1.7 m particle
size C18 beads (Part No. 186005792, Waters). A gradient of basic
reversed-phase buffers (Buffer A: 0.1% formic acid, ammonium hy-
droxide pH 10; Buffer B: 0.1% formic acid, 80% acetonitrile, ammo-
nium hydroxide pH 10) was run on a Prominence HPLC system
(Shimadzu, Duisburg, Germany) at a flow rate of 150 l/min at 60 °C.
The LC run lasted for 240 min with a starting concentration of 5%
buffer B increasing to 30% over the initial 120 min and a further
increase in concentration to 60% over 70 min. This elution gradient
was followed by a 95% wash and re-equilibration. Fraction collection
started after 0.2 ml elution and fractions were collected every 140 s
resulting in 72 fractions used for concatenation into 24 fractions as
described previously (31).
Inlet Capillary and CaptiveSpray—In our instrument, in contrast to
many other commercial ion source designs, the high voltage for the
electrospray (ES) process is applied to the vacuum capillary inlet,
whereas the sprayer is kept at ground, which allows for a simpler
source design (supplemental Fig. S1A). To electrically decouple the
ES voltage and the electrical potential of the vacuum section, we use
an inlet capillary made from high resistive glass (1GOhm). Position-
ing the ES voltage at the capillary entrance means that the ions are
transported opposite to the electrical gradient by the gas flow (32). In
this configuration, charged molecules travel somewhat slower than
the surrounding gas. According to Bernoulli’s law, ions are then
focused toward the area of highest gas velocity along the center axis
of the capillary. The set-up tends to reduce the contamination of the
inner capillary walls (33).
The Bruker CaptiveSpray nanoflow ES source is directly attached
to the vacuum inlet capillary via a short capillary extension that can be
heated using the instrument’s drying gas (Supplemental Fig. S1A).
The spray tip is automatically mechanically aligned on axis with the
capillary inlet without the need for any adjustments. The principle of
the CaptiveSpray is a vortex gas (usually air) that sweeps around the
emitter spray tip at three different stages. The first one is designed to
assist spray formation, the second and third one help to focus the
spray plume into the MS inlet capillary. All three flows are created
solely by the vacuum of the MS system, which requires that the entire
source is vacuum sealed.
The spray emitter consists of a 2 cm long, 20 m ID fused silica
capillary. Its tip is etch-tapered, thus the inner diameter remains
constant to the very end of the tip making it very robust against
clogging. Furthermore, it also allows using the same emitter at flow
rates ranging from 50 nl/min to 5 l/min, thereby supporting a wide
range of column types. Fused silica columns, which are often used for
proteomics, are typically connected to the emitter via a low dead
volume union (supplemental Fig. S1A), which also provides the elec-
trical contact for keeping the electrospray at ground potential.
Minimizing Postcolumn Dead Volume—Using the described de-
sign, the CaptiveSpray source provides very stable ionization; how-
ever, when we initially coupled it to the LC set-up used in the Munich
laboratory (17, 34), we observed broader LC peak elution distributions
than we normally do (supplemental Fig. S1B). Furthermore, we
wished to incorporate a column oven and pulled tip columns. We
therefore constructed a modified source, which keeps the back end
of the CaptiveSpray but replaces the front end by the standard set-up
used in our department. The modified set-up incorporating the tip
column is displayed in supplemental Fig. S1C. The modified design of
the column holder allows for exact aligning and fixation of the column
inside the CaptiveSpray source. Electrical grounding was applied
using a connecting tee at the column head. This setup produced the
desired, narrow LC peak distributions (supplemental Fig. S1D) and
was used for the proteomic analyses described in this article.
LC-MS/MS Analysis—We used an Easy nLC-1000 (Thermo Fisher
Scientific) on-line coupled to an impact II (Bruker Daltonics) with a
CaptiveSpray ion source (Bruker Daltonics). The peptide mixtures
(1 g) were loaded onto an in-house packed column (50 cm, 75 m
inner diameter) filled with C18 material (ReproSil-Pur C18 AQ 1.9 m
reversed phase resin, Dr. Maisch GmbH, Ammerbuch-Entringen, Ger-
many). Chromatographic separation was carried out using a linear
gradient of 5–30% buffer B (80% ACN and 0.1% FA) at a flow rate of
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250 nl/min over 90 min. Because of loading and washing steps, the
total time for an LC-MS/MS run was about 40 to 50 min longer.
Generally, LC-MS/MS data were acquired using a data-dependent
auto-MS/MS method selecting the 17 most abundant precursor
ions in cycle for fragmentation and an MS/MS summation time
adjusted to the precursor intensity (Compass 1.8 acquisition and
processing software, Bruker Daltonics). For the deep proteome
measurements of a cell line in combination with peptide fraction-
ation, we used a “dynamic method,” with a fixed cycle time of 3 s.
The mass range of the MS scan was set to extend from m/z 150 to
1750. Dynamic exclusion duration was 0.4 min. Isolation of precur-
sor ions was performed using an m/z dependent isolation window
of 1.5–5 Th. The collision energy was adjusted between 23–65 eV
as a function of the m/z value.
For the quantitative analysis of the UPS standards in yeast we used
a trapping column set-up (PepMap pre-column, 2 cm x 100 m;
Thermo Scientific) and a Dionex HPLC pump (Ultimate 3000, Thermo
Scientific). For this experiment, peptides were separated on a Pep-
Map UHPLC column (50 cm x 75 m, 2 m particles; Thermo Sci-
entific) using a 90 min multistep ACN gradient (buffer A: 0.1% FA;
buffer B 100% ACN in 0.1% FA). The unmodified CaptiveSpray ion
source (see above) was used to interface the LC system to the
impact II. For quantification full scan MS spectra were acquired at a
spectra rate of 1Hz followed by acquisition of 1 MS/MS spectrum. Six
replicates per sample were acquired. For data acquisition of the
UPS-1 in yeast sample, the 17 most intense precursor ions were
selected for fragmentation, resulting in a total cycle time of 1.2 s.
Intact Protein Analysis—Adalimumab was cleaved at the hinge
region with IdeS (FabRICATOR, Genovis) and reduced to obtain the
Fc/2, Fd and light chain sub units as recently described in (35). The
subunits were separated by chromatography (35) prior to analysis on
the impact II. Data was analyzed using the SNAP algorithm to fit the
theoretical pattern (36, 37).
Development of MaxQuant for QTOF Data—In general all process-
ing steps from the standard MaxQuant computational workflow,
which was optimized for the analysis of Orbitrap data, are also ap-
plied to QTOF data. The nonlinear mass recalibration algorithm ex-
perienced major adaptations. Its original form for the Orbitrap applies
a recalibration function with nonlinear dependence on the two vari-
ables m/z and retention time. It has been extended to include the
peak intensity as a third dimension that the mass recalibration de-
pends on. This is necessary because of appreciable systematic non-
linear intensity dependent peak mass shifts that are typically found in
time of flight data. The intensity dependence is parameterized as a
polynomial in the logarithm of peak intensities. The new mass reca-
libration algorithm allows for high mass accuracy without the use of
internal or external calibrants.
We added a new instrument type called “Bruker QTOF” in which
several relevant parameters of algorithms for the processing of spec-
tra are set to default values that are suitable for the analysis of data
generated by the impact family. These parameters include mass
matching windows for the assembly of 3D peaks, mass tolerances for
assembling isotope patterns and labeling pairs, initial peptide mass
tolerance windows for the Andromeda search and minimum required
number of scans per 3D peak. Raw data can be immediately read
from the proprietary Bruker binary format and no conversion to inter-
mediate file formats is needed. Peak centroids are utilized as deter-
mined by the centroiding algorithms of in the Bruker software. The
viewer module of MaxQuant is enabled for QTOF data, among other
features allowing to visualize MS data in m/z-retention time maps and
to annotate and export MS/MS spectra to fulfil journal requirements
for reporting of spectral evidence.
Analysis of Proteomic Data—All data were analyzed with the Max-
Quant software (version 1.5.2.8 or version 1.5.0.1) (38, 39) with the
Andromeda search engine (38) with the adaptions and developments
described above. The false discovery rate (FDR) was set to 1% for
both proteins and peptides and we specified a minimum length of
seven amino acids. MaxQuant scored peptides for identification
based on a search with an initial allowed mass deviation of the
precursor ion of up to 0.07 Da after time-dependent recalibration of
the precursor masses. The allowed fragment mass deviation was
40 ppm. The Andromeda search engine was used for the MS/MS
spectra search against the Uniprot human database (downloaded on
June 21, 2014, containing 88,976 entries and 247 contaminants), the
Uniprot Saccharomyces cerevisiae database (downloaded on June 21,
2014, containing 6643 entries), the Uniprot mouse database (down-
loaded on June 21, 2014, containing 51,573 entries) and UPS fasta
file provided by Sigma-Aldrich (http://www.sigmaaldrich.com/life-
science/proteomics/mass-spectrometry/ups1-and-ups2-proteomic.
html) for quantitative study. Enzyme specificity was set as C-terminal
to Arg and Lys, also allowing cleavage at proline bonds and a max-
imum of two missed cleavages. Carbamidomethylation of cysteine
was selected as fixed modification and N-terminal protein acetylation
and methionine oxidation as variable modifications.
The “match between runs” feature of MaxQuant was used to
transfer identifications to other LC-MS/MS runs based on their
masses and retention time (maximum deviation 0.7 min) and this was
also used in quantification experiments. Quantifications were per-
formed with the label-free algorithms described recently (39). We
required a minimum peptide ratio count of two and at least one “razor
peptide” for quantification. For cerebellum, the quantification was
based on normalized protein intensities. Further analysis of data was
performed in the MaxQuant Viewer, in the Perseus post data acqui-
sition package that is part of MaxQuant (all freely available at www.
maxquant.org) and in the R statistical computing environment (40).
Potential contaminants as well as proteins identified only by site
modification were strictly excluded from further analysis.
For the quantitative analysis of the UPS standards in yeast, entries
were only accepted if they had valid values in all 12 replicates. Results
were then filtered for Welch-significant regulation of UPS-2 proteins.
Analysis of the yeast samples were based on label-free intensities
(LFQ values). After filtering (3 valid values in at least one group),
remaining missing values were imputed from a normal distribution
(width: 0.3; down shift: 1.8). Two-sample t test was performed with a
FDR  0.01.
For global cell line comparison, triplicates were analyzed twice
for a total of six single shot measurements per cell line (except the
NSC-34 cell line, which was only measured once). For the principal
component analysis (PCA) of the different cell lines, we furthermore
limited the data set (LFQ intensities) to entries with a minimum of
four valid values in at least one group of six replicates. Remaining
missing values were imputed from a normal distribution (see
above).
Protein intensity (summed peptide intensity) for cerebellum sam-
ples were divided by the molecular weight for ranking by proteins
abundance. Annotations (GO molecular function, biological process,
cellular component; KEGG and Uniprot Keywords) were matched to
protein groups with Perseus. We performed a 1D annotation enrich-
ment (41) on the normalized protein intensities. To evaluate the pro-
teome coverage, we counted the occurrence of categories in our
sample and compared it to the category count for the complete
murine proteome in Perseus.
MS raw data and data for protein and peptide identification and
quantification were submitted as supplementary tables to the Pro-
teomeXchange Consortium via the PRIDE partner repository with the
data set identifier PXD001592.
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RESULTS AND DISCUSSION
Overview of the Instrument—The Bruker impact II is a QTOF
in a benchtop format, featuring several improvements in its
design (Fig. 1). Briefly, ions are produced in the CaptiveSpray,
which is in an encased nanoelectrospray source that features
a well-defined gas stream to guide the ions into the vacuum
via a capillary inlet. A double ion funnel, based on principles
described by Smith and co-workers (42), is positioned off
axis, which prevents neutrals from further transmission along
the ion path. The pressure drops by several orders of magni-
tude from the capillary exit to the postfunnel stage (3 mbar to
3  104 mbar), while the ion current is virtually undiminished
(see below). Additionally, the funnel allows for soft transfer
based on low electrical field strength independent of the mass
(typically 10 V/cm, much lower than in nozzle-skimmer de-
signs). By introducing electrical acceleration in-between the
two funnels, in-source fragmentation can still be achieved
intentionally. There is a hexapole ion guide between funnel
and the analytical quadrupole mass filter, which has a mono-
lithic design based on high precision glass. Precursor ions
can be isolated by this quadrupole for subsequent fragmen-
tation in the collision cell. Intact ions or fragments can be
stored and extracted from the collision cell and enter the
orthogonal deflection region as a very narrowly focused ion
beam ( 500 m). Here they are accelerated into a field-free
drift region. A newly designed, two-stage reflectron further
compensates the velocity distribution orthogonal to the beam
direction. Finally, the ions impinge on an MCP detector coupled
to a 10-bit, very high frequency (50 Gbit/s), zero noise digitizer.
Data collection is coordinated by the Bruker Compass data
system and in the experiments described here, post-ac-
quisition data processing is performed in the MaxQuant
environment.
Optimization of the Collision Cell—Efficient fragmentation
of precursor ions on an LC-MS/MS time scale is a key for the
identification of peptides in shotgun proteomics strategies.
We optimized several aspects of the collision cell (supplemen-
tal Fig. S2A): Precise geometrical alignment allows focusing of
the ions along the axis of the collision cell, directly translates
into well-defined starting conditions for the orthogonal accel-
erator and is therefore mandatory for high mass resolution.
This is implemented via a quadrupolar configuration of the
collision cell device providing a narrow pseudo potential well
(43). We also introduced a radial ejection step between any
two MS or MS/MS experiments, in order to reduce the dead
time. The ion path has to be emptied to avoid crosstalk
between two consecutive spectra without introducing sub-
stantial ion losses. Most importantly, we optimized the time of
ion fragmentation and extraction within the fragment spectra
to ensure efficient high frequency MS/MS by implementing an
electrical axial field gradient. This gradient directs the ions
toward the exit of the collision cell, reducing the time it takes
for the first ions to reach the extraction lens after quenching
the collision cell. From here, they can be rapidly released
toward the orthogonal accelerator, forming packages that
match the orthogonal pulser frequency. The ion densities after
3 ms (upper red traces in supplemental Fig. S2B–S2C) reveals
two important aspects: Using the axial field gradient results
in comparable ion density at the collision cell exit in much
shorter time than without, i.e. after about 1 ms instead of
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FIG. 1. Schematic of the impact II mass spectrometer (not to scale).
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3 ms, respectively. This suggests a three times faster ion
transfer. Moreover, the overall number of ions within the
collision cell is reduced to less than 50% at the moment of
quenching, which should reduce ion losses related to
quenching accordingly.
The pseudo potential calculations and simulation were con-
firmed in different experiments comparing the performance of
the optimized collision cell on the fragmentation yield of Glu-
Fibrino-Peptide B at different MS/MS acquisition rates (sup-
plemental Fig. S2D). This revealed that the reduced quench
losses in fact improve the number of ions detected at a
spectra rate of 16 Hz by a factor of two. We further observed
that the axial field gradient improves the stability of the system
even in the presence of slight contaminations on the rods.
High Transfer Efficiency to the Orthogonal Acceleration
Unit—The ions travel through the flight tube and require as
much time as the largest m/z species needs to reach the
detector, before the HV pulser can send the next ion package
toward the detector (typically between 100 and 150 s). To
avoid excessive loss of ions, orthogonal TOF instruments are
therefore often operated in a mode in which the ions are
stored in the collision cell during the TOF scan and released in
time for the next extraction pulse of the orthogonal accelera-
tor. This would allow for 100% duty cycle if all ions were
indeed transferred such that they arrive in the orthogonal
accelerator at the same time and with the same kinetic en-
ergy. In practice, however, the extraction time from the colli-
sion cell toward the gate lens is a function of ion mobility. We
have analyzed these combined effects by varying the time
from opening the gate lens to the extraction pulse of the
orthogonal accelerator (transfer time) for different m/z ratios
(Fig. 2A). Simulations of ion trajectories and extraction times
reveal that about 80% of a single ion species can be accel-
erated into the drift tube of the TOF analyzer under optimal
transfer time conditions. In the impact II the high transfer
efficiency is further optimized by reducing the distance be-
tween the trapping region and the orthogonal accelerator—it
is about four times higher compared with conventional QTOF
systems operated in continuous operation mode. Figure 2A
summarizes the relative transmission efficiency of selected
precursors (m/z  322 Th, 922 Th and 1522 Th) at a transfer
time of 100 s, which is a standard setting to cover the mass
range relevant in shotgun proteomics. The analysis highlights
that ions with low m/z are compromised most, which we have
previously counteracted in proteomics experiments by adding
special extraction conditions (44). To tackle this problem in a
more general way, Bruker introduced the “transfer time step-
ping” operation mode, where first high mobility species are
extracted followed by species with a lower mobility. During
the initially short opening times of the gate (typically 50% of
the total scan) only the higher mobility, low m/z ions pass the
gate lens, while the lower mobility ions are still accumulated in
the collision cell. In the second transfer time steps, extraction
times are increased to allow the low mobility, higher m/z ions
to pass the gate lens. Spectra with and without transfer time
stepping, reveal the beneficial effect on low mass ions without
appreciable loss in the standard mass range (Fig. 2B). This is
particularly beneficial for labeling experiments that rely on
quantification of low mass reporter ions as shown in the
figure. These ions are transferred with greater than 60% effi-
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ciency during the low m/z extraction phase and the total
amount of ions in the analyzed fragment spectrum is in-
creased by 58%.
Together, our developments led to an overall transmission
efficiency of  60% into the orthogonal acceleration unit. This
compares favorably to a recent report, in which ion mobility
was performed on fragment ions and their arrival times were
synchronized with orthogonal extraction, which lead to an up
to 10-fold improvement of detection sensitivities to standard
operation (27).
Sensitivity and Ion Transfer—The number of ions that suc-
cessfully pass through the instrument and are finally recorded
determine a mass spectrometer’s sensitivity. We were inter-
ested in the transfer efficiencies along the ion path, from
entering the vacuum system to the detector. To experimen-
tally determine this, we infused a 1 pmol/l BSA solution or
blank solution and measured the difference in the ion current
between these conditions. When operating the outlet of the
capillary and the funnel region as a Faraday cage, we mea-
sured a net ion current of 63 pA, which we defined as the
starting value (100%) (Fig. 3). The large ion acceptance aper-
ture of the first funnel efficiently captures in the ion flux leaving
the capillary. It transfers the ions to the second funnel, which
also passes the ions in an almost lossless manner through the
next stage as evidenced by a net current reading of 57 pA
(90%) after the hexapole. Likewise, more than 90% of the
ions are transferred through the quadrupole (in nonmass se-
lecting operation) and the collision cell. More than 60% of
these ions are transmitted into the flight tube by the orthog-
onal accelerator (see above). The reflectron contains two
grids, which are each passed twice, leading to a geometrically
defined overall transmission of 74%. Although all these ions
hit the MCP, not all of them enter the channels and not all of
them result in secondary electrons (detector quantum yield).
However, when secondary ions are generated they are greatly
amplified (106 fold), and can be efficiently discriminated
from electronic noise (zero noise detection). Together, this
leads to an estimated detection probability of 30% for our
MCP detector. Although not all of these measurements and
estimates are very precise, they suggest an overall detection
63 pA
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52 pA
dual funnel and transfer multipole:
> 90% transmission
quadrupole and collision cell:
> 90% transmission
orthogonal accelerator:
62% for proteomics mass range
reflectron:
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zero noise; single ion counting; 50 Gbit/s;
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FIG. 3. Ion transfer efficiency of mass range most relevant in shotgun-proteomics experiments (m/z 100–1500). Inset shows net
analyte ion currents at the indicated measurement points and transfer efficiencies at the orthogonal accelerator at various stages along the
flight path of the impact II instrument.
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probability of ions transmitted into the vacuum system of
about 10%. This excellent number is because of the fact that
the continuous beam generated by the ES source can be
utilized and that all the ion guiding elements have been suc-
cessfully optimized for high transmission.
Resolution and Mass Accuracy—For the impact II several
improvements were implemented: symmetrical shielding for
better ion focusing; line grids to increase the transmission;
low temperature coefficient ceramic spacers to decrease
temperature related mass drift and improved axel bearings for
precise alignment. Together this led to about 35% increased
resolution over the full proteomics mass range. As this im-
provement is reached solely by better focusing of the ions,
mass accuracy and signal to noise are expected to increase
accordingly. Improvements to the MCP detector include an
increased entrance aperture, higher electron accelerating
fields and optimized shielding. Overall, these measures lead
to 2-fold faster ion impact transients and 30% higher detec-
tion efficiency of the MCP.
In summary, the resolving power of the TOF analyzer is
expected to increase by about 70 to 80% by the introduction
of the new collision cell, reflectron and detector. To test this
experimentally on a standard proteomic sample, we analyzed
data from a HeLa digest. Resolution for typical peptides is in
excess of 33,000 as illustrated by an example in Fig. 4A.
Further increase in the resolution can be obtained by the
“Focus mode,” which involves real time processing and align-
ment of successive pulses and increases accuracy of flight
time determination, when multiple ions of one species reach
the detector at the same time (45). This can be helpful to
resolve the isotope distributions of proteins, as shown in
Fig. 4B, which features a resolution in excess of 60,000 for an
antibody subunit ( 25 kDa). In TOF measurements, resolu-
tion tends to increase with m/z (Fig. 4C), and reached more
than 40,000 for the TuneMix component at m/z 1222. This
constitutes a 70 to 80% improvement over the previous im-
pact model, the impact HD.
This increase in resolving power should also imply better
mass accuracy in proteomics samples, which we tested
using the software package MaxQuant, which we adapted
to QTOF data as described under “Experimental Proce-
dures.” A special feature of MaxQuant is the extraction of
individual mass accuracy values (46, 47), which allows to
make efficient use of high mass accuracy in the identification
of peptides. MaxQuant was originally developed on the basis
of data from hybrid Orbitrap instruments. Here we developed
MaxQuant further in order to analyze QTOF data and also in
this context profit from the high mass accuracy provided by
nonlinear mass recalibration algorithms. A special challenge
in QTOF data is the drift in the mass scale because of
thermal expansion caused by ambient temperature drift.
MaxQuant employs a double search strategy, in effect sup-
plying hundreds of reference masses internal to each pro-
teomic sample. This feature efficiently removes any effect of
the temperature related mass drift. This “software lock mass”
feature makes it unnecessary to use dedicated molecular
species for the calibration of spectra (48). With these devel-
opments in MaxQuant, we analyzed the peptide mass error
distributions over a 90 min gradient run (Fig. 4D). This showed
an average absolute mass deviation of around 1.45 ppm,
which is excellent for a QTOF instrument.
Impact II Performance for Single Shot Analysis—To inves-
tigate the performance of the impact II for shotgun proteo-
mics, we first analyzed a complex peptides mixture derived
from a mammalian cell line in the single-run format (Experi-
mental Procedures). We separated 1 g of peptide digest by
on-line HPLC with the standard 90 min gradient employed in
our laboratory and performed triplicate analysis. The typical
data dependent acquisition scheme in bottom-up proteomics
consists of an MS scan followed by N MS/MS fragment scans
of the most intense precursors (topN method). It is desirable
to choose N such that the total cycle is less than a few
seconds. For our measurements we aimed at a duty cycle of
around 1.3 s and designed a top17 method, consisting of
200 ms for MS acquisition and a MS/MS integration time
adapted to the precursor intensity. We found this to be a good
balance between acquiring high S/N in the MS and achieving
optimal ion intensities in the MS/MS spectra for the HeLa
digest. This method reached more than 7000 MS and 79,700
MS/MS scans. In each run MaxQuant identified on average
35,580 unique peptide sequences, which results in total of
48,172 unique peptide sequences in the triplicate analysis
TABLE I
Identification from HeLa and yeast lysate triplicate analysis using a standard 90 min gradient
MS scans
Isotope
pattern
MS/MS scans
Identification
rate %	
Peptide sequences
identified
Proteins identified
HeLa_1 7002 759,774 79,704 47.09 35,547 4870
HeLa_2 7181 769,355 79,876 47.22 35,572 4864
HeLa_3 7272 796,086 81,389 46.57 35,621 4828
Total 46.96 48,172 5210
yeast_1 4873 528,682 63,682 31.08 17,066 3361
yeast_2 4732 541,194 66,441 30.88 16,921 3325
yeast_3 4691 556,675 66,978 31.98 17,494 3369
Total 31.32 24,131 3627
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(Table I). These peptides mapped to an average of 4854
proteins per run, and a total of 5210 proteins of the HeLa
proteome with the three 90 min gradients (Fig. 5A), indicating
that a deep coverage can be achieved using relatively short,
single shot analysis. Transferring identification between the
runs based on their mass precision and retention time (“match
between runs” feature in MaxQuant) led to around 5100 pro-
teins identifications per single run. Comparing protein identi-
ties between the triplicate analyses (without “matching be-
tween runs”), we observed that more than 90% of proteins
were identified in each of them (Fig. 5B). This indicates high
reproducibility and a minimal ‘missing value’ problem. This
conclusion is further supported by excellent reproducibility
(R2  0.998) in the label-free intensities determined in pair-
wise comparison between runs (MaxQuant LFQ values (39,
49)) (Fig. 5C). We also determined the number of proteins
identified in a single shot run of 1 g yeast digest. On average,
we identified 3352 proteins per single, 90 min gradient, and a
total of 3627 proteins when combining the three single shot
measurements (Fig. 5D).
Reproducibility and Accuracy of Quantification—To evalu-
ate the reproducibility of the method for label-free quantifica-
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tion, we determined the coefficients of variation (CV) of the
label-free intensities, determined in pair-wise comparison be-
tween three technical HeLa replicates (see above). For more
than 90% of the quantified proteins the CV was smaller than
10% (Fig. 5E). For the lowest intensity quantile the median
was 0.05 and for the highest one 0.03 (Fig. 5E, supplemental
Fig. S3). This shows reproducible quantification over four
orders of magnitude.
Accurate quantification of differently expressed proteins
remains challenging over a wide concentration range and
benefits from a very stable analytical platform. QTOF instru-
mentation has been used widely for label-free quantification,
which in principle allows convenient analysis and comparison
of an arbitrary number of samples. For evaluation of the
label-free quantitative capabilities of the impact II platform in
complex mixtures we wished to use a reference sample set
with known ratios for a small subset of proteins. We spiked
the Universal Protein Standard 2 (UPS-2), consisting of 48
proteins covering a dynamic range of five orders of magni-
tude, in two different concentrations into the yeast proteome.
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This generated two samples, in which the yeast peptides
should be 1:1 whereas ratios for UPS-2 peptides should be at
1:2. To increase the number of identified peptides we then
used the equimolar UPS-1, which we also spiked in a yeast
background. This allowed transfer of peptide identifications to
unsequenced peptides in the UPS-2 in yeast runs via the
‘match between runs’ algorithm in MaxQuant. We identified all
of the 48 human UPS proteins in the sample containing yeast
with the equimolar UPS-1 standard. Of these proteins, 23
were identified in each one of the 12 single shot yeast mea-
surements with the dynamic UPS-2 standard either directly via
MS/MS or via match between runs and 18 of these proteins
showed Welch-significance (Fig. 5F). We identified and quan-
tified UPS-2 proteins over more than three orders of magni-
tude in these relatively fast measurements (90 min gradients).
The UPS-2 proteins have an average fold change of 0.49 (

0.06), which is close to the theoretical ratio of 0.5.
Quantification of Changes in the Yeast Proteome—To test
the workflow in a systems biology context, we analyzed pro-
teome changes of diploid and haploid (Mat cell) S. cerevi-
siae. We analyzed 2 g of yeast digest from haploid and
diploid cells in technical quadruplicates with our standard
90 min gradient. This identified 3769 proteins using “match
between runs.” For statistical analysis, we only considered
LFQ intensities that were detected in at least three replicates
of the haploid or diploid groups. After filtering, 3222 proteins
remained for further analysis (Experimental Procedures). Re-
maining missing values were imputed from a normal distribu-
tion. The technical replicates correlated much more with each
other than they correlated to the other genotype (R2 greater
0.98 versus R2 about 0.92; Fig. 6A). As in our previous large-
scale analysis on SILAC labeled haploid and diploid yeast
(50), we found transposons more abundant in haploid cells
than in diploid cells (Fig. 6B). Ste3, the pheromone a factor
receptor, was specific to haploid yeast, as expected from its
mating status. Also absent in diploid but present in haploid
cells were Sst2, a GTPase-activating protein for Gpa1 (51),
which, consistently, showed higher expression in haploid
cells. Conversely, Sps100, which is a sporulation-specific wall
maturation protein turned out to be specific for diploid cells.
Doing such systems-wide comparisons by traditional meth-
ods would have required thousands of individual Western
blots. Even compared with our previous large-scale study
performed by quantitative MS (50), we here used less than 1%
of yeast input material and measurement time. This illustrates
the rapidity by which MS-based proteomics is becoming a
viable method for answering biological questions.
Global Proteomic Comparison of Different Cell Lines—As a
second example of typical proteomics experiments, we ap-
plied the QTOF-based workflow to the characterization of
common cellular disease model systems. For this purpose,
we compared the proteomes of spinal cord neuron-neuro-
blastoma (NSC-34), mouse hepatoma (Hepa 1–6) and mouse
embryonic fibroblast (MEF) cell lines in a quantitative manner.
All cell lysates were analyzed in single shots using 90 min
gradients and subsequently quantified using the MaxQuant
label-free quantification algorithm. The observed LFQ inten-
sities were highly reproducible between biological and tech-
nical replicates as indicated by Pearson correlations coeffi-
cients  0.97 (supplemental Fig. S4).
After stringent filtering (Experimental Procedures) we per-
formed a principal component analysis (PCA) to evaluate the
similarities and dissimilarities of the cell lines on a global
scale. Replicates from a single cell line clustered very tightly in
the PCA space and the first two principal components ac-
counted for 71% of the cumulative variance within our data
set (Fig. 6C). Interestingly, the motoneuronal cell line NSC-34
was clearly separated from Hepa 1–6 and MEF cells in the
first principle component, whereas the variance between both
non-neuronal cell lines was described by the second, orthog-
onal, principal component. In the latter component, NSC-34 is
positioned half-way between Hepa 1–6 and MEF.
To assess individual proteins that are the main drivers for
the separation between the three cell lines, we plotted the
loadings of the first two principal components (Fig. 6D). Hepa
1–6 cells were characterized by gene products involved in
regulatory and metabolic processes. As we had found before
(52), proteins related to the glycolysis pathway, such as the
aldehyde dehydrogenase (Aldh) family, were highly repre-
sented in Hepa 1–6. Not surprisingly, proteins driving the
separation of MEF were predominantly linked to collagen
synthesis, such as the COL gene family and the precollagen
C-endopeptidase enhancer 1 (Pcolce). Proteins that differen-
tiate along principal component 1 encompassed various com-
ponents of the cytoskeleton axons, including Prph and the
heavy and light chains of neurofilaments (Nefh and Nefl). In
addition, gene products involved in axon guidance (Enah,
Dypsl5 and Tubb3) and neuron projection (Uchl1, Gap43)
were highly distinctive for NSC-34. Proteins separating NSC-
34 from the other cell lines were significantly enriched for
neurotransmitter transport while we observed enrichment for
collagens and xenobiotic processes for the MEF and Hepa
1–6 cells on component 2, respectively, further showing how
proteomics can highlight biological function. This is even
more remarkable, given that we previously found that the
proteomes of motoneuronal cell lines, including NSC-34, lack
distinctive neuronal characteristics, as several key actors in
axon growth and guidance were either depleted or low abun-
dant (28). As a result, we had placed motoneuronal cell lines
only halfway between in vivo motoneurons and non-neuronal
controls. Nevertheless, our label-free QTOF-based workflow
is very well suited to differentiate subtle alterations in biolog-
ical systems in a short time of analysis.
Impact II Performance for Deep Proteome Analysis of a Cell
Line—To evaluate the impact II for deep proteome coverage
we performed high pH reverse-phase pre-fractionation with
fraction concatenation as described in ref (31). We loaded
175 g of a HeLa peptide mixture, collected 72 fractions and
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combined them into 24 fractions (Experimental Procedures).
These fractions were analyzed in technical triplicates using a
standard 90 min LC-MS/MS gradient (total measurement time
of 48 h per replicate). Instead of the simple Top17 method
described above, we here used a so-called “dynamic
method” with a fixed cycle time and a MS/MS integration time
adapted to the precursor intensity. We found that this method
helped to generate high quality MS/MS spectra also for low
abundant peptides.
Figure 7A depicts the cumulative number of unique pep-
tides identified as a function of the number of fractions ana-
lyzed. The increase is nearly linear, indicating a small overlap of
peptide identification between fractions and the good orthogo-
nal separation power as also observed by others using high-pH
fractionation (49). The figure also indicates that the reproduc-
ibility was very high between the technical replicates. On aver-
age we identified 107,038 unique peptides, mapping to around
8995 proteins (protein FDR 1%; Fig. 7B). In total we identified
138,086 unique peptides, resulting in 9515 different protein
groups. This is to our knowledge the deepest proteome cover-
age of a human cell line measured with a QTOF instrument.
Impact II Performance for Ultra-Deep Proteome Analysis of
Tissue—Tissues are more challenging to analyze by proteo-
mics than cell lines, because they are made up of different cell
types, the extracellular matrix and other structural and connec-
tive elements. Among the different tissues, the brain is thought
to be the most complex one. To evaluate the Impact II in this
context, we homogenized the cerebellum of a single mouse,
digested it using our standard workflow and separated part of
the resulting tryptic peptides using high pH fractionation (Ex-
perimental Procedures). In total, we identified 11,257 proteins
from a single analysis of 24 fractions (2 days of measurement
time) (Fig. 7B, supplemental Table S1). To our knowledge, this
is the deepest proteome measurement of any tissue reported
by TOF instrumentation so far. Protein abundance, as indi-
cated by the summed and normalized peptide signal varied by
more than five orders of magnitudes (Fig. 7C). We identified
many high to medium abundant proteins involved in neuro-
degenerative disorders (Fig. 7C marked in red). The transcrip-
tion factors and DNA binders Pax6, Lhx1/5, Otx1/2, and Neu-
rod1 (Fig. 7C, marked in blue) are examples of proteins that
have been reported to be specifically expressed in cerebel-
lum (53). Like various neuronal receptors, transcription fac-
tors populate the medium to low abundance range (Fig. 7C,
marked in green). The distribution of molecular functions
throughout the abundance range is similar to that observed
in previous studies (Fig. 7D, supplemental Table S2) (54, 55).
The very high depth of this cerebellum proteome is shown
by almost complete coverage for neuronal, general meta-
bolic and disease relevant processes (Fig. 7E, supplemental
Table S2). Rapid estimation of protein abundances in the
brain regions of a single mouse could be useful for studying
tissue characteristics and disease specific alterations. For
instance, knowledge about changes in the complete pro-
teome would provide an additional layer of information on
the pathological processes in neurodegeneration.
CONCLUSION
Here we have described the construction and performance
of a state of the art QTOF instrument, the impact II. We
documented significant improvements in the ion path, colli-
sion cell performance and, in particular, in the performance of
the reflectron and detector. The latter allow a mass resolution
and mass accuracy that is compatible with the high demands
of shotgun proteomics of complex mixtures. For the first time,
we measured and modeled the ion transmission from capillary
to the detector, which revealed an excellent efficiency of
about 10%. The new features of the impact II allow deep
characterization in single shots, where we identified more
than 5200 proteins in HeLa cells and 3600 proteins in yeast.
Using off-line high pH reversed-phase fractionation we iden-
tified more than 9500 proteins in HeLa cells and 11,250 pro-
teins in a single cerebellum tissue analysis. These are ex-
tremely high numbers for any platform and additional method
developments should further improve these results. We also
document excellent quantitative reproducibility and accuracy
in a label-free format. In concordance with others (26, 27), we
conclude that the improvements in QTOF technologies in
recent years now clearly enable demanding, in-depth analysis
of very complex proteomes.
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The Q Exactive HF, a benchtop mass spectrometer with a pre-filter, 
high-performance quadrupole and an ultra-high-field  
Orbitrap analyzer 
A major limiting factor in proteomics is the performance of the mass spectrometer. Because in 
proteomics there is no amplification step like in oligonucleotide-based sequencing technologies, the 
sensitivity, dynamic range, resolution and speed of the mass spectrometer has a very large impact on 
the robustness, depth and accuracy of the proteome analysis. The introduction of the benchtop 
quadrupole Orbitrap mass spectrometer (Q Exactive) has made a compact and powerful instrument 
available to the biological community for quantitative proteomics. We optimized and benchmarked 
the latest type of hybrid Orbitrap mass spectrometer, and determined the parameters for peak 
performance. We used a Design of Experiment (DoE) approach to determine these optimal 
parameters in a robust and unbiased manner. In contrast to the conventional strategy of ‘changing 
one parameter at a time’, DoE allows to determine higher order dependencies of parameters 
systematically with a minimal set of experiments. With the optimized set of parameters, we were 
able to identify 5,000 proteins within 90 min mass spectrometric analysis of mammalian cell lysate. 
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Scheltema RA, Hauschild JP, Lange O, Hornburg D, Denisov E, Damoc E, Kuehn A, Makarov A, 
Mann M.  
Contribution: In this project, Thermo Fisher and the group of Matthias Mann (MPI of Biochemistry) 
presented, benchmarked and optimized the latest generation of hybrid quadrupole Orbitrap MS for 
proteomics research. To assess the complexity and dependencies of parameters that affect proteome 
analyses in the Q Exactive HF, I designed experiments to quantify and model the effects of various 
instrument parameter on the machine performance. I conducted the measurements, data analysis and 
interpretation and employed a central composite faced design (CCF, DoE) to model a response 
surface for parameter settings. This approach provided confident information on the parameters 
dependencies and their optimal settings. 
The Q Exactive HF, a Benchtop Mass
Spectrometer with a Pre-filter, High-performance
Quadrupole and an Ultra-high-field Orbitrap
Analyzer*□S
Richard Alexander Scheltema‡, Jan-Peter Hauschild§, Oliver Lange§,
Daniel Hornburg‡, Eduard Denisov§, Eugen Damoc§, Andreas Kuehn§,
Alexander Makarov§, and Matthias Mann‡¶
The quadrupole Orbitrap mass spectrometer (Q Exactive)
made a powerful proteomics instrument available in a
benchtop format. It significantly boosted the number of
proteins analyzable per hour and has now evolved into a
proteomics analysis workhorse for many laboratories.
Here we describe the Q Exactive Plus and Q Exactive HF
mass spectrometers, which feature several innovations in
comparison to the original Q Exactive instrument. A low-
resolution pre-filter has been implemented within the in-
jection flatapole, preventing unwanted ions from entering
deep into the system, and thereby increasing its robust-
ness. A new segmented quadrupole, with higher fidelity of
isolation efficiency over a wide range of isolation windows,
provides an almost 2-fold improvement of transmission at
narrow isolation widths. Additionally, the Q Exactive HF has
a compact Orbitrap analyzer, leading to higher field
strength and almost doubling the resolution at the same
transient times. With its very fast isolation and fragmenta-
tion capabilities, the instrument achieves overall cycle
times of 1 s for a top 15 to 20 higher energy collisional
dissociation method. We demonstrate the identification of
5000 proteins in standard 90-min gradients of tryptic di-
gests of mammalian cell lysate, an increase of over 40% for
detected peptides and over 20% for detected proteins. Ad-
ditionally, we tested the instrument on peptide phosphory-
lation enriched samples, for which an improvement of up to
60% class I sites was observed. Molecular & Cellular Pro-
teomics 13: 10.1074/mcp.M114.043489, 3698–3708, 2014.
Mass spectrometry (MS)-based1 proteomics aims at the
comprehensive analysis of proteins present in a biological
sample (1), and the field has expanded in many surprising
directions (2). Application of the developed techniques has
revealed novel insights into fundamental biology, as well as
produced analysis techniques with implications for clinical
applications. A major hurdle, however, is the complexity of the
systems under scrutiny, as it has been shown that human cell
lines, for instance, express at least 10,000 genes that are
detectable as proteins (3–5). If we further consider all the
peptides produced in bottom-up proteomics experiments,
this hurdle is compounded, as ideally many hundreds of thou-
sands of analytes should be characterized in order for the
proteins giving rise to them to be fully reconstructed (6). In
principle, issues of sample complexity and dynamic range
could be addressed by a very high degree of up-front frac-
tionation. However, this strategy faces diminishing returns
and leads to unacceptably long analysis times for most pur-
poses. Given the fact that even with optimal chromatographic
resolution many peptides with abundance differences of
many orders of magnitude elute within the same time frame,
there remains a need to improve the mass spectrometric
detection in terms of speed, resolution, and sensitivity.
Nanoscale liquid chromatography coupled online to mass
spectrometry is the current technique of choice for the anal-
ysis of complex peptide mixtures. In a top-N shotgun strat-
egy, a full scan, providing a complete overview of isotope
patterns resulting from ionized peptides, is followed by N
fragmentation scans performed on the most abundant not-
yet-sequenced isotope patterns currently visible in the full
scan. During fragmentation, the goal is to cleanly isolate the
intended precursor peptide ion, which today is generally done
either by a linear ion trap or by a quadrupole mass filter.
Fragment ions are then mass measured by an Orbitrap mass
analyzer, a time-of-flight analyzer, or, less often, ion cyclotron
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resonance–Fourier transform or linear or three-dimensional
ion traps.
Apart from the MS instrumentation, recent developments in
the proteomics workflow include a move toward automated
online quality control systems (7, 8) and single-run analyses
(9), which require very high-performance peptide chromatog-
raphy (10, 11).
The Orbitrap mass analyzer was introduced commercially
almost 10 years ago, and hybrid instruments based on this
tool have become very popular in proteomics (12). They con-
sist of an upfront mass spectrometer coupled to a so-called
C-trap, which stores and compresses the ion population (gen-
erally up to one million charges) prior to injection into the
Orbitrap analyzer. Up to the Orbitrap Velos and Elite members
of this family of instruments, the precursor selection (and
usually the fragmentation) occurred in the linear ion trap (13),
but a few years ago an instrument based on a quadrupole
front end—the Q Exactive mass spectrometer—was devel-
oped (14). Compared with the linear ion trap, quadrupole
mass filters have the advantage of being capable of nearly
instantaneously selecting a small mass region by modulating
the RF field, allowing only a select set of ions to have stable
trajectories when passing through the rod assembly. As we
described previously, this near-instantaneous mass selection
capability and the C-trap’s capability of storing ions enable
multiplexing of different ion populations (e.g. fragment ions of
two or more distinct precursor ions) prior to analysis in the
Orbitrap mass analyzer (14). However, that instrument did not
use the highest efficiency quadrupole technology (15), and it
did not use the compact high-field Orbitrap analyzer that had
been introduced in the Orbitrap Elite instrument (16).
Here we describe the advances incorporated into the Q
Exactive Plus and the Q Exactive HF instruments. These
include improved robustness effected by a low-resolution
filter upstream of the quadrupole, a segmented quadrupole,
and, in the case of the Q Exactive HF instrument, an ultra-
high-field mass Orbitrap analyzer, doubling resolution or ac-
quisition speed. We describe these capabilities in the context
of single-shot complex mixture analysis of peptides and
phosphopeptides.
EXPERIMENTAL PROCEDURES
Construction of the Q Exactive Plus—The instrument is based on
the previous-generation Q Exactive mass spectrometer (14) with the
same general design elements. Briefly, these consist of an atmo-
spheric pressure ion source, a stacked-ring ion guide (S-lens) and an
injection flatapole in the source region, a bent flatapole containing a
large bore at the bend ejecting solvent droplets and other neutral
species to prevent them from entering further into the instrument, a
segmented quadrupole mass filter, a C-trap, a higher energy colli-
sional dissociation cell, and an Orbitrap mass analyzer (Fig. 1). In
contrast to the previous generation, the injection flatapole was
equipped with ion selection capabilities, providing a low-resolution
selection mechanism for the removal of undesirable ions from the ion
beam before higher resolution selection in the quadrupole mass filter.
The new, segmented quadrupole mass filter has improved ion trans-
mission and mass selection characteristics (see below). Lastly, the
instrument can optionally be equipped with a compact Orbitrap an-
alyzer (Q Exactive HF), leading to a higher field and consequently
higher frequency of ion motion. This in turn leads to almost twice the
resolution in the same scan time relative to the previous cell (16).
Alternatively, this analyzer can be used to achieve twice the scan
speed while remaining at nearly the same resolution, a strategy we
utilize here.
The covered mass range in the Orbitrap analyzer is m/z 50–6000.
Precursor mass selection by the quadrupole is possible up to m/z
2500, and isolation windows can be set between 0.4 and 5600 Th.
The instrument software automatically adjusts the required ion injec-
tion time to compensate for loss of transmission when reducing the
isolation width. Acquisition speed with the classic Orbitrap analyzer
remains the same as previously reported, whereas for the high-field
Orbitrap it ranges from 27 Hz for resolving power 15,000 specified at
m/z 200 (corresponding to 10,000 at m/z 400) to 1.5 Hz for resolving
power 240,000 at m/z 200 (corresponding to 170,000 at m/z 400). The
vacuum in the Orbitrap compartment can be electronically adjusted
5-fold, enabling high-resolution analysis of most analytes including
large peptides and small proteins.
FIG. 1. Construction details of the Q Exactive HF. This instrument is based on the Q Exactive series and improves on it with a mass
selection pre-filter implemented at the injection flatapole (A), an actively guiding bent flatapole (B), and a segmented quadrupole (C). This
combination prevents contamination from traveling far into the instrument and improves the ion transmission almost 2-fold. The ultra-high-field
Orbitrap analyzer (D) is optional.
Q Exactive with Ultra-high-field Orbitrap Analyzer
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Preparation of HeLa Lysates—HeLa cells (ATCC, S3 subclone)
were cultured in DMEM containing 10% fetal bovine serum, 20 mM
glutamine, and 1% penicillin-streptomycin. Cells were collected via
centrifugation at 200g for 10 min, washed once with cold PBS, and
centrifuged again. Supernatant was carefully discarded, and cell pel-
lets were shock frozen in liquid nitrogen and stored at 80 °C. Ali-
quots of 3e7 cells were re-suspended in 1 ml of water; then 1 ul of
trifluoroethanol was added, and samples underwent incubation for 10
min on ice, a 2-min sonication at duty cycle 30% and output control
3 (Branson, Danbury; sonifier model 250), and 1 min of vortexing.
After 20 min of incubation at 56 °C, 25 l of 200 mM DTT was added
to reduce proteins, and samples were incubated at 90 °C for 15 min.
Alkylation was then performed by adding 100 l of 200 mM iodoac-
etamide and incubating for 60 min at room temperature in the dark.
The sample was diluted using 8 ml of 50 mM NH4HCO3 to reduce the
final trifluoroethanol concentration to 10% (v/v), after which the sam-
ple was digested for 1 h at 37 °C by LysC at an enzyme:protein ratio
of 1:100 and then overnight at 37 °C after the addition of trypsin at a
ratio of 1:100. Digests were then diluted 1:4 with 0.1% formic acid
(v/v) and purified with Sep-Pak tC18 cartridges according to the
manufacturer’s instructions. The peptide concentration was deter-
mined using a NanoDrop spectrophotometer (Thermo Scientific).
Phosphorylation Enrichment of Non-stimulated HeLa Cells—Pep-
tides were collected from a population of 1e8 unstimulated HeLa cells
prepared using the filter-aided sample preparation method (17). In
brief, cell pellets were solubilized in 4% SDS, 100 mM Tris/HCl, pH
7.6, 0.1 M DTT; incubated at 95 °C for 5 min; and sonicated at duty
cycle 30% and output control 3 (Branson Ultrasonics). The protein
concentration was determined from tryptophan fluorescence emis-
sion at 350 nm using an excitation wavelength of 295 nm. A total of 30
mg of protein extract was then split on top of five 30,000 molecular
weight cutoff centrifugal filters (20 mg per filter), spun down, and
washed twice with 7 ml of 8 M urea, 100 mM Tris/HCl, pH 8.5.
Alkylation was performed with 50 mM iodoacetamide for 30 min at
room temperature in the dark in the same buffer. After two further
washes with 7 ml of 8 M urea, Tris/HCl, pH 8.5, in 0.1 M and three with
7 ml of NH4HCO3, digestion was performed by adding LysC at an
enzyme:protein ratio of 1:50 and incubating overnight at 30 °C. The
digested peptides were eluted from the filters via centrifugation,
quantified with a NanoDrop spectrophotometer, and then further
digested by trypsin added at a ratio of 1:100. After incubation at 37 °C
for 5 h, peptides were shock frozen in liquid nitrogen and lyophilized.
Peptides (around 10 mg per Falcon tube) were re-suspended in 10 ml
of ACN 80%, TFA 6%, and insoluble peptides were spun down by
centrifugation at 100g for 1 min. Supernatants were moved into new
15-ml Falcon tubes, and samples were incubated twice with 50 mg of
TiO2 beads on a rotating wheel for 45 min. TiO2 beads from all the
enrichments were then pooled together and washed three times with
12 ml of ACN 80%, TFA 6% and three times with 12 ml of ACN 80%,
TFA 0.1%. Beads were then re-suspended in 2 ml of ACN 80%, TFA
0.1%, transferred into 12 Empore-C8 StageTips (18), and washed
once with ACN 80%, TFA 0.1%. Peptides were eluted from each
StageTip with 200 l of 60% NH4OH (25% NH3 solution in H2O) in
40% ACN. The volume was reduced via SpeedVac to 10 l to elim-
inate ACN and brought back up to 200 l with 0.1% formic acid.
Phosphorylation enriched peptides were pooled and purified with
Sep-Pak tC18 cartridges according to the manufacturer’s instructions.
The peptide concentration was determined using a NanoDrop spec-
trophotometer. The final concentration was brought to 400 ng/l with
0.1% formic acid, and 5.5-l aliquots were frozen at 20 °C.
LC-MS/MS Analysis—Online chromatography was performed with
the Thermo Easy nLC ultra-high-pressure HPLC system (Thermo
Fisher Scientific) coupled online to either an original Q Exactive or a Q
Exactive HF with a NanoFlex source (Thermo Fisher Scientific). Ana-
lytical columns (50 cm long, 75-m inner diameter) were packed
in-house with ReproSil-Pur C18 AQ 1.9-m reversed phase resin (Dr.
Maisch GmbH, Ammerbuch-Entringen, Germany) in buffer A (0.5%
acetic acid). During on-line analysis the analytical column was placed
in a column heater (Sonation GmbH, Biberach, Germany) regulated to
a temperature of 55 °C. A peptide mixture of 2 g dry weight was
loaded onto the analytical column with buffer A at a maximum back-
pressure of 980 bar (generally resulting in a flow rate of 450 nL/min)
and separated with a linear gradient of 5% to 30% buffer B (80% ACN
and 0.5% acetic acid) at a flow rate of 250 nL/min controlled by
IntelliFlow technology over 90 min (generally at a back-pressure of
around 500 bar). Due to the loading, lead-in, and washing steps, the
total time for an LC-MS/MS run was about 40 to 50 min longer. Online
quality control, including automated detection of large droplet forma-
tion, HPLC parameters, and acquisition-related computer status, was
performed with SprayQc (8).
MS data were acquired using a data-dependent top-10 method for
the Q Exactive and a top-15 method for the Q Exactive HF, dynam-
ically choosing the most abundant not-yet-sequenced precursor ions
from the survey scans (300–1650 Th). Sequencing was performed via
higher energy collisional dissociation fragmentation with a target
value of 1e5 ions determined with predictive automatic gain control
(supplemental Fig. S6). Isolation of precursors was performed with a
window of 3 Th for the Q Exactive and 1.4 Th for the Q Exactive HF,
because of the latter’s superior quadrupole (Fig. 3C). Survey scans
were acquired at a resolution of 70,000 at m/z 200 on the Q Exactive
and 60,000 at m/z 200 on the Q Exactive HF (“Results and Discus-
sion”). Resolution for HCD spectra was set to 17,500 at m/z 200 with
a maximum ion injection time of 120 ms on the Q Exactive and 15,000
at m/z 200 with maximum ion injection time of 25 ms on the Q
Exactive HF (supplemental Fig. S3). The normalized collision energy
was 25 for the Q Exactive and 27 for the Q Exactive HF (supplemental
Fig. S2; this difference was due to different scaling functions in the
instrument software). The “underfill ratio,” specifying the minimum
percentage of the target ion value likely to be reached at the maxi-
mum fill time, was defined as 10% (supplemental Fig. S5). Further-
more, the S-lens RF level was set at 60, which gave optimal trans-
mission of the m/z region occupied by the peptides from our digest
(supplemental Fig. S4). We excluded precursor ions with single, un-
assigned, or six and higher charge states from fragmentation selec-
tion (supplemental Fig. S2).
In the comparison between the Q Exactive and the Q Exactive HF,
we noticed that there was a 1.5-times overestimation of the number
of ions offered for fragmentation on the Q Exactive HF relative to the
Q Exactive runs. To determine whether this had an additional effect
on the performance of the instrument, we investigated performance
on different target values. From this we found that the original Q
Exactive target value of 1e5 ions remained optimal for the Q Exactive
Plus and Q Exactive HF (supplemental Fig. S6).
Data Analysis—All data were analyzed with the MaxQuant pro-
teomics data analysis workflow, version 1.4.0.6 (19), with the An-
dromeda search engine (20). The false discovery rate was set at 1%
for protein, peptide spectrum match, and site decoy fraction levels.
Peptides were required to have a minimum length of seven amino
acids and a maximum mass of 4600 Da. MaxQuant was used to score
fragmentation scans for identification based on a search with an
allowed mass deviation of the precursor ion of up to 4.5 ppm after
time-dependent mass calibration. The allowed fragment mass devi-
ation was 20 ppm. Fragmentation spectra were searched by Androm-
eda in the International Protein Index human database (version 3.68;
87,061 entries) combined with 262 common contaminants (20). En-
zyme specificity was set as C-terminal to arginine and lysine, also
allowing cleavage at proline bonds and a maximum of two missed
cleavages. We set carbamidomethylation of cysteine as a fixed mod-
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ification and N-terminal protein acetylation and oxidation (M) as vari-
able modifications for the HeLa total cell lysates; additionally, Phos-
pho (STY) was set as a variable modification for the phosphorylation
enriched samples. Further downstream analysis of the results was
performed with in-house-developed tools for the extraction of meta-
data from the mass spectrometry files based on MSFileReader
(Thermo Fisher Scientific) and with the R scripting and statistical
environment (21) using ggplot (22) for data visualization. The datasets
used for analysis have been deposited at the ProteomeXchange
Consortium via the PRIDE partner repository.
RESULTS AND DISCUSSION
The ion path during quadrupole isolation of the Q Exactive
HF (as well as the Plus) has been updated with the objective
of improving robustness and optimizing the ion transmission
during quadrupole isolation in order to be able to meet the
demand created by the increased speed of the ultra-high-field
Orbitrap mass analyzer. Various hardware components mak-
ing up the path are detailed in “Experimental Procedures.” We
start our discussion by investigating their behavior using the
standard ESI Positive Ion Calibration Solution (Thermo Fisher
Scientific) electrosprayed by direct infusion. We then charac-
terize the performance of the instrument based on results
from HeLa whole cell lysates measured via shotgun top-N
methods.
Injection Flatapole as Pre-filter—We and others had found
that due to the intense peptide ion beam, the Q Exactive could
be prone to contamination issues under heavy load that de-
graded its performance after a prolonged period of measure-
ments. The leading cause was determined to be peptides
excluded during mass selection coating the rods of the qua-
drupole. Therefore, the first update was made to the injection
flatapole with the objective of making the instrument more
robust. This component now acts as a low-resolution quadru-
pole capable of rough pre-filtering of the incoming ion beam
before proper precursor selection in the analytical quadru-
pole, thereby providing an protective filter for contaminants.
We tested the pre-filter on the tetra-peptide MRFA present in
the electrospray ionization calmix solution (Fig. 2A). When the
pre-filter was activated for the MRFA peak at 524.27 Th in an
isolation window of 80 Th, a clean exclusion of peaks was
achieved outside the selected isolation range. This is evident
from the inset zoom-in to below 1% on the relative ion abun-
dance scale. To determine the isolation width at which the
pre-filter has optimal ion transmission, we started with a
10-Th selection window and increased it in 10-Th steps to 200
Th. The signal increased with increasing window size until 80
Th, after which hardly any increase in transmitted ions oc-
curred (Fig. 2B). At this isolation width more than 90% of the
used m/z scan-range (300–1650 Th) was excluded. By com-
paring the summed ion abundance of the signals from a HeLa
total cell digest that were discarded when employing this
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FIG. 2. Performance details of the injection flatapole pre-mass filter. A, the calmix spectrum when isolating MRFA (524.27 m/z) in an
isolation window of 80 Th. The inset zooms in on the isolation window and its direct surroundings. B, isolation efficiency of the pre-mass filter
over a range of isolation windows. C, effectiveness of the pre-mass filter over a range of isolation windows on a HeLa whole cell lysate. D,
picture of the injection flatapole after 3 months of continuous measurements.
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inject flatapole setting to the total ion current, we estimated
that over 75% of the ion beam was excluded, for more than
75,000 of over 90,000 fragmentation scans (Fig. 2C). (Note
that these numbers are somewhat dependent on the m/z
range chosen.) With this low-resolution pre-filtering, a large
portion of the selection load is moved to the robust inject
flatapole. This, in turn, makes the task for the analytical qua-
drupole easier and should lead to less deposition on the
selection quadrupole. The majority of non-precursor peptide
ions are instead deposited on the injection flatapole (Fig. 2D),
which is located in the outer cage and is readily accessible for
cleaning.
Segmented Quadrupole—The original hyperbolic-rod qua-
drupole has been replaced by a segmented version capable
of achieving more rectangular isolation efficiency over the
complete isolation window (Fig. 3A). This is of relevance for
acquisition strategies like SWATH (23) and co-isolation of
SILAC partners (for example, in selected ion monitoring
scans), which require rectangular isolation windows in order
to generate accurate quantitative information at their edges.
Relative to the quadrupole in the Q Exactive, we observed
markedly improved isolation efficiency at the low-mass side of
the isolation window. Additionally, the transmission of the
quadrupole for narrow isolation windows has been improved.
We measured this improved efficiency for the set of calmix
ions and found an almost 2-fold increase (Fig. 2B). Note that
the figure also shows a transmission benefit for larger isola-
tion windows, especially for high-m/z ions, that is due to the
focusing effect of the exit segment of the quadrupole. This
improvement roughly corresponds to the increase in ion cur-
rent needed to support the doubling of the scan speed that
the Orbitrap high-field analyzer is capable of (because the fill
time corresponds to the transient time in fully parallel opera-
tion of the instrument).
Previously, the smallest isolation windows that we used
were about 2.2 Th because transmission declined drastically
below this value (24). As the segmented quadrupole also
promised the ability to narrow isolation windows, we tested a
range of window sizes on a complex HeLa whole cell lysate.
We analyzed the data both with and without the “second
peptide” option in Andromeda, which attempts to identify a
second peptide from already identified MS2 scans after re-
moval of the fragments associated with the first peptide (20).
The Q Exactive HF performed optimally in terms of peptide
identifications at an isolation window of 1.4 Th both with and
without the second peptide option (Fig. 3C), whereas for the Q
Exactive this value was 2.2 Th. The narrower isolation window
also resulted in a reduced addition to the unique peptide
sequences given by the second peptide option, because of
the lower likelihood of co-isolated peptides that can be iden-
tified in this second step. At the optimal window of 1.4 Th this
was 6.5%, down from 8% at the former optimal isolation
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window of 2.2 Th. We determined the purity of isolation by
calculating the precursor ion fraction (24) for the same range
of isolation windows. At the narrowest isolation window of 0.4
Th, the majority of isolations achieved greater than 80% purity
(Fig. 3D). Such a low precursor ion fraction might to some
degree be helpful for tandem mass tag labeling experiments
(25, 26). For the optimal isolation window of 1.4 Th, the
precursor ion fraction was slightly reduced to 70% in the large
majority of cases. As this is still well within the range of
tolerance for a clean and identifiable fragmentation spectrum,
we adopted this isolation value as the default.
Performance of the Ultra-high-field Analyzer—The ultra-
high-field Orbitrap analyzer consists of an outer barrel-like
electrode (dark gray in Fig. 4A) of maximum radius R2 and a
central spindle-like electrode (light gray) along the axis of
maximum radius R1, with the outer electrode maintained at
the virtual ground of the preamplifier and the central electrode
at a voltage Ur (Ur  0 for positive ions) (16). In a standard
Orbitrap analyzer, R1  6 mm and R2  15 mm (5), whereas
the ultra-high-field analyzer is more compact, with R1  5 mm
and R2  10 mm (Fig. 4A) (i.e. the outer electrode is scaled
down by a factor of 1.5). A decrease of the R2/R1 ratio from
2.5 to 2 allows an increase in the electric field and hence the
detected frequency in addition to the scaling factor, thus
bringing the total gain to about 1.8-fold. The smaller cell
required an increase of the injection ion energy of about
1.4-fold for the same 5000-V voltage on the central electrode.
Despite the increase in space charge density in the analyzer
by a factor of (1.5)3  3.4, the additional shielding provided by
the relatively thicker central electrode keeps space-charge-
induced frequency shifts even slightly below those in the
standard analyzer (27). A miniature electrostatic lens provides
sharp spatial focusing of ions coming into the injection slot
located on one of the injection electrodes. As ion packets
from the C-trap enter the analyzer off-axis, axial oscillations
are initiated without the need for any additional excitation and
without a loss of synchronization with the moment of ejection
from the C-trap. This facilitates the use of enhanced Fourier
transform (28) for all modes of operation in the same way as
in the preceding Q Exactive instrument.
The Q Exactive HF is preset to record spectral data at five
distinct resolutions, namely, 15,000, 30,000, 60,000, 120,000,
and 240,000 at m/z 200 Th. Each resolution corresponds to a
transient time denoting the time spent on analyzing the ion
population in the Orbitrap mass analyzer, respectively consis-
ting of 32, 64, 128, 256, and 512 ms. These resolutions are
slightly reduced for the ultra-high-field analyzer relative to the
equivalent settings for the classic analyzer, as the total gain of
the resolution at the same transient time is a factor of 1.8 rather
than 2. The Q Exactive HF instrument additionally makes a
higher maximum resolution of 240,000 available. By comparing
the time difference between each consecutive scan for the
ultra-high-field Orbitrap analyzer to the theoretical values for the
transient times, we found that the overhead for each scan was
between 6 and 14 ms (Fig. 4B). This constitutes an improvement
over the 17-ms scan time overhead for the Q Exactive. When
the increased transient speed is utilized to double the number of
scans at roughly the same resolution, this reduction of the scan
time overhead is required to keep the injection times at a rea-
sonably high level when the instrument is running in fully parallel
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mode. For instance, for the 15,000 resolution setting the tran-
sient time is reduced from 64 to 32 ms; at a scan time overhead
of 17 ms, more than half of the available time for the scan would
have been lost without minimizing overhead. For shotgun anal-
ysis of complex mixtures, running in full parallel mode is desir-
able in terms of peptide identifications. We found the 15,000
resolution setting (corresponding to 32-ms transients) in com-
bination with a maximum injection time of 25 ms to be best for
complex mixtures such as total cell lysates (supplemental Fig.
S3). To investigate the effect of the minor nominal reduction of
instrument resolution, we measured the actual resolution of the
identified peaks of a whole HeLa cell lysate. A slight drop in the
resolution of those peaks was indeed observed (Fig. 4C); how-
ever, this is a minor effect, and we did not notice any impact on
downstream data analysis. As described below, the increased
scan speed indeed resulted in significantly increased numbers
of peptide and protein identifications (Fig. 4D). We also note that
one can double the MS resolution for the Q Exactive HF relative
to that of the Q Exactive (120,000 versus 70,000) without detri-
mental consequences. This is because the transient time gained
through acquisition at the lower resolution would be only 128
ms, which at 10% is an insignificant part of the total cycle.
Optimal Parameter Value Verification—After individually op-
timizing the parameters for the Q Exactive HF, we performed
an independent verification of the optimal values for each of
the parameters using a design-of-experiment approach (29,
30) using MODDE (Umetrics, Frankfurt, Germany). A benefit of
such an approach is that it gives insight into parameters that
have potentially interacting properties. For the analysis we
chose the parameters that previously gave the greatest effect
in our experiments, consisting of normalized collision energy
(20–40), S-lens rf level (40–80), and isolation window (0.4–3
Th). The range of the parameters was chosen to be large and
center on the previously found optimal values. All RAW data
were recorded based on the experimental design established
by the software. From the results of this study we concluded
that the previously described values are optimal and that in
our set there were no significantly interacting parameters
present from which a performance benefit could be gained.
As the conclusion remained the same and a design-of-exper-
iment approach can deal with sparse data, this can be an
attractive study type for quickly optimizing LC-MS/MS met-
rics for different types of samples and chromatography sep-
aration (supplemental Fig. S10).
Q Exactive Performance for Total Cell Lysate Analysis—We
next directly compared the Q Exactive HF to the Q Exactive
using the standard top-10 method on a 2 h gradient for the Q
Exactive, which has demonstrated effectiveness in address-
ing a wide variety of biological questions. We ensured a fair
comparison by running the test within one day, using the
same sample, HPLC, and analytical column on both systems.
We wished to make use of the increased speed of the Q
Exactive HF while still achieving a cycle time of around 1 s and
occupying the instrument with close to the maximum number
of fragmentation scans in each cycle. For this, we found a
top-15 method to be the most effective. An example of the
MS spectrum with the subsequent fragmentation spectra can
be seen in supplemental Fig. S1. In this comparison, we
achieved cycle times of 1.1 s on the Q Exactive and 0.9 s on
the Q Exactive HF. The extra five scans per cycle at roughly
the same cycle time translate into a speed increase from 10
scans per second to 17 scans per second (Fig. 5A). In a direct
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comparison between the Q Exactive and the Q Exactive HF,
we found that the higher speed delivered an increase of
almost 60% more scans (variation over five runs  620
scans). At an identification success rate of 62% in both cases,
this translated into 48% more MS2 identifications (variation
over five runs  313 identifications) and 43% more unique
sequences (variation over five runs  238 sequences)
(Fig. 4D).
One prominent feature of the cycle-time plot is that the Q
Exactive reached the full top N early on in the gradient,
whereas the Q Exactive HF achieved the full top N much later
in the gradient. We interpret this to mean that even in highly
complex samples such as HeLa full cell lysates, the initial part
of the gradient does not contain sufficient precursor ions that
fulfill the criteria for selection for fragmentation at these very
high sequencing speeds.
To investigate and compare the impact of the extra se-
quencing speed, we determined the achieved peak depth for
each of the instruments. Here we define this value as the
position of the precursor in the list of all visible precursors in
the cycle where it is sequenced, sorted on descending ion
abundance. For complex HeLa digests, we found that this list
contained around 400 precursors (distilled from around 4000
individual peaks in the spectrum) at any given time during the
linear part of the gradient (supplemental Fig. S7). The Q Ex-
active probed this list to a medium depth of 18%, or around
72 precursors per cycle, whereas the Q Exactive HF, with its
enhanced speed, achieved a depth of 27%, or around 108
isotopes per cycle (Fig. 5B). This additional peak depth was
indeed translated into more fragmented precursors, which
were increased by 53% from 48,449 to 74,383. As both in-
struments exhibited a sequencing success rate of more than
50% over the entire gradient, this translated into an increase
of 43%, from 27,256 to 39,119 unique peptide sequences
(Fig. 5C). There was a slight reduction in the number of visible
peptides (cumulative green, red, and gray population), which
we attribute to the lower resolution of the full scans for the Q
Exactive HF. From the histogram, however, it is evident that
the instrument sequenced down to lower abundance peptides
(cumulative green and red population) and is capable of suc-
cessfully identifying a greater proportion of available peptides
(green population). These additionally sequenced peptides
contribute to new protein identifications, as opposed to only
extending the sequence coverage of already accessed pro-
teins. This is evident from a 21% increase in identified pro-
teins, from 3912 to 4740. Thus, the sequencing speed
enabled by the ultra-high-field Orbitrap analyzer allows iden-
tification of a greater percentage of total detectable precur-
sors, but a majority of unfragmented peptides remains. This is
not entirely due to their low abundance, as many peptides in
the gray population have a signal similar to those of frag-
mented and successfully identified peptides. This suggests
that further increases in sequencing speed would still be
useful for particularly congested parts of the gradient. Plotting
the cumulative number of proteins over the gradient revealed
that the Q Exactive HF improved the maximum protein se-
quencing rate by 25%, from 80 to 100 proteins per minute
(Fig. 5D).
Further investigations into the dynamic range of the identi-
fied peptides revealed that both instruments reliably se-
quenced over 3 orders of magnitude, indicating that the per-
formance increase of the Q Exactive HF can be attributed to
its ability to sequence more peptides in the busy regions of
chromatography. This additional speed is also responsible for
a higher inter-replicate reproducibility at the peptide identifi-
cation level, where the instrument achieves better reproduc-
ibility for lower peptide abundances (supplemental Fig. S8).
To investigate the Q Exactive HF performance on different
gradient lengths and to provide an indication of optimal per-
formance for the instrument, we additionally ran a gradient
titration series on the standard HeLa samples, which revealed
that gradients over 4 h did not further improve identification
performance for our sample. Based on the increase per time
unit, we concluded that a 150-min gradient represents the
optimal length. The trend in our and other laboratories to
measure over 4-h or longer gradients can now to some extent
be reversed (supplemental Fig. S9).
As we observed that the Q Exactive HF did not routinely
achieve the full top N, we hypothesized that the peak depth
was limited by chromatography rather than the sequencing
speed of the mass spectrometer. To address this question,
we employed DMSO as a dopant in the mobile phase buffers,
as it had been reported to significantly increase the ion flux
and consequently the performance of shotgun proteomics
experiments (31). On the standard 2 h gradient, peptide iden-
tifications increased by 13%, from 39,119 to 44,446, and
protein identification increased by 16%, from 4740 to 5492
(Fig. 6A). Even with this addition of potentially sequenceable
peptides, the instrument still did not reach the full top N per
cycle, meaning that further increases in ion abundance would
be beneficial. The achieved protein sequencing rate over the
actual gradient (subtracting the lead-in time of 5 min for the
buffers to arrive and a washout phase of 15 min) was 55
proteins per minute for these optimized conditions. When
comparing the copy numbers for HeLa cells to the detected
proteins (32), we found that the instrument was capable of
successfully sequencing in an estimated protein dynamic
range from 90 million down to 115 copies per cell (Fig. 6B),
enabling the analysis of highly complex samples down into
the transcription factor range in reasonable time. Although the
dimethyl sulfoxide dopant in our experiments had clear ben-
efits in terms of performance, we do not routinely use it
because it represents a potential contamination source for the
quadrupole rods, which cannot be resolved through the in-
corporation of the selecting inject flatapole. Further studies
are clearly needed to confirm its effects on instrument
robustness.
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Application to Phosphoproteomics—Given the observed in-
crease in performance for the whole cell lysates, we reasoned
that the Q Exactive HF might be capable of improved per-
formance on sample types requiring high mass spectrometric
sensitivity as well. In order to test this, we measured an
unstimulated HeLa lysate enriched for phosphorylated pep-
tides with both instruments. Phosphopeptides are generally of
low abundance, and therefore it is advantageous to allow for
longer ion injection times for the fragmentation scans to ac-
cumulate a sufficient amount of ions for a successful se-
quencing event (33). Here we chose a maximum of 111 ms for
the Q Exactive and 45 ms for the Q Exactive HF, which took
the 17-ms scan time overhead of the original Q Exactive into
account (leaving the Q Exactive HF at a slight disadvantage).
Fig. 7A illustrates the analysis on both instruments for the
same phosphorylated peptide. Even though in both cases the
maximum allowed ion injection time was reached—meaning
that not enough ions were present to fulfill the request of 1e5
ions for the higher energy collisional dissociation scan—
almost full sequence coverage was achieved in both cases.
The Q Exactive HF, however, achieved this coverage in less
than half the ion injection time. We investigated whether the
automatic gain control target could still be achieved at these
restricted maximum injection times for all the MS2 scans and
found that it could in the majority of cases for both instru-
ments. As in the above example, most of the MS2 events for
the classic instrument required almost double the time in this
experiment (supplemental Fig. S11). The longer ion injection
time in the sensitive method already allows the Q Exactive to
probe deeper into the list of visible precursors, from a median
of 18% for the normal method to 23% for the sensitive
method. However, the additional speed of the Q Exactive HF
allowed it to go even further, from a median of 27% for the
normal method to 33% for the sensitive method (Fig. 7B).
Overall, the increased sequencing speed in combination with
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FIG. 7. Phosphorylation enriched samples. A, example fragmentation spectra of the same phosphorylated peptide identified on the Q
Exactive (top) and on the Q Exactive HF (bottom). In both cases the maximum allowed ion injection time was reached. B, comparison of the
achieved peak-depth on the Q Exactive and the Q Exactive HF. C, comparison of the successfully sequenced Class I phosphorylation sites.
Q Exactive with Ultra-high-field Orbitrap Analyzer
3706 Molecular & Cellular Proteomics 13.12
the improved quadrupole transmission translated into 64%
more class I phosphorylation sites identified in a single run in
this particular experimental situation (Fig. 7C). However, in
experimental situations where the phosphopeptide amounts
necessitated longer fill times, we have observed much smaller
gains.
Conclusions and Outlook—Here we have described the
next iteration of the Exactive family of mass spectrometers,
the Q Exactive Plus and the Q Exactive HF, and investigated
its performance on analytical standards and on complex pep-
tide mixtures for shotgun proteomics using our standard 90-
min gradient. The ultra-high-field Orbitrap analyzer doubles
the sequencing speed at the same resolution, for which the
improved ion transmission characteristics of the segmented
quadrupole at least partially provide the necessary increase in
precursor ion abundance. The higher speed translates well to
actual shotgun proteomics improvements, as we observed
increases of more than 40% in unique peptide sequences and
more than 20% in proteins relative to the previous generation
on our standard gradient with the HeLa cell lysate.
We observed that the mass spectrometer did not fully make
use of its potential sequencing speed, as there were insuffi-
cient ions in parts of the gradient to satisfy the requirements
for attempting a sequencing event. In order for this to be
resolved, optimizations such as dopant-enhanced mobile
phases (31), higher sensitivity analytical columns (34), or
brighter ion sources (35) will be required to increase the
precursor ion abundance. In applications with very complex
samples containing a sufficient number of sequenceable pre-
cursors, we anticipate that researchers will be able to boost
the instrument productivity almost 2-fold while still achieving
the same sequencing depth as before. With such a large
reduction in analysis time, any overhead between LC-MS/MS
runs becomes increasingly undesirable. For example, cur-
rently the loading times on our single analytical column setup
(50 cm; C18) are around 30 min. During this time the mass
spectrometer is not recording useful data, which is still ac-
ceptable for an analysis time of 2 h given that this loss
corresponds to two runs per day. At a 1-h analysis time,
however, an overhead of 30 min results in a loss of almost
eight runs per day. Thus optimized chromatography setups,
such as pre-columns that do not degrade resolution or double
analytical columns, will be needed in order for the instrument
to be used most effectively.
In conclusion, this new generation of quadrupole Orbitrap
instruments is designed for significantly greater robustness,
and our experiments confirmed that the majority of undesired
ions were confined to the front part of the instrument. We
likewise observed significantly enhanced selection character-
istics of the new segmented quadrupole, which should be
useful in many proteomic experiments. Finally, and most im-
portant, the ultra-high-field Orbitrap analyzer in the Q Exactive
HF routinely provided doubled resolution in MS scans without
downsides and doubled the potential sequencing speed in
MS/MS mode.
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Proteomics Tools to Investigate 
Neurodegeneration 
Neurodegenerative diseases (NDs) are an increasing burden for our aging society. A wide spectrum 
of these pathologies is characterized by progressive neuronal death causing functional impairment of 
the affected brain regions. Despite decades of intense research, neither effective treatments nor 
preventions are available, rendering neurodegeneration one of the major causes of morbidity and 
mortality. In this thesis, proteomics tools were developed and employed to provide novel insights 
into the pathology of neurodegeneration.  
Mass spectrometry based proteomics provides quantitative measures for protein abundance 
and allows us to monitor the physiology of tissues and cells as well as changes during the 
development of pathologies. Article 1 demonstrates a paradigm example of how the physiological 
properties of primary neurons and neuronal model cell lines can be assessed with proteomics. We 
evaluated different in vitro cell systems for their cellular properties in comparison to primary 
motoneurons. The motoneuronal model cell lines investigated are widely used to study 
neurodegeneration. Surprisingly, our proteomics results indicated that these cell lines significantly 
differ from primary motoneurons both on the global pathway and individual protein levels. The 
neuronal lineage of the motoneuron model cell lines only became evident in comparison to 
non-neuronal cell lines. With the results from article 1 it is possible to infer which pathways and 
functionalities are preserved in the cellular model systems, allowing data driven decision which 
cellular model system to use for specific questions. In addition, our approach illustrates how 
proteomics can be used as a tool to probe almost the entire proteome for physiological and 
pathological changes in a few hours of measuring time. 
Toxic aggregates are a hallmark of NDs. However, they differ in many aspects such as size, 
localization, associated pathology and composition. While the first three properties can be 
investigated with standard biochemical approaches, proteomics is the only technology that can assess 
the composition of aggregates in an unbiased and quantitative fashion. In article 2 we analyzed the 
proteomic composition of SDS insoluble poly-dipeptide repeat aggregates (pDRP) that are associated 
with a c9orf72 hexanucleotide repeat expansion, the most common genetic cause for ALS and 
FTD 48. We observed a strong association of the UPS with the pDPR aggregates and discovered 
UNC119, which is quantitatively sequestered into the aggregates, as a novel player in ALS and FTD 
pathologies. In primary neurons, overexpression of UNC119 is sufficient to rescue the pDRP 
phenotype partially, whereas its deficiency compromises neuronal survival. In post mortem brain 
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tissue, sequestration of UNC119 correlates better with the degree of degeneration than the pDPR 
aggregate formation itself. Further investigation on these effects as well as on the contribution of 
other proteins that we determined to be highly enriched in the aggregates in vivo are ongoing. 
Important questions in neurodegenerative research include how the toxicity of aggregates can 
be modified and which natural mechanisms have evolved to cope with proteostatic stress. We 
employed yeast as a model system in article 3 to address these questions. In yeast, the toxicity of 
N-terminal fragments of huntingtin containing a polyQ stretch (103Q-GFP) can be modulated in 
genetic screens, providing a versatile screen for toxicity modifying mechanisms. We assessed how 
proteins that suppress 103Q-GFP toxicity, like the non-essential transcription factor GTS1, affect 
aggregate composition. We analyzed the HTT interactome and discovered that the composition of 
the aggregates significantly changes upon pertubation. In the presence of overexpressed GTS1 the 
association of HTT with prion-domain containing proteins is decreased, whereas chaperone 
association is increased. Moreover, we showed that overexpression of the prion-like polyQA domain 
of GTS1 alone is sufficient to suppress 103Q-GFP toxicity and to alter aggregate composition. Yeast 
expresses a set of proteins with a prion-like behavior. For yeast, those prion proteins do not 
necessarily exert toxicity and our findings support the proposed beneficial effects under certain 
circumstances 120. Furthermore, proteins with prion like domains are not unique to yeast; and indeed, 
many proteins of higher eukaryotes contain prion like domains 121 and might partially contribute to 
proteostasis with related mechanisms.  
Protein aggregates in NDs differ in general features such as localization, shape and 
co-aggregating proteins. This suggests that the toxicity of protein aggregates is not generally 
mediated via a simple mechanism like sequestration of a small number of proteins but rather involves 
a multicomponent network. Such a network would include various deleterious effects such as protein 
aggregates and impaired proteostasis, disturbed RNA metabolism, non–cell autonomous toxicity and 
neuroinflammation. In line with the ‘multiple hit hypothesis’ as applied to neurodegeneration 44,229, 
the different neurodegenerative pathologies might be linked in this complex network, of which we 
only have a partial understanding so far. Unbiased quantitative approaches such as proteomics could 
help to gain comprehensive insights into this network, identifying the missing links and shedding 
light on the pathological hubs. From a proteomics point of view, we can address three major aspects: 
(1) The physiology of neurons and glial cells and how the complete proteomes alter during the 
pathology (2) A comparison of sub proteomes of neurons and glia cells in the context of various NDs 
and (3) Characterization of different neurodegeneration associated aggregates. 
(1) Characterizing Complete Proteomes: Most non-neuronal cells, but even some neurons 
such as the oculomotor nerve in ALS, are less prone to degeneration. An unbiased characterization 
of primary cells or post mortem tissue of different neurons by mass spectrometry will help to 
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understand why certain neurons are particularly susceptible. Besides primary cells or post mortem 
tissue dissections, patient derived induced pluripotent stem cells (iPSC) differentiated into individual 
neurons could provide powerful disease models for proteomics analysis. Moreover, a longitudinal 
proteome analysis during a differentiation process of iPSC towards neurons and the onset of a 
phenotype would give detailed insights into pathological cascades and causality. As a control, one 
could use cells derived from healthy family members. To rescue from specific mutations one could 
perform genome editing with CRISPR-Cas9. A proof of concept for genome editing in the context 
of neurodegeneration was published in 2011 using zinc finger nucleases to generate isogenic human 
iPSC 230. In addition to the analysis of neurons, non-cell autonomous toxicity in NDs can be 
investigated. Glia cells are important to maintain neuronal homeostasis and regulate inflammatory 
processes 18,30. On the one hand, the specific neuronal and glial morphology and interconnection 
renders an analysis of individual cell types from this tissue almost impossible. On the other hand, 
iPSC derived and primary cells lack the cellular context that might play a pivotal role in 
neurodegeneration. Therefore, a combined analysis of both, tissue and primary / iPS cells is likely 
necessary for comprehensive understanding of the pathology. Expanding the proteomics 
characterization of primary cells, tissues and patient derived iPSC to multiple pathologies would 
allow discrimination of common and unique neurodegenerative features on a global scale. As 
different NDs affect different parts of the brain, healthy controls are required to normalize for the 
tissue bias. 
(2) Characterizing Sub Proteomes: Detailed mechanistic insights in pathogenic cellular 
mechanisms can be gained by focusing on subcellular proteomes. Disturbance of neuronal transport 
processes could be investigated by focusing on the vesicle cargo 136 and analyzing the proteomic 
content of axons. The later can be achieved by using specifically designed growth chambers that 
allow separating the axons from the cell body 231. Proteins secreted by neurons and glial cells are 
especially interesting to characterize non-cell autonomous toxicity. The inflammatory response of 
microglia to extracellular aggregates or the changed secretion pattern of neurons and glial cells 
harboring neurodegeneration associated mutations could be investigated using in vitro systems like 
primary cells or iPSC.  
(3) Characterizing Protein Misfolding and Aggregation: Article 2 and 3 illustrate 
approaches in two model systems that provided novel insight to ALS / FTD and prion pathology. An 
unbiased resource for the composition of many different aggregates does currently not exist, however 
it is known that inclusions show specificity for only a subset of aggregation prone proteins. For 
instance, some ALS associated aggregates are TDP positive while others are TDP negative 232. 
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Generally, this could have many reasons including different cellular localization, altered abundance 
of proteins, and might also point to the requirement of specific interfaces for co-aggregation 101.  
This compatibility for transmission and amplification of ‘misfolding information’ shows 
intriguing conceptual parallels to classic prions, which propagate ‘folding information’ in an 
(auto-)catalytic fashion and are transmissible between organisms. A growing body of evidence points 
towards intercellular transmission and prion like behavior for proteins not previously thought to be 
involved in prion pathologies. Prominent examples of proteins that can propagate misfolding 
information to other proteins are tau, alpha-synuclein, SOD1, HTT and TDP-43 34,36,233,234. Although 
propagation of these proteins within one organism has been described, there is no evidence of natural 
transmission across species or even between individuals of one species 34. However, this remaining 
difference may solely reflect the protein stability and ability to cross the cellular barriers into the 
central nervous system. Which sequence features and conditions render proteins compatible for 
coaggregation and how generic and specific epitopes contribute to that process could be assessed 
with comprehensive data on the ‘aggregomes’ of many neurodegenerative diseases. Such data would 
facilitate the understanding of the biophysical principles of misfolding, propagation of misfolding 
information and protein aggregation in diseases.  
Article 3 provides an example of how the toxicity of aggregates correlates with the change in 
aggregate structure and composition. Quantifying the proteomic composition of aggregates in 
different pathologies would allow to investigate whether cells attempt to alter aggregate composition 
in general in response to proteostasis stress. If so, protein aggregates should contain the following 
groups of proteins. First, pathologically irrelevant binders consisting of proteins that stick to 
aggregates with little impact on the cell viability. Second, proteins that are sequestered causing loss 
of function toxicity and third, proteins that reduce the toxicity of the aggregates. Correlating the 
aggregate content with toxicity and the soluble protein content in established model systems such as 
primary neurons would help to discriminate these groups: if the protein abundance in the soluble 
fraction anti correlates with toxicity, this is consistent with a loss of function due to sequestration. 
However, if the abundance in the aggregates correlate with improved cell survival, it suggests that 
the protein acts as suppressor of aggregate toxicity. Unfortunately, this approach is complicated by 
the fact that toxicity can also be exerted by soluble oligomers of misfolded proteins. Therefore, a 
biochemical characterization and purification of the different species is imperative. 
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Technological Advances in Proteomics 
Despite the huge technological improvements over the last decade, a need for improved MS 
performance will continue for many years. Swissprot currently lists 20,198 proteins for H.sapiens 
(March 2015). State of the art mass spectrometry can quantify more than 10,000 proteins 129 and cells 
cannot possibly express all possible proteins at the same time. Yet it is clear that current sample 
preparation and MS workflows are far from sensitive enough to achieve complete sequence coverage 
of all the expressed proteins. Over 90,000 isoforms are predicted in the human proteome 235. Those 
are often particularly difficult to quantify as they can have very subtle sequence differences to each 
other. In conjunction with all PTMs, the potential complexity of the proteome is many orders of 
magnitude higher than the current capacity of MS technology. Some applications are particularly 
challenging due to very limited material or extraordinarily high dynamic ranges. Extremely high 
sensitivity, for example, would allow the analysis of the axonal proteome via microdisection. This 
could be used to investigate neuronal-oligodendrocyte crosstalk at the myelin interface, which is 
important for neuron homeostasis and is impaired in neurodegeneration 236. Dynamic range is an 
issue, for example, when one wishes to investigate patient serum to diagnose diseases. In serum, less 
than 0.1 % of the proteins account for 95 % of proteome mass 237. To meet these challenges, further 
developments of the MS workflow are urgently required. 
Sample preparation enabling efficient and unbiased isolation of all proteins is the first step in 
proteome analysis. Many efforts have been made to decrease sample loss during proteolytic digestion 
and to increase the efficiency of protein isolation for low amount samples 238,239. Although trypsin 
and LysC have proven to be invaluable proteases for most proteomics approaches, supplementing 
these by other proteolytic strategies can be useful. Combination of proteases can increase the 
sequence coverage by generating more peptides that can potentially be detected in the MS. In 
article 4 we employed various proteases and partial digestion to characterize a so far unknown third 
proteolytic pathway in Alzheimer’s disease and consequently identified a novel toxic peptide termed 
Aη-α. To increase the sequence coverage further one could employ less specific proteases like 
proteinase K. However, this approach would reduce the intensity of individual peptides roughly by 
the amount of additional peptides, compromising sensitivity. In addition, the expanded search space 
increases the computational load in down-stream data analysis. Apart from online liquid 
chromatography separation, the complexity of protein or peptide mixtures can be reduced by various 
fractionation methods usually based on ion exchange, hydrophobicity or isoelectric focusing 212,240-
243. Employing extensive fractionation of the sample can provide data with a higher dynamic range. 
However, more input material and measuring time is required and the additional processing steps can 
reduce quantitative accuracy. Ultimately, the best approach depends on the biological question that 
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is asked. For instance, high throughput screenings might rather benefit from fast and highly accurate 
data collection while a complete characterization of a cellular system may instead require extensive 
fractionation and a very deep proteome. 
In the future, several MS developments will increase the quality of proteomics data and range 
of applications. More than ten years ago, the introduction of Orbitrap analyzers constituted a 
breakthrough for proteomics and since then it has contributed to the increasing popularity and 
applications of MS. The newest generation of hybrid Orbitrap MS evaluated in article 6 almost 
doubled performance compared to its predecessor, featuring twice the resolution or sequencing speed 
with the same gradient length. The sensitivity was significantly improved by higher transmission 
efficiency in the segmented quadrupole. In addition, a pre-mass filter increased robustness of the 
machine significantly. Especially for clinical applications were speed and robustness are critical, the 
new generation quadrupole Orbitraps is a leap forward. The performance boost of the current 
generation was partially achieved by decreasing the size of the Orbitrap analyzer. However, for future 
iterations of hybrid Orbitrap MS reducing the cell size further will eventually decrease the ion 
capacity and increase space charge effects, decreasing accuracy and dynamic range. In addition, the 
finite ion capacity of the C-trap has always been a bottleneck for the achievable dynamic range. The 
beam type TOF mass analyzer, in contrast, has no ion capacity limitation, potentially allowing a very 
high dynamic range. Moreover, the TOF has the advantage to scale performance with drift 
path-length of ions in contrast to the reduction required for the Orbitrap. In article 5 we benchmarked 
the next generation hybrid QTOF instrument and showed significant performance improvement for 
proteomics applications. With increasing resolution, practically unlimited mass range and higher 
dynamic range TOF technology has the capacity to potentially outcompete the Orbitrap technology 
in the future.  
A potentially very useful addition to the current hybrid mass spectrometer would be ion 
mobility separation (IMS). IMS allows separating ions by shape and interaction with the gas phase 
and thereby adds orthogonal information to the molecule 244. Especially complex mixtures could 
benefit from this additional separation and the shape-information may be useful to infer ion identity 
and to match peptides only identified in one samples to other samples. An early example is the 
investigation of the plasma proteome using IMS in combination with TOF 245. The capacity of ion 
mobility to separate by shape may also become very useful to investigate glycosylation patterns and 
discriminate carbohydrate isomers. These are specifically interesting in determining 
immune-relevant antigens or in profiling carbohydrate dependent drug binding capacity of proteins 
and peptides.  
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To date, two different acquisition modes are employed in shotgun proteomics. In DDA ions are 
selected for fragmentation depending on the MS1 information. This is a hypothesis free and very 
efficient acquisition as signals that are more likely to provide sufficient information for identification 
are preferred. The partially stochastic nature of DDA, however, makes it prone to undersampling, 
which adds variation to the data. The high sequencing speed of the current Q Exactive and QTOF 
generations make undersampling a minor issue (article 5 and 6), however, higher sensitivity or 
shorter gradients will increase the ‘need for speed’. In contrast to DDA, SRM / MRM are a hypothesis 
driven approaches. They are sensitive but not suited for discovery, as they require prior knowledge 
about the sample. Like these targeted approaches, SWATH is a DIA method but it does not rely on 
prior knowledge. The strength of SWATH is that it aims to record all information on the MS2 level 
and that this information can be queried post acquisition. However, data interpretation is much more 
challenging. The theoretical advantage of SWATH that it record all MS features, is in practice limited 
by mass spectrometric performance. The limited speed and accuracy of the current mass spectrometer 
generation is not yet sufficient to match the performance of DDA in complex mixtures. In SWATH 
“useful” information is effectively diluted with signals that cannot be interpreted. In the future, both 
DDA and DIA could eventually merge, as with very fast MS it would be possible to subject any MS1 
feature or any MS1 range to fragmentation avoiding the undersampling issue.  
Data analysis is a central aspect of proteomics. A recent breakthrough was the development of 
highly accurate label free algorithms 214. Especially clinical applications and investigation of primary 
tissues benefit from the general applicability and almost unlimited scalability of label-free 
quantification. In combination with the potential to estimate copy numbers, quantitative label-free 
proteomics has matured into the method of choice for most applications. Nevertheless, labeling 
strategies such TMT might become more relevant due to their multiplexing capacity. Especially for 
screens in the clinical context were throughput and accuracy are equally important, the multiplexing 
capability of TMT has high potential. Another promising but yet unexplored application of MS based 
proteomics is de novo sequencing. De novo sequencing faces technical challenges discussed in 
chapter 2.7. Despite these current limitations, many applications would greatly benefit from de novo 
sequencing. For instance, proteins from diverse or unknown sources like unsequenced 
microorganisms could be characterized in this way. Finally, fast MS instruments would allow 
screening for protein modifications or splice variants by identifying the composition of MS1 features 
that show interesting patterns in the samples under investigation. 
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Neurodegeneration is exceptional devastating. It comprises a spectrum of fatal progressing 
pathologies. While the full awareness of increasing morbidity in ALS is one extreme, progressing 
loss of one’s self in diseases such as Alzheimer’s is the other. Theses pathologies are accompanied 
by immense suffering of patients and kin, underlining the urgent need for therapeutic interventions 
and therefore a better understanding of the molecular mechanisms. In this thesis I demonstrated how 
MS based proteomics can be applied to provide novel insights into the molecular mechanisms of 
neurodegenerative diseases. Furthermore, I presented recent developments in mass spectrometry 
instrumentation. With the technology advancing, the field of application will expand from basic 
research to clinical applications and diagnostics and eventually, early diagnosis of neurodegeneration 
and other diseases might be possible as routine procedure.  
In my opinion, the greatest achievement in the history of humankind is the concept of scientific 
theory. It makes us aware of logical fallacies and superstitious believes, originating from the often 
misleading intuition that is partially imprinted in our genes. Science provides the most 
comprehensive understanding of reality and it is the purest, most promising method to learn from 
the past, understand the present and shape the future. 
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Abbreviations 
AD Alzheimer’s disease  
ALS Amyotrophic Lateral Sclerosis 
BSE bovine spongiform encephalopathy 
CNS central nervous system 
CRM charge residue model 
CID collision-induced dissociation  
CTF-h C-terminal fragments of APP 
DIA data independent acquisitions 
DDA data dependent acquisition 
DoE design of experiment 
DC direct current  
ECD electron capture dissociation 
ETD electron transfer dissociation 
ESI electrospray ionization  
eFT enhanced Fourier transformation 
XIC extracted ion current  
FDR false discovery rate 
FTICR Fourier transform ion cyclotrons 
FT Fourier transformation 
FWHM full width half maximum  
HCD higher energy c-trap dissociation  
HD Huntington’s disease  
QTOF Hybrid quadrupole time-of-flight  
iPSC induced pluripotent stem cells 
IEM ion evaporation model 
IMS ion mobility separation  
LTQ linear ion traps 
LTP long-term potentiation 
MS mass spectrometer  
MALDI Matrix-assisted laser desorption / ionization 
NAC nascent polypeptide associated complex  
ND neurodegenerative disorder 
103Q-GFP N-terminal fragments of huntingtin containing a polyQ stretch 
PD Parkinson’s disease 
ppb parts per billion  
ppm parts per million  
pDRP poly dipeptide repeat 
polyQ poly-glutamine 
PEP posterior error probability  
PTMs posttranslational modifications 
PrPC prion Proteins correctly folded 
PrPSC prion Proteins misfolded 
Abbreviations 
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PrESTs Protein Epitope Signature Tags 
RF radio frequency oscillating alternating current 
RAN 
translation repeat associated non-ATG translation 
RAC ribosome-associated complex  
S / MRM single or multi reaction monitoring 
sAPP-h soluble APP ectodomain  
SMA Spinobulbar Muscle Atrophy  
SILAC stable amino acid labeling in cell culture  
TOF time of flight 
TSE transmissible spongiform encephalopathies 
TF trigger factor  
UPS ubiquitin / proteasome system  
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